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Abstract
Antimicrobial resistance is an urgent global health threat. It is critical that we understand
how bacteria respond to antibiotics in order to formulate alternative treatment strategies
to combat bacterial infections. β-lactam antibiotics are known to induce a morphological
transition in Pseudomonas aeruginosa populations; the bacteria shed the cell wall and
make the reversible transition from the native rod shape to a fragile spherical shape,
consequently evading the effects of the antibiotic.
Through the formulation and analysis of mathematical models, this thesis investigates
the impact of the morphological transition during the growth of P. aeruginosa infections.
Our results suggest that the immune system may play a vital role in clearing persistent
spherical populations. By analysing suitable parameter spaces, we show that the inter-
play between the immune response and the spherical cells could determine the success
of combined treatments. We investigate the use of genetic algorithms to obtain tailored
treatment strategies and show the need to consider the morphological transition when ap-
plying this method to P. aeruginosa infections. We advocate the use of an antivirulence
drug in combination with antibiotics or antimicrobial peptides as a sequential therapy to
eliminate P. aeruginosa infections in which the morphological transition occurs.
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Pathogenic bacteria are prokaryotic cells that are able to reproduce asexually through the
process of binary fission; the basic structure of a prokaryote can be seen in Figure 1.1.
Bacterial infections occur when pathogenic bacteria enter the body and disrupt the cellular
processes of the host cells or kill the host cells. Once the bacterial population is detected,
the immune system can initiate an immune response in an attempt to eliminate the
infection. The immune response can subsequently cause many symptoms as it attempts










Figure 1.1: The cell structure of a typical prokaryotic cell. Public domain image adapted
from [71].
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In cases where the immune response is unable to eliminate the infection, further treat-
ment is necessary. Over the last century we have managed to treat bacterial infections
using multiple classes of antibiotics. However, the use of antibiotics has placed an evo-
lutionary pressure on bacterial species and as a result, pathogenic bacteria have adapted
and mutated to become less susceptible to antibiotics. Antimicrobial resistance (AMR) is
now acknowledged as an urgent global health threat and the severity of the situation was
highlighted by the World Health Organization 2014 report that discusses the increasing
incidence of resistance-induced health problems in every region of the world [84]. A “post-
antibiotic” era is described, where even a simple infection can become fatal as current drug
strategies fail to ameliorate previously manageable infections.
It was Paul Ehrlich’s idea of a “magic bullet” that first sparked the concept of a drug
that would only target pathogenic microbes and not the host cell. His ideas led him to
systematically screen different derivatives of the toxic drug Atoxyl in search for a drug
that would cure syphilis without causing unwanted side effects. The screening process,
which took place between 1904 and 1909, was a success and is often credited for the
change in drug research strategies within the pharmaceutical industry. This systematic
approach was similar to that of the most famous antibiotic advancement, the discovery
of penicillin by Alexander Fleming in 1929 [37]. Howard Florey and Ernest Chain (1945)
[21] followed Fleming’s work and published a paper describing the purification strategies
needed to enable scientists to clinically test penicillin and subsequently mass produce and
distribute the first globally acknowledged antibiotic. The following decades between 1950
and 1970 are referred to as the golden era of antibiotic discovery, with many novel classes
of antibiotics being discovered in this time [4]. However, since then, there have been
few advancements in novel antibiotic discovery and substantial resistance to most classes
has been observed [24]. Resistance was identified even in the earliest stages of antibiotic
discovery but the positive impact of using the drugs was assumed to outweigh the possible
threat of resistance. This is no longer the case, and the potential of resistance to become
a worldwide epidemic is becoming more appreciable, as an increase in resistant strains
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and phenotypic changes within common bacteria means our ability to cure infections with
antibiotics alone becomes increasingly more challenging.
Many bacterial populations also display persistent characteristics that make it very
difficult to completely clear bacterial populations. Persistence, is a result of heterogeneity
and describes the ability of a subpopulation of a bacterial population to survive antibiotic
exposure by adapting their functionality [18]. This subpopulation of persister cells form
due to environmental pressure, such as antibiotic exposure, and can lay dormant until
more favourable conditions occur, at which point the possibility of reversion results in
persistent infections that do not necessarily rely on resistance genes. Persistence differs
from resistance, the second of these can be defined by the ability of a bacterial species
to grow at high concentrations of antibiotic and can be quantified using the minimum
inhibitory concentration (MIC) value [18]. Whilst antibiotic-susceptible and -resistant
bacteria have distinct differences in their genetic make-up, it is important to note that
persistent bacteria are genetically identical, yet phenotypically different, to the rest of
their population. Both phenomenon are examples of survival modes that bacteria can
use to survive antibiotic action; as these strategies become more prevalent in bacterial
species, humans and animals become more vulnerable.
Since the report by the World Health Organization, more pressure is being placed on
governments and pharmaceutical companies to invest in the fight against AMR. The wide
interpretation of how to tackle the problem of AMR has resulted in a wealth of research
from a vast number of scientific areas from chemistry to social science and interdisciplinary
work has proven essential in harnessing new ideas and techniques. A constitutive area in
which we can help make those advances is with involvement of mathematical modelling.
Identifying and understanding the population dynamics of bacterial growth can provide
insight into the behaviour of the bacteria under different drug strategies. If it is possible
to predict the effects of a drug using mathematical analysis, we can corroborate existing
experimental advances and direct future laboratory work, helping to cut down the time
and money needed to make further advances.
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It is crucial that we find new ways to cope with bacterial infections and that we not
only understand the pathogenesis of a bacterial infection but also how the mechanisms of
antibiotics work, the bacterial responses that occur due to the threat of antibiotic action
and how this results in the emergence and maintenance of resistance within bacterial pop-
ulations. The more we discover about bacteria, the better chance we have of formulating
novel treatment strategies. Additionally, as we increase our understanding of currently
used treatments, we increase our ability to optimise them in order to try and minimise
the development of resistance.
1.2 Pseudomonas aeruginosa and meropenem
Pseudomonas aeruginosa is a Gram-negative pathogenic bacteria that shows notable lev-
els of resistance to many antibiotics. This extremely versatile, opportunistic pathogen
is able to acquire nutrients from a wide range of organic matter, meaning that it can
easily infect damaged tissues in animals and humans. P. aeruginosa is a leading cause of
nosocomial infection and can thrive in moist environments and on hospital instruments
such as catheters. Infections are often found in airways, urinary tracts and in burns and
wounds and can often be asymptomatic until a biofilm forms. Biofilm formation can
overwhelm the immune system, cause bacteraemia, pneumonia and sepsis, and can ulti-
mately lead to death; this makes P. aeruginosa especially threatening to those who are
immunocompromised, including in particular patients with cystic fibrosis [62].
In comparison to other pathogens, P. aeruginosa is relatively hard to eradicate, due to
its capability to survive under extreme stresses, including antibiotic action. P. aeruginosa
bacteria can readily adjust physiological processes in response to environmental cues and
employ a diverse range of resistance mechanisms.
There are several antibiotics that still have activity against P. aeruginosa including
some classes of β-lactams, the most widely used group of antibiotics. β-lactams are identi-
fied by possessing a β-lactam ring in the molecular structure and this class of antibiotics,
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also including penicillin derivatives and cephalosporins, inhibits cell wall synthesis by
binding to penicillin binding proteins (PBPs). Inhibition of cell wall synthesis results
in structural changes to the bacteria and ultimately leads to lysis. Carbapenems are a
class of β-lactams that exhibit a broader spectrum of activity to other classes within
the β-lactam family and include imipenem and meropenem. Meropenem has enhanced
activity against Gram-negative bacilli compared to other carbapenems due to its affinity
for both PBP2 and PBP3 enzymes, which lead to inhibition of peptidoglycan synthesis
at different regions of the bacterial wall [101]. Meropenem has been shown to induce
morphological changes within populations of P. aeruginosa with both large spheroplasts
and long filamentous cells observed [104].
In addition to the multi-drug resistant strains of P. aeruginosa that cannot be treated
using traditional antimicrobial therapies, there is also evidence that some genetically sus-
ceptible strains are able to tolerate the presence of many β-lactams, including meropenem,
for periods of time. We will now discuss some of the characteristics and mechanisms that
can permit P. aeruginosa to survive antibiotic exposure.
1.3 Mechanisms of resistance and persistence
1.3.1 Resistance mechanisms used by P. aeruginosa
There are multiple mechanisms that, when expressed, permit bacteria to resist antibiotics;
some resistance mechanisms are intrinsic whilst others are acquired and enable previously
susceptible bacteria to develop resistance. Intrinsic resistance mechanisms are part of
the genetic make-up of a bacteria and can incur a basic level of resistance to certain
classes of antibiotics. Bacteria can also acquire resistance via chromosomal mutation or
by obtaining new genetic material.
Intrinsic resistance can be defined as the innate ability of a bacterial species to resist
or tolerate antibiotic through features of its inherent structure or characteristics. Intrinsic
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resistance mechanisms can be found in common strains of bacteria and lead to high MICs.
Occurring irrespectively of antibiotic exposure, these mechanisms render many classes of
antibiotics ineffective in clearing bacterial infections.
In addition to the chromosomal encoded resistance mechanisms, bacteria can easily
acquire additional genes that can increase the efficacy of the intrinsic mechanisms and
result in further resistance. Genetic resistance involves the acquisition of new informa-
tion via vertical gene transfer (VGT) or horizontal gene transfer (HGT). VGT refers
to mutational events that occur during bacterial proliferation and can enhance intrinsic
mechanisms. The mutational frequency rate will differ depending on the bacteria and
antibiotic and mutations can cause various levels of resistance in bacteria. A single muta-
tion could have a limited effect on bacterial resistance or it could cause the bacteria to be
completely untreatable by certain antibiotics. Additionally it is possible that a number
of mutations could work synergistically to cause much higher levels of resistance than if
the mutations occurred in isolation.
Bacteria may also acquire genetic resistance from other bacteria. HGT is often
plasmid-mediated; the plasmid (or other DNA element) acts as a vehicle and delivers
the genetic material to the recipient, usually via conjugation. Plasmids that carry mul-
tiple resistance genes can induce multidrug resistance and it is possible for broad host
plasmids to transfer genes to other bacterial species.
Additionally, unfavourable conditions, such as sub-inhibitory antibiotic concentration
levels, can induce adaptive resistance. Adaptive resistance is relatively poorly under-
stood, yet it can lead to higher antibiotic tolerance of bacteria. Resistance of this type
is unstable and not inherited; the bacteria express the resistance genes whilst the envi-
ronmental stresses are unfavourable and revert to the wild-type and regain susceptibility
once conditions become more favourable.
P. aeruginosa is known for its decreased susceptibility to multiple classes of antibiotics;
high levels of intrinsic resistance and an array of adaptive mechanisms allow even clinically
susceptible strains to persist and survive. In combination with acquired mechanisms of
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resistance or due to mutations, P. aeruginosa is able to achieve clinical resistance and
can become extremely difficult to treat. Here we introduce some of the main resistance
mechanisms used by P. aeruginosa to evade antibiotic effects.
Low membrane permeability
P. aeruginosa strains can be intrinsically resistant to many classes of antibiotics and
genetically susceptible strains often have lower antibiotic susceptibility than other bacte-
ria. One mechanism that is often credited to the inherently reduced susceptibility of P.
aeruginosa is its low membrane permeability [43].
The cell envelope of a Gram-negative bacteria is characteristically comprised of a
cytoplasmic membrane and an additional outer membrane. The outer membrane itself
is made up of a lipid bilayer that acts as a hydrophobic barrier around the cell and is
impermeable to large charged molecules. Embedded within the outer membrane are outer
membrane proteins (OMPs) that mediate diffusion of molecules across the membrane.
There are multiple types of OMPs, including porins, water filled channels that allow
diffusion of hydrophilic molecules, such as nutrients or β-lactams, across the hydrophobic
core. Porin channels differ in size and specificity and therefore successful translocation
will often depend on the size and type of the molecule.
The outer membrane of P. aeruginosa, which is 12-100 times less permeable than
that of Escherichia coli, imposes a restriction on the level of antibiotic uptake compared
to other bacterial species [79]. In addition to low intrinisic permeability, P. aeruginosa
down-regulates porin expression to further decrease membrane permeability. By decreas-
ing the number and size of non-specific porin channels, the bacteria are able to slow down
the transportation of antibiotic molecules into the cell. Specifically, the uptake of car-
bapenems, including meropenem, occurs through the OprD porin; it has been shown that
many strains that show resistance to these antibiotics are OprD deficient mutants [105].
Whilst low membrane permeability does restrict antibiotic uptake within a cell, it
does not permit resistance to all classes of antibiotics. For significantly high levels of
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intrinsic resistance, the bacteria depend on secondary intrinsic and adaptive resistance
mechanisms, such as efflux and enzyme production, that benefit from the decrease in
intracellular antibiotic caused by low membrane permeability.
Efflux pumps
Active efflux systems provide an additional mechanism to decrease the intracellular an-
tibiotic concentration and contribute to resistant properties of bacteria. In Gram-negative
bacteria, such as P. aeruginosa, multidrug resistance (MDR) efflux systems often form
tripartite systems comprising of three proteins. Specifically, the efflux of antipseudomonal
antibiotics is mediated by efflux systems belonging to the resistance-nodulation-division
(RND) family [67, 66]. The arrangement of these proteins can be seen in Figure 1.2; the
first protein, located in the cytoplasmic membrane, acts as the pump with wide substrate
specificity. There is a second membrane fusion protein that links the membrane proteins
and finally a gated outer membrane protein. Together, these proteins combine to pro-
duce a pump system that can remove antibiotic molecules and other toxic molecules from
within the cytoplasmic membrane or periplasm of a bacterium.
Efflux systems are ubiquitous in all living cells and efflux expression at low levels can
contribute to intrinsic resistance. It was initially thought that the naturally low suscepti-
bility of P. aeruginosa was a result of low membrane permeability but it is now accepted
that active efflux is a codeterminent of intrinsic resistance, along with membrane imper-
meability. Upregulation of efflux systems often occurs due to mutations in the bacterial
genome; overexpression of RND efflux systems can increase multidrug resistance and de-
crease susceptibility to antibiotics that were previously effective, including meropenem
[66].
It is also believed that efflux pumps assume additional roles in bacterial physiology
that augment bacterial virulence. It is thought that they can be highly influential in the
quorum sensing systems due to their ability to translocate quorum sensing signal molecules
across the cellular membrane [2]. The impact of these molecules on bacterial virulence
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suggests that efflux pumps may not only be associated with resistance but influential in












Figure 1.2: The arrangement of proteins formulating an efflux pump system within the
cell membrane. Antibiotics that have been successful in crossing the membrane can be
effluxed out along with molecules in the periplasm.
β-lactamases
In addition to decreasing the level of antibiotic within a cell, bacteria produce enzymes
that are capable of modifying antibiotics, rendering them inactive and therefore allowing
the bacteria to resist antibiotic effects. Different bacterial species can produce an array
of enzymes that may be used to target a certain class of antibiotic or a specific antibiotic
within that class. As we are interested in the resistance mechanisms of P. aeruginosa in
response to β-lactams, and particularly meropenem, we focus on the β-lactamase class of
enzymes.
There are multiple β-lactamases that are effective against multiple classes of antibi-
otics including penicillins, cephalosporins and carbapenems. The mode of action of these
enzymes involves hyrodlysing the β-lactam ring, found in all β-lactam molecules, render-
ing it ineffective at binding to the bacteria. In Gram-negative bacteria, these enzymes
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are often found in the periplasm and hydrolyse antibiotic molecules that have managed
to traverse the cell wall. Therefore, in P. aeruginosa bacteria enzymes can take full ad-
vantage of the low intracellular antibiotic concentrations that occur due to low membrane
permeability.
The chromosomal-encoded AmpC β-lactamase confers intrinsic resistance to some β-
lactam antibiotics and the genes for enzyme production are expressed upon exposure to
the antibiotic. Baseline levels of AmpC have been shown not to deter the effects of broad
range β-lactams including meropenem, which has shown high levels of resistance to β-
lactamases. Nevertheless, it is possible that extended mutational derepression of AmpC
production may cause resistance to most classes of antibiotics, including meropenem.
In addition to the intrinsically encoded production, and possible overproduction, of
AmpC β-lactamase, P. aeruginosa can resist more classes of antibiotic by acquiring ge-
netic information via HGT. Additionally, pre-exposure to sub-inhibitory levels of an-
tibiotics can cause an increase in β-lactamase. An example of adaptive resistance, this
mechanism enables the bacteria to survive further exposure to antibiotics. Of particular
clinical importance is the spread of plasmids that encode extended-spectrum β-lactamases
(ESBLs), which are effective against multiple classes of β-lactam antibiotics. An increase
in bacteria carrying EPBL genes resulted in an increase in the use of carpabenems. Conse-
quentially, an increase in isolates carrying carpabenem-specific β-lactamases has increased
and although initially chromosomal, these genes are now plasmid-mediated [88, 89, 107].
The prevalence of these enzymes within multiple bacterial species threatens the clinical
efficacy of all antibiotic classes.
1.3.2 Persistence mechanisms
As with adaptive resistance, persistence arises in response to environmental stimuli that
threaten bacterial survival. However, persistence differs to resistance in that not all bacte-
ria in the population display the same characteristics that allow them to survive. Instead,
only a small subpopulation of a clonal population display persistent characteristics. The
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persistent subpopulation will adapt in order to survive environmental stresses such as nu-
trient limitation, oxidative stresses and antibiotic exposure. Under the stress of antibiotic
exposure, the subpopulation of persister cells will survive for longer whilst the remaining
non-persisting bacteria are quickly killed.
Persistence can occur due to a range of adaptations by the bacteria and the underlying
mechanisms of persistence are not fully understood. Persister cells may reduce metabolic
processes, such as virulence factor expression and proliferation, and lay dormant until
environmental stresses subside. It is widely hypothesised that persistence is often char-
acterised by a slower growth rate or an extended lag phase. Both of these characteristics
reduce the susceptibility of the bacteria since many bactericidal antibiotics, such as β-
lactams, target actively growing cells.
Persisters may sacrifice bacterial growth and development in order to survive and once
more favourable environmental conditions occur, they can revert back to their original
form and regain susceptibility in the process. The persister cells have not acquired resis-
tance and as with adaptive resistance, decreased susceptibility is non-inheritable. It was
shown that if a subpopulation of persister cells is initially grown in the absence of an-
tibiotic and then re-exposed to antibiotic, the same heterogeneous response was recorded.
Instead of the total population of daughter cells also displaying persistent characteristics,
only a subpopulation of cells formed a persister population [15].
Many bacterial species display persistence-led survival including E. coli, Staphylococcus
aureus and P. aeruginosa. Dealing with persistence is of great clinical importance and
P. aeruginosa strains with high levels of persister cells have been shown as a major
threat to the eradication of infection in cystic fibrosis patients [78]. Additionally, it
has been suggested that persistence could be the cause of the disparity between in vitro
MIC values and in vivo efficacy of antibiotics [43]. Although little is known about the
underlying mechanisms that cause persistence in P. aeruginosa, persistence genes that
have been identified could hint towards prospective targets for novel treatments [31]. New
treatment strategies must be designed to not only cope with multiple strains, including
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resistant strains, but also to acknowledge heterogeneous populations that include persister
populations.
1.3.3 Cell wall deficient bacteria
The cell wall is a critical component of the cell structure and we have previously reviewed
the role of the outer membrane in controlling the translocation of molecules across the
cell envelope. The semi-permeability of the cell wall protects the bacteria from external
influences and bacterial division also relies heavily on cell wall machinery. Additionally,
cell shape and integrity are determined by the cell wall as it counteracts the outward
pressure from within the cell and maintains the balance of turgor pressure. As an integral
constituent of the bacterial structure, the cell wall has become an attractive target for
antimicrobials, including the cell wall synthesis inhibiting β-lactams. Furthermore, the
cell wall is also recognizable to the immune system, making it a target to host defence
cells such as neutrophils and macrophages, collectively referred to as phagocytes.
Despite the importance of the cell wall, many bacterial species, including P. aerugi-
nosa, can convert to a cell wall-deficient form in the presence of an inducing agent [35].
These cell wall-deficient bacteria (CWDB) can have no or little intact cell wall; the con-
sequent imbalance of internal pressure will often cause the cell to change shape and form
a large round cell. These pleomorphic forms have altered characteristics to the wild-type
(WT) and characteristics such as viability will depend on several decisive factors such as
the nutrient availability and external pressure.
Originally discovered in 1935 by Emmy Klieneberger [57] these bacteria were named
L-forms, in honour of the Lister Institute where Klieneberger worked. Following this
discovery there has developed some uncertainty surrounding the terminology used to
describe cells that shed the cell wall in this way with terms such as L-forms, spheroplasts
and protoplasts all being used to describe cells with varying characteristics. Often L-forms
are described as CWDB that can proliferate, albeit at a much slower rate than walled
bacteria and under specific osmoprotective conditions [35]. An L-form that is unstable is
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assumed to be able to revert back to the cell-walled form whereas a stable L-form cannot
and will stay in the spherical shape [35]. Additionally, protoplast and spheroplasts are
described by their inability to proliferate and are distinguished by whether the bacteria is
Gram-positive or -negative respectively [28, 36]. The controversy surrounding the correct
nomenclature for these cells may have arisen due to the difficulty to accurately grow
and identify these cells in vitro and because of the varying characteristics of CWDB
in different bacterial species. Throughout this work we will refer to these pleomorphic
forms as CWDB and we focus our interest on the CWDB that emerge in P. aeruginosa
populations.
CWDB can be induced in vitro and have also been extracted from multiple bacterial
infections. They have intrigued scientists for years and whilst the clinical relevance of
these cells is often queried the potential threat and consequences of these aberrant forms
should be appreciated [35, 83]. CWDB pose the potential to evade antibiotic effects and
the possibility of reversion suggests that CWDB could permit the persistent characteristics
of many bacterial species.
The work of Monahan et al. [75] investigates the tolerance of P. aeruginosa to β-
lactam antibiotics, including meropenem, and suggests that the ability of the bacteria to
withstand high concentrations of β-lactams can be attributed to a rapid transition of the
population to a cell-wall deficient state. The experimental results show that antibiotic
exposure induces a transition in morphology that produces a subpopulation of spherical
CWDB. Whilst it was first thought that the cell wall deficient spherical cells would lyse due
to the delicate structure of the cell, it was found that not only did the whole population
of cells transition from rod-shaped to spherical within 24 hours, but also 84% of these
cells were viable and able to transition back to rod-shaped cells in the absence of the
meropenem [75].
This study suggests that the morphological transition of the WT bacteria to CWDB
could be described as a survival strategy that enables the bacteria to evade antibiotic
effects. Conversely, in [28], the formation of spheroplasts is accredited to the cell-wall
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inhibiting properties of β-lactam antibiotics, such as meropenem, with no mention of
CWDB. Whilst spheroplasts are acknowledged, it is suggested that the formation of these
CWDB merely confirm the mechanism of action of the drug. Whether this large scale
transition is an observation of the mechanistic interactions between the drug and the
bacteria or a mechanism used as a defensive strategy controlled by the bacteria, the
viability of these cells and the possibility of a reverse transition could explain some of
the persistent characteristics of P. aeruginosa infections. In [75], it is proposed that
the CWDB can lay dormant until more favourable, antibiotic-free conditions occur, at
which point they possess the ability to transition back into rod-shaped cells and resume
proliferation. Although this shift in morphology does not indicate persistence as described
in Section 1.3.2, the varying characteristics of the subpopulations we see when meropenem
is added to P. aeruginosa form an analogous environment.
1.4 Novel approaches to treating P. aeruginosa in-
fections
1.4.1 Understanding the role of selective pressure in the devel-
opment of AMR
P. aeruginosa is ubiquitous and due to its arsenal of intrinsic and acquired resistance
mechanisms, strains have developed that can evade traditional treatment methods. It is
imperative that we try to gain a deeper understanding of currently used drug treatments
and formulate new approaches to tackle the threat of multi-drug resistant strains. More-
over, we must consider the possibility of resistance to new strategies and understand the
role of persistent populations, including the transition of CWDB, in population survival.
Before we discuss some of the novel approaches that are being considered to deal with
the threat of resistant bacteria, it is necessary to understand why resistant populations
emerge and what drives the evolution of resistance. We have previously discussed the
adaptations that permit bacteria to survive antibiotic action yet we have not considered
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why a resistant strain may flourish in a multi-strain environment.
Selective pressures are factors that drive selection for characteristics in an organism,
The consequences of selective pressure can be directly linked to natural selection; organ-
isms that express genes that provide an advantage under a certain selective pressure will
be selected for since the organisms that do not express those genes will be at a disad-
vantage and may not survive. At a bacterial level, selective pressures include the site of
infection, host responses and antibiotic concentration. All of these pressures will deter-
mine the survival of a pathogen and influence its pathogenesis, which is dictated by its
virulent properties.
In the work of Levin and Svanborg Edén [63] we see that a clear distinction must be
made between two types of selective pressure, those that lead to direct selection and others
that lead to coincidental expression. Firstly, and most simply, direct selection represents
characteristics or genes which, when expressed, result in a reward by some benefit to the
species. In a bacterial species, expression of these genes can result in increased transmis-
sion or can strengthen its ability to proliferate, invade and survive at a within host site.
For example, S. aureus faces the threat of being killed by reactive oxygen species (ROS)
at a site of infection; in order to protect themselves from this they produce CrtM, an
enzyme responsible for the production of a golden pigment called staphyloxanthin, which
provides the bacteria with protection from ROS [3]. The expression and maintenance
of the virulence factor results in increased bacterial fitness and enables the population
to continue with their invasive pathogenicity, inferring that these genes will be directly
selected [63].
Alternatively, many bacterial characteristics are believed to be expressed as a result of
coincidental selection. These factors do not benefit the pathogen in a parasitic sense
but are often the by-products of selection for other non-pathogenic adaptations that
coincidentally result in virulence [19, 63]. In other words, expression of these factors
is positively correlated with host damage but will not benefit the bacterial fitness (via
increased growth or transmission for example) at the site of infection. They may be the
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coincidental result of an adaptation required to promote survival or proliferation at an
extra-host site or at a within-host site at which they are not symptomatic. To give a
clear example we look to the expression of P pili adhesins by extraintestinal pathogenic
E. coli (ExPEC) strains. These are opportunistic pathogenic strains of E. coli that are
often found in the healthy intestinal microbiota but become virulent and cause disease
in specific extraintestinal sites such as the brain or urinary tract. In the commensal site
of the intestine, the expression of these adhesins leads to persistence; implying a directly
positive impact on the bacterial fitness. Similarly, in urinary tract inections (UTI) the
expression of P pili adhesins facilitates colonization, however, the inflammatory response
to these adhesins, which cause the painful syptoms of a UTI, can result in clearance of the
bacteria. This raises the question of whether there are measurable benefits to bacterial
fitness at these extraintestinal sites and it is therefore believed that selection for this
virulence factor in extraintestinal sites is not a result of direct selection at the site of
infection but alternatively arises coincidentally from the direct selection at the intestinal
site, where the factor is beneficial to bacterial fitness [3].
We can directly translate these ideas of selective pressure within pathogenesis to the
pressures that surround the emergence and sustainment of drug-resistant strains. The
consequences of antibiotic action on mortality and growth result in direct selection for
strains that hold an advantage i.e. resistance to the antimicrobial. The continued use, or
pressure, of antimicrobials has led to the development of multi-drug resistant strains that
have been selected for as they are able to survive exposure to multiple drugs.
As we place pressure on pathogens, in the form of antimicrobials, we are supporting
the selection for phenotypes that can evade antibiotic action and therefore it is essential
to understand in which situations selective pressure will promote these phenotypes. When
investigating novel treatments, it is critical that we consider the effects of this pressure on
the bacterial population and acknowledge the varying phenotypes within a population.
Additionally, by optimising currently used treatment strategies, it may be possible to
limit the pressure placed on pathogens and thus limit the emergence of resistance.
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1.4.2 Antibiotics vs. antivirulence drugs
The mechanism of any antibiotic compound is to be either bactericidal, which means
to kill the bacteria, or bacteriostatic; here the aim is to inhibit growth or reproduction
and interrupt population growth. All mechanisms involve targeting processes that are
crucial for microbial survival and therefore the presence of any antibiotic incurs a fitness
cost to the population of susceptible bacteria [20]. The resistant population is ultimately
rewarded by not being affected by the antibiotic and there will be direct selection for
these resistant characteristics [3]. Consequently, with a diminished susceptible population,
a competitor-free environment will arise. There is decreased competition for essential
nutrients and as a result of this the resistant strain thrives.
New alternative strategies being developed involve disarming the pathogen using an-
tivirulence drugs; instead of targeting the survival of the bacteria, these would target its
pathogenic characteristics or virulence factors [3]. Virulence, although defined in varying
ways depending on the context, can be typically understood as harm or mortality to a
host. Without virulence, a pathogen is no longer able to harm a host and it is these so-
called virulence factors, characteristics of the pathogen resulting in virulence, that drive
pathogenicity. Each pathogen has a wide array of virulence factors, all of which may
be contributory or instrumental in completing pathogenic goals such as colonization or
immunosuppression.
The mode of action of antivirulence drugs is to inhibit the mechanisms within the
micro-organism that cause harm to the host, promote infection or enable the bacteria
to evade the effects of the host immune system. If this has no or little effect on the
fitness of the bacteria then the limited fitness cost will reduce the selection pressure for
resistance. These drugs should theoretically initiate the evolution of a new population of
bacteria that will not damage its host and are under less evolutionary pressure to develop
resistance. An additional advantage of this is the likely preservation of the host microflora,
a complex and vital biosystem that can be significantly disturbed by administration of
antibiotics [91]. Whilst the potential of this concept has been studied, a great deal of
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further screening and clinical testing is needed before this antivirulence approach can be
employed.
1.4.3 Antivirulence drug resistance
The concept of a drug which disarms bacteria but does not attempt to affect the net
growth of a pathogen seems logical, but we should also study the likelihood of bacteria
developing resistance to antivirulence drugs. However, it is necessary to redefine the mean-
ing of resistance in this context. Antibiotic resistance is defined as a micro-organism’s
ability to resist the effects of an antibiotic drug that would have previously eradicated the
population. Resistance in this context refers to an adaptation that helps the pathogen
population recover, following exposure to antibiotics. Since antivirulence drugs do not
attempt to diminish the population directly we need to define resistance to antivirulence
drugs in terms of the virulence factor that it targets, instead of growth recovery. We
can define resistance in this sense as the recovery of the virulence factor, following the
exposure of the pathogen to antivirulence drugs [3].
Identifying target factors for antivirulence compounds involves screening a pathogen
for non-essential genes that do not affect bacterial growth in rich in vitro media, yet cause
increased virulence during infection. It is then necessary to understand the consequences
of virulence expression on pathogen fitness in vivo; a factor may or may not be bene-
ficial to the pathogen at the site of infection, or it can be collectively beneficial to the
whole population. Here, we can refer back to the introduction of direct and coincidental
pressure introduced in Section 1.4.1. The consequences which lead to the expression of a
virulence factor can help infer whether or not resistance would develop, should the factor
be targeted.
If a virulence factor is non-beneficial at the site of infection or in rich in vitro media
then there may be no selective advantage for resistance. This suggests that this type
of virulence factor would provide an ideal target for antivirulence strategies. In Section
1.4.1 we introduced coincidental virulence factors, which in sites of infection can often be
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non-beneficial. These are factors found in opportunistic pathogens that usually exploit
distinct environments. These factors are coincidentally selected for, due to the natural
environment of the pathogen. This would imply that if an antivirulence drug was to target
the site of infection then it may be successful in removing the virulence without imposing
selection for resistance. If we refer back to the example of P pili expression in ExPEC
strains then we can hypothesise the effects of an antivirulence drug at an exclusive ExPEC
site of infection in comparison to a general within-host application. If the drug were to
directly target a site infection such as the urinary tract (where P pili expression does not
confer a direct benefit) then we could expect both a decrease in pathogenicity and that
there would be no selection for resistance. However, if the drug was not so specific in its
target site and was applied to the intestine as well then we would presume that resistance
would be selected for as the drug would infer a direct decrease in bacterial fitness due to
P pili being necessary for bacterial progression in the intestine.
Although antivirulence drugs attempt to decrease the virulence of a bacterial popula-
tion, instead of reducing the population itself, it has still been shown that some antiviru-
lence drugs can aid clearance [45]. This may only be in the presence of an intact immune
response or whilst in combination therapy with antibiotics, but it still gives evidence that
the virulence factors targeted by these drugs must be beneficial to the pathogen, at the
site of infection, in some way and supports the theory of direct selection. A result of this is
that if the pathogen fitness and virulence factor are positively correlated then a resistant
mutant would be strongly selected for as this would recover the pathogen fitness. Again
we can refer back to Section 1.4.1; if an antivirulence factor were to suppress the ability
of S. aureus to produce the protective enzyme CrtM then this would result in it becoming
defenceless to reactive oxygen species (ROS). Consequently, if a resistant strain emerges
then this strain will be invulnerable to the ROS and this will lead to strong selection for
the recovery of the virulence factor.
It is important here to discuss the class of beneficial virulence factors, which not only
affect the fitness and benefit the focal bacterium but are collectively beneficial to the
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population of bacteria. These virulence factors become ‘public goods’ which may come
as a costly contribution for the individual, but are beneficial to their neighbours. In this
case, we must explore the effects of social cheating and cooperative behaviour within the
bacterial population. Social evolution theory suggests that non-producers may become so-
cial cheats, exploiting their neighbours that are able to produce the goods. The resulting
possibility of resistance developing in this type of environment will largely depend on how
the population is structured. For example, in a well mixed environment, antivirulence
drugs targeting a collectively beneficial virulence factor would cause susceptible bacteria,
unable to contribute, to become social cheats [72]. Resistant bacteria will be the subpop-
ulation who can still produce the virulence factor. This subpopulation will be exploited
by the social cheats; the cheats will be able to use the virulence factor produced by the
resistant bacteria without having to pay the high metabolic cost of producing it. This
may result in strong selection against resistance in a well mixed environment [3]. This
example highlights how structure, environment and fitness benefits need to be considered
when choosing a target virulence factor.
Antivirulence resistance has already been reported, however, this does not necessarily
mean that resistance will hinder the efficiency of these drugs [68]. There is no doubting
that resistance mechanisms exist, but it is important to distinguish between the existence
of these mechanisms and whether these resistance mechanisms will develop and be selected
for. If the evolution of the pathogen chooses against selection of the resistant strain
then the efficiency of the drug will not be affected. For example, many pathogens rely
on adhesion mechanisms to efficiently bind with host cells in order to deploy virulence
factors and effector proteins into the cell. Anti-adhesion drugs target these mechanisms
and inhibit the ability of the bacteria to bind to the host. Resistance to these drugs is
possible but any resistant mutations to specific binding mechanisms would directly impact
the ability of the bacteria to bind to the host and negatively impact the fitness of the
pathogen. In the following section we review some of the relevant biological mechanisms
that could be used as targets for novel antivirulence strategies.
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1.4.4 Target mechanisms for antivirulence drug strategies
When targeting virulence, there are several pathogenic characteristics that we may at-
tempt to inhibit. These virulence factors are often non-essential to bacterial growth but
cause harm to the host during infection. In Allen et al. [3] several factors were identified
and investigated to decide whether each targeted virulence factor provided a selective
advantage to the pathogen in an in vivo site of treatment. In the following sections we
discuss some examples of possible targets.
Microbial attachment
In order for a bacterium to infect a cell it firstly needs to attach itself to the cell via
adhesion. It produces an adhesin which mediates the interaction between the pathogen
and the cell-surface ligand on the host cell. Pathogens are able to present multiple adhesins
depending on the site or time so it is unlikely that a universal class of anti-adherence
drugs will be developed. However, several adhesive strategies have emerged as hallmark
requirements for virulence thus becoming targets for antivirulence drugs. The importance
of adhesion in the early stages of the infectious process means that this represents an ideal
strategy to hinder bacterial pathogenesis. Impairing bacterial adhesion would directly
impede the ability of the bacteria to successfully infect cells and hence prevent growth of
the bacterial infection.
Most adhesins are incorporated into extracellular fibres called fimbriae or pili; these
fibriae are not only required for the attachment to host cells, but they are also crucially
involved in the fitness and formation of intracellular bacterial communities (IBCs) [115].
An example of this can be seen in the importance of pilus adhesion in biofilm formation of
E. coli in the pathogenesis of UTIs. The IBCs formed by Uropathogenic E. coli (UPEC)
provide protection from the host defences of the urinary tract and antibiotics, meaning
that UTIs can become recurrent and chronic. Whilst adhesion may facilitate colonisation,
it does not confer a direct benefit to individual cell viability. Therefore, due to the
importance of the pilus in IBC formation and adhesion, these fimbriae are ideal candidates
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for an antivirulence drug target [60].
There are three main strategies in targeting pilus-mediated function; the first involves
physically preventing the pathogen binding to the host cell. This approach is adhesion
specific and involves blocking the adhesive properties of already formed pilus. This can
be achieved by various competitive binding strategies. For example, FimH is the adhesive
subunit of type 1 pili in fimbriated UPEC that binds to mannosides on the host cell via
mediation by carbohydrates. FimH antagonists, such as biphenyl mannosides have been
shown to successfully bind to the FimH subunit before it is able to bind to the host
receptors rendering the bacteria unable to bind with the host [42].
Alternatively, peptide-based inhibitors can inhibit adhesion by binding to the host
receptors before the bacteria. The bacterial surface protein multivalent anti-adhesive
molecule 7 (MAM7) has shown potential for inhibiting adhesion and therefore infection,
in several pathogenic species such as E. coli, Vibrio cholerae and P. aeruginosa [58, 59].
The third strategy involves preventing the initial formation of the pilus via inhibitory
action towards the chaperone-usher systems involved in pilus assembly. This approach,
in comparison to the first approach, could lead to a broader range of drugs and could also
impact on the ability of pathogens to form IBCs [20]. It is this approach that has been
taken in the attempt to inhibit P pili production in E. coli. Bicylic 2-pyridones are able
to bind to the PapD chaperone thus preventing further interaction of the chaperone-pilus
subunit with the usher unit, located in the membrane [87].
One of the advantages of anti-adhesion strategies that makes them so appealing as an
alternative approach to antibiotics and other conventional antimicrobials is that their use
may not induce resistance. This is because they inhibit adhesion, which is beneficial to the
population as it facilitates colonisation but it does not always directly benefit pathogen
fitness. Therefore, this may infer little to no selective pressure for resistance mechanisms.
It is theoretically possible that a resistance mutation could occur, however, it is possible
that resistance to the anti-adhesion drug could also render the mutant unable to bind to
the host. We consider the MAM7 anti-adhesion therapy as an example. If a resistant
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bacterium appeared it would need to produce an entirely new receptor protein to bind to
the host cell in an alternative way. The energy required for this could negatively impact
the pathogenic fitness and may not be selected for as a result of this. An additional
advantage of this type of antivirulence drug is that they would be unaffected by efflux
pumps due to their extracellular nature.
Toxin secretion systems
Another potential focus when looking for antivirulence targets are bacterial secretion
systems. Pathogenic bacteria can secrete toxins and molecules in a number of ways and
the effects of these secretions can lead to severe symptoms.
Toxins are usually exported by type II secretion systems and an example of the ef-
fects of these toxins can be seen in the severe dehydration and diarrhoea symptoms of
the cholera toxin produced by V. cholerae and the shiga toxins associated with E. coli.
Possible ways of targeting this type of virulence factor include gene expression inhibition
and neutralising toxins using antibodies.
Type III secretion systems (T3SS) are another type of secretion system used by many
Gram-negative pathogens, such as E. coli and Yersinia pseudotuberculosis. They allow
pathogens to translocate macromolecules, known as effector molecules, across the bacte-
rial envelope into the host. These molecules could be enzymes, proteins or toxins and
after entering the host cell, they are able to adjust and regulate the host’s defence re-
sponse. This increases the survival rate of the pathogen and can decrease the presence
and effect of the host’s immune response. Small-molecule inhibitors have been found that
inhibit the T3SS systems of both Y. pseudotuberculosis and Chlamydia trachomatis and
this is attributed to conserved elements that are found in the T3SS machinery of many
pathogens. The idea that many T3SS systems include these elements gives reason to
believe that broad range T3SS inhibitors could be developed [20, 55, 80, 95, 114].
Finally, type IV secretion systems also allow for the translocation of molecules, result-
ing in similar effects to those of T3SS but they also allow for the mediation of transmis-
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sion of genetic material, such as resistance genes, to other cells [14, 23]. This results in a
twofold contribution to virulence. Both of these functions have an additional contribution
to pathogenicity and resistance respectively and therefore make these systems attractive
targets for novel drugs.
Many of the molecules and drugs that target the secretion systems of pathogens bind
extracellularly and this is beneficial when considering resistance via efflux pumps [14].
Quorum sensing
Quorum sensing (QS) is the term to describe the chemical signalling that occurs between
bacteria. It can be seen as a way for the bacteria to communicate with one another.
Occurring via the production and recognition of small molecule signals called autoinduc-
ers, it can coordinate gene expression and regulate many processes that are involved in
community behaviour, cell growth and also virulence. Only a subpopulation of signals
are directly involved in virulence and although some of these signals are not necessar-
ily virulence factors themselves, they can induce the expression of many other virulence
factors.
This area has received a lot of attention as a possible therapeutic target due to its
role in many inter-cell processes. There are two types of possible drugs: signal-response
and signal-supply inhibitors. Signal response inhibitors will render susceptible bacteria
“signal-blind” and there will be a subsequent reduction in the production of the quorum
sensing virulence factors. Resistant bacteria will therefore be a subpopulation that can
still detect the signal and produce the virulence factors. Selection for resistance will
therefore be dependent on the beneficiaries of the virulence factors and will follow the
ideas outlined in Section 1.4.3.
Signal-supply inhibitors will inhibit the bacteria from supplying the quorum sensing
signals, thus causing a decrease in the amount of signal produced in the population. Re-
sistant bacteria will be those who can still produce the signals. In this situation “social
cheating”, as discussed in Section 1.4.3, may arise. If the resistant population is initially
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small then there will still be a small amount of signal supplied in the environment. In a
mixed environment, this will be available to all bacteria, meaning that quorum sensing-
controlled virulence factors will be expressed by all bacteria to an equal extent, if there is
enough signal. The antibiotic-susceptible bacteria become social cheats and remain viru-
lent. However, in a structured environment, the signal will be detected only by resistant
bacteria, meaning that resistance will be selected for if that virulence factor is beneficial
to the individual. Quorum sensing is extremely influential in bacterial populations, which
makes it an attractive target for antivirulence drugs. However, there are concerns that
changing such an integral part of a cell’s function may automatically promote resistance
mechanisms [3].
1.4.5 Combination therapies
Formulating novel therapies, such as antivirulence treatments, will help to combat the
ever-growing threat that antimicrobial resistance poses to humans and animals. However,
new approaches may take years to develop and test until they become clinically available
and antibiotic-resistant bacteria are already present. Strategies to use current antibiotics
more effectively are being developed to minimise the emergence of resistance.
Combination therapy and sequential therapy involve the administration of multiple
drugs to a patient, either simultaneously or in succession. This strategy, which has be-
come common practice in hospitals, aims to exploit the varying mechanisms of action of
drugs with the hope that they will act synergistically to minimise the rate of evolution
of resistance within bacterial populations. If a strain emerges that is resistant to one
antibiotic, it may remain susceptible to the other drug. Multi-drug resistance is feasible
and the efficacy of combination treatment may be limited if drug interactions are not well
researched [117]. A common combination therapy for treating P. aeruginosa bacteremia
and sepsis is the administration of the β-lactam-aminoglycoside pairing. Whilst studies
report conflicting results regarding the advantages of combination therapy over monother-
apy using this antibiotic pairing [16, 47, 70], it has been stressed that the results of these
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studies are often not comparable due to different study designs [22].
In [75], the combination of meropenem and antimicrobial peptides (AMPs) is investi-
gated as a potential therapy for P. aeruginosa infections. AMPs are relatively inactive
against rod-shaped P. aeruginosa as they induce cell death by creating pores in the cyto-
plasmic membrane, which remains unexposed in normal bacillary cells. However, it was
found that spherical cells displayed large areas of exposed cytoplasmic membrane which
gave reason to believe that the CWDB would be more susceptible to the bactericidal
effects of AMPs. This hypothesis was supported by experimental data that saw a com-
bination therapy of meropenem and AMPs leading to lower bacterial load in vitro. In
spite of these results, it is unclear whether this combination would have any effect on the
emergence of a resistant strain. Before novel combinations are used it is crucial that we
investigate how resistance would be affected by any combination of drugs and also, as
in the case of the β-lactam-aminglycoside pairing, that the drug combination is in fact
effective.
1.4.6 Optimising antimicrobial usage
The use of combination therapy could, in theory, help prevent the emergence of resistance,
unless a strain emerges that is resistant to both treatments. In some cases the use of com-
bination therapy may not be an option, for example in countries where antibiotics are not
readily available (making cycling through multiple antibiotics unviable). Vast amounts
of research must also must be done to investigate compatibility of drug combinations.
Another strategy to prolong the lifetime of currently used antibiotics is to optimise their
usage.
It is clear that the development of antibiotic resistance can be affected and accelerated
by several factors, some of which are bacteria-specific such as mutation rate and biological
fitness. In [82] the authors highlight the need to consider the antibiotic-induced impact
on these bacteria-specific factors, and specifically the impact on bacterial fitness, when
choosing a suitable antibiotic. For example, a suitable antibiotic would be one that may
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induce an increased fitness cost for resistant bacteria or for which mutations are rare [82].
Research has also indicated that the inappropriate use of antibiotics and sub-optimal
dosing strategies could impact the spread of resistance [12, 32]. The WHO defines the
appropriate use of antimicrobials as “the cost-effective use of antimicrobials which max-
imizes clinical therapeutic effect while minimizing both drug-related toxicity and the
development of antimicrobial resistance” [85]. Whether a single antibiotic is used or a
combination, the concentration of antibiotic at the site of infection and the dose duration
will determine the extent to which resistance develops. Traditional dosing regimens in-
volve a fixed number of the same dose and it is now widely accepted that these regimes
may be sub-optimal and could in fact perpetuate the emergence of resistant strains. It
is crucial that we find new ways to optimise regimens so that infections can be cleared
without involving a level of pressure that could perpetuate the spread of resistance. Math-
ematical approaches can be used to pinpoint suitable concentrations and doses that could
minimise the development of resistance and some of these will be discussed in Chapter 5.
In addition to investigative work into optimal treatment strategies, the general use
of antibiotics must be improved. To successfully implement the appropriate use of an-
tibiotics, educative campaigns have been used to target both physicians and the general
public and increase awareness of the threat of resistance. In [49] an extensive review
into national and regional campaigns in high-income countries is undertaken. It is sug-
gested that campaigns do have a positive impact on antimicrobial usage, however, it is
unclear whether the observed decrease in usage is because of a change in the prescribing
behaviour of physicians or the behaviour of the public. Finding data to support any
hypothesis surrounding the results of these campaigns would also prove difficult.
We have reviewed the characteristics of P. aeruginosa, the mechanisms that enable
the bacteria to evade antibiotic effects and some potential strategies to overcome resis-
tance. The task of providing new treatment strategies and exploring the interactions
between drugs and bacteria has traditionally fallen to the pharmaceutical industry but
with the waning effectiveness of classic antibiotic strategies, it is imperative that we can
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harness ideas and techniques from other disciplines in order to explore how we can control
antibiotic resistance. The following sections aim to give a brief overview of the role of
mathematical modelling in combating AMR, with a specific focus on the formulation of
population dynamics models and their applications.
1.5 Mathematical modelling of bacterial infections
Mathematical models are used to investigate biological systems in an abstract manner.
The biological processes and characteristics of a system can be translated into mathemat-
ical formulae that are used to predict the behaviour of the system. The model can be
validated by comparing the model predictions to observed biological behaviour or exper-
imental data; if a model does not match the expected behaviour then this indicates that
some process is missing from the model. If the results from the model provide a success-
ful approximation to the expected biological outcome then this provides support to use
the model as an analogous system to obtain predictions of unknown biological behaviour.
Whilst a mathematical model can often be a simplification of the respective biological
system, the potential to investigate complex systems and produce useful conclusions is
compelling.
There are numerous approaches and methods used to formulate mathematical models
and the type of model will depend on the system that it is describing. Models can be
continuous or discrete depending on the objects that are being modelled; large scale events
such as fluid flow or population growth are often modelled as continuous, whilst micro-
scale systems are often described using discrete models. Models can be deterministic,
where the outcome will be dependent on the pre-determined parameter values in the
model and the initial conditions, or stochastic, where randomness is incorporated into
the model. A deterministic model will produce the same results for a given set of initial
conditions, however, a stochastic model may produce varying results as the variable states
are defined by probability distributions instead of given values.
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Mathematical modelling is increasingly being used to study the changes in growth
of bacterial populations, the effects of antibiotics and the emergence of resistance. By
incorporating mathematical models into the research strategy, it is possible to connect
concepts from areas such as epidemiology, microbiology and pharmacology and meld ex-
isting hypotheses and conclusions in order to understand the biological processes involved
in the emergence and development of resistance. Mathematical modelling can simulate
lengthy and expensive experiments relatively quickly and provide predictions that can
guide experimental design.
Throughout this thesis we assume that the population is large enough to ignore
stochastic effects and we exclude spatial effects as we assume the population to be well-
mixed. Therefore, we focus our attention to deterministic population dynamics models,
which are commonly used to model populations of humans, animals and microorganisms.
Population dynamics models generally use mass action kinetics to assign rates of biological
processes to the species involved. In the remainder of this chapter we will explore terms
that are used within ODE models to describe some of the relevant biological processes
involved in the evolution of a bacterial infection.
1.5.1 Formulating an ODE population dynamics model to de-
scribe bacterial growth
Modelling bacterial growth
Before considering the effects of an antibiotic or any other influential factors, we consider
how bacterial growth can be described mathematically. If we consider the growth of
a homogeneous population of bacteria in vitro, there are well established mathematical
terms that can be used to successfully describe the experimentally observed characteristics
of bacterial growth. Bacterial growth, or proliferation, occurs by the asexual process
known as binary fission and results in one parent cell splitting into two daughter cells. If
a single bacterium was to grow without regulation then we would expect the population to
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continue proliferation indefinitely. The bacterial population, B, would grow exponentially




with a constant growth rate, η. The growth rate will be specific to the species and strain of
bacteria and the environment in which it grows. The environment will also dictate other
factors that may limit growth, such as space or nutrient. These growth limiting factors
mean that in many environments bacterial growth occurs at a non-constant rate. The
logistic growth term, proposed by Verhulst in 1845, is frequently used to model population
growth as it incorporates resource limitations. The logistic equation describes the growth









Here, η is the maximal bacterial growth rate and k is the carrying capacity or saturation
number. When using (1.2), population growth is dependent on the population size; the
initial growth stage is approximately exponential and as the population grows the rate
of growth slows until the carrying capacity is reached. Once the population has reached
its carrying capacity, growth will stop. Other nonlinear growth functions include the
Gompertz equation [41] and Richards’ model [93]. These sigmoidal models incorporate
competition of resources phenomenologically instead of explicitly considering the amount
of substrate or resources; one way to incorporate the amount of substrate available is to
use Monod kinetics [76]. Monod kinetics describe growth of bacteria and depletion of


















B(0) = B0, S(0) = S0. (1.5)
Here, S is the concentration of substrate, η is the maximum growth rate, K50 is the
saturation constant, the concentration of substrate for which half maximum growth rate is
achieved and y is the yield factor. Monod kinetics are similar to Michaelis-Menten kinetics
as the rate of growth is dependent on the concentration of substrate. The equations can
be solved under the assumption that the yield factor is constant to obtain,
B∞ = B0 + yS0, (1.6)
where B∞ is the limit of the bacterial population as t → ∞. Equation (1.6) indicates
that the limiting population is dependent on the initial amount of substrate and the initial
bacterial load. This differs to the logistic equation where the limiting population value
depends entirely on the carrying capacity k.
Both the logistic equation and monod equation are used to model in vitro data and
specifically batch growth experiments. The Monod equation is more mechanistic com-
pared to the phenomenological sigmoidal models that include mathematical parameters
that may have limited biological interpretation. However, following Zwietering et al., it
is possible to reparameterise models such as the logistic equation, to reflect microbial
growth parameters such as lag time and maximum growth rate [118]. Furthermore, in
Kargi et al. the monod and logistic equations are shown to be theoretically related, with
the logistic equation being a special case of the Monod kinetics, thus making it a suitable
choice in certain cases [54].
Incorporating a treatment
We are interested in how the addition of a treatment will affect the overall growth of a
bacterial population and therefore look towards terms that can describe this process. In
order to describe the effects of a treatment we must consider how the treatment interacts
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with the bacteria and include a suitable term within the model. If the concentration of
antibiotic changes over time then this must also be included within the model.
To include the concentration and effects of an antibiotic in a model we introduce con-
cepts from pharmacokinetics (PK), the study of drug absorption and elimination, and
pharmacodynamics (PD), the study of the response of the bacteria in the presence of the
drug. Previously, PK models have been used to obtain suitable treatment regimes that
are effective and limit toxicity; they can be used to quantify information about the con-
centration of a drug at the site of infection, which will depend on how and when the drug
was administered. The concentration of a drug at a specific time point, A(t), will depend
on the initial amount of antibiotic administered and how much has been eliminated. Drug
elimination is commonly assumed to follow first order kinetics (exponential decay) and




with decay rate b. The decay rate can be calculated using the half-life, which can be
obtained experimentally.
We may then employ PD to integrate ideas from PK into our population model.
Equation (1.7) determines the concentration of the antibiotic and we can then use mass
action laws to incorporate the effect it has on the bacterial population. A commonly used








where E(A) defines the total antibiotic effect on the rate of change of the bacteria, which
is dependent on the antibiotic concentration A [8, 48, 64, 69]. Here, EMAX represents the
maximum effect rate, A50 is the concentration for half maximal effect and n dictates the
slope of the curve. Equation (1.8) is a Hill function and n is the Hill coefficient; if n = 1
then we have an equation that is similar to the Monod kinetics, discussed previously as a
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Figure 1.3: Graphs displaying the saturating term, equation 1.8 used to model antibiotic
action with n = 1. (a) shows varying values of A50 with EMAX = 0.5 and (b) has fixed
A50 = 5 and varying values of EMAX .
suitable function to model bacterial growth.
Figure 1.3 shows how this term behaves for varying values of A50 and EMAX . As A
increases, the overall effect will tend to the maximum rate representing a saturating effect.
In Figure 1.3 (a), the antibiotic effect tends to the maximum rate for all values of A50
but as A50 increases more antibiotic is needed to reach EMAX . Conversely, if we fix A50,
shown in Figure 1.3 (b), then the antibiotic effect tends to the different values of EMAX
with the same slope. This saturation model approach can represent biological processes
such as reactions involved in metabolism and the finite number of binding sites to which
drugs must bind in order to initiate antibiotic effects.
When considering the effects of bactericidal antibiotics that aim to kill the bacteria,
the saturating term can be used with mass action laws to create a separate antibiotic-
induced death term. For bacteriostatic antibiotics, it may be more suitable to use a
different approach when modelling antibiotic action. Bacteriostatic antibiotics aim to
stop the bacteria proliferating which may not necessarily kill them and the effects of
these antibiotics can be incorporated via a decrease in overall bacterial growth. In Baker
et al. [10], antibiotic effects are modelled as a reduction in growth and a Hill-function
(similar to the saturating term above) is used to determine the extent to which growth is
hindered by the antibiotic. In D’Agata et al. [29] the impact of the antibiotic on bacterial
growth is assumed to be constant and the antibiotic concentration is not considered.
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In Abel zur Weisch et al. [1], to incorporate antibiotic effects, the model includes
the number of intracellular binding sites available to the antibiotic. This explicitly incor-
porates the cohesion of binding kinetics, an intracellular mechanism, into a population
dynamics model. The results give biological insight into the specific mechanisms involved
in various previously unexplained antibiotic effects, such as post antibiotic growth sup-
pression, a phenomenon witnessed in bacterial populations after exposure to antibiotics.
Obtaining a detailed understanding of this type of phenomena is key in devising optimal
treatment strategies and investigating the emergence of resistance.
The mathematical terms used to model antibiotic effects are relatively consistent.
Antivirulence drugs represent a new treatment approach and therefore there are fewer
models that incorporate their effects. However, there has been some modelling of the tar-
get mechanisms discussed in Section 1.4.4, in particular regarding QS. Ward et al. [111]
and Dockery and Keener [34] both produced ODE models to describe the signalling pro-
cesses involved in QS in P. aeruginosa and a subsequent model incoporating QS inhibitors
supported the idea that this could be a practicable treatment strategy that should be in-
vestigated further [6]. Additional research in this area led to similar models describing
the QS system of S. aureus [51] and also a spatial model that aimed to predict the effects
of QS inhibitors and antibiotics on a biofilm poulation of P. aeruginosa [5]. A more gen-
eral framework was produced in Ternent et al. [102] to investigate the effects of using a
combined treatment of both antibiotic and an antivirulence drug that increased bacterial
susceptibility to the host immune system. Results then suggested that the efficiency of
antivirulence treatments would depend largely upon the host’s immune system.
Host cells
Until now we have only considered mathematical terms used to describe bacterial growth
and the effects of a treatment. Simple models that only consider these interactions are
useful when describing bacterial growth in vitro but in order to investigate the growth of
an infection in vivo, it is important to consider host defences.
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The immune system is extremely complex and many models have been formulated
to describe the initial dynamics of the immune response. These models do not consider
antibiotic effects and instead focus on the specific regulatory mechanisms involved in the
immune response such as inflammatory responses, cytokine production and different types
of immune cells [38, 113]. Other notable models of the initial immune response can be
seen in [53, 98]; both studies attempt to formulate simpler models of the initial dynamics
of the immune response, whilst maintaining a focus on specific aspects of the immune
system such as the individual components of the immune response involved in a lung
infection [98] or the interactions between the bacteria and immune response with respect
to inflammatory damage [53].
Detailed studies are useful to investigate the specific interactions that may cause the
initial immune response to succeed or fail in clearing an infection. However, our interest
lies in modelling the bacterial infection over the time course of a treatment and hence we
can assume that the initial immune response has been ineffective in clearing the bacteria
alone. Whilst the immune response may not succeed in clearing the infection alone, it can
dictate whether a treatment is successful or not. For example, the immune system can
have a considerable impact when the antimicrobial in use is bacteriostatic as it can work
synergistically with the drug [44]. Similarly, it was suggested that the immune response
could support antibiotic action when a persistent population was present [7]. For that
reason, it is important that we include host defences within models that attempt to analyse
suitable treatment methods and notable examples can be seen in [7, 29, 39, 44, 64, 102].
Studies that have investigated the role of host defences during antibiotic treatment
have used various approaches when including the immune response within the mathemat-
ical model. In some cases, host defences are considered implicitly; in Lipsitch and Levin
[64], the effects of the immune response are incorporated into the model via a decrease
in bacterial growth. Similarly, in [29], the number of activated phagocytes is assumed to
be at equilibrium and thus taken as constant. Here, a Monod term is used to include the
effects of phagocytosis and the authors formulate a simple multi-strain model that can
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investigate the impact of dosing regimens on the emergence of resistant bacteria, through
HGT, without having to add another equation for the phagocyte population.
If we assume that the immune response may vary over the course of the infection or
treatment period, then it could be unsuitable to include it implicitly within the model.
Instead, the immune response can be included explicitly; an additional equation can be
formulated to describe the strength or number of immune cells alongside the bacterial
population. In Handel et al. [44] the strength of the immune response, normalised to be
between 0 and 1, is modelled. Modelling the strength of the immune response indicates
a more phenomenological approach and could be a suitable strategy if there are multiple
types of immune cells involved within the immune response. An alternative approach
would be to model the number of immune cells, whether that be a combined immune cell
population or multiple subpopulations of specific immune cells [7, 9, 39].
Following the principles of population dynamics, the equation to describe the immune
response will include terms to describe the growth and decay of the immune cell population
The population of immune cells will increase due to recruitment, which occurs when the
immune system detects that a pathogen is present in the body. Pathogen-associated
molecule patterns (PAMPs) are molecules that are present in the pathogen and can be
recognized by receptors, thus inducing an influx of immune cells into the environment.
A suitable term must be chosen to describe the process of recruitment, which can vary
depending on the type of immune cell. We consider two scenarios: recruitment is pathogen
density-dependent (PDD) or pathogen density-independent (PDI) [7]. For the former,
a term that includes the bacterial population must be chosen and for a PDI response
the bacterial population will not appear within the term. Both PDD and PDI terms
are investigated in Handel et al. [44] and Ankomah et al. [7]; both studies compare
different recruitment terms to investigate the effects of different immune responses on
the emergence of resistance and different treatment methods. Additionally, many studies
choose to use a saturating term for recruitment under the assumption that there will be
limitations on the strength of the immune response [7, 44, 102].
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To model the clearance of phagocytes from the environment, we focus our attention to
two processes: natural clearance and pathogen-induced apoptosis, which occurs when the
engulfed bacteria excrete toxins that induce immune cell death. Whilst some models only
consider natural clearance ([7, 39, 44]) and assume that the rate of clearance is constant,
others include a term for each of the two processes. In Ternent et al. [102] natural
clearance is assumed to occur at a constant rate and a mass-action type term is chosen
to describe the density dependent process of bacteria-induced apoptosis.
We have considered the dominant processes that will characterise the growth of the
immune response. Finally, we must integrate the effects of the immune system on bacterial
growth into the model. In many models it is assumed that immune-mediated killing
bacteria occurs at a rate that is directly proportional to the size of the immune response
and a mass-action term is added to the equations that describe the bacterial populations
[7, 102]. However, in Handel et al. [44] they considered a saturating term in addition to
the mass-action term. It was acknowledged that immune cells may take time to complete
phagocytosis and that under this condition, the mass-action term would break down for
high bacterial load.
Introducing host defences into a mathematical model provides the opportunity to
model bacterial growth in vivo and we shall see in later chapters that it is crucial to
consider the effects of the immune system when investigating ways to optimise treatment
strategies. Similarly, in order to explore the emergence and development of resistant
strains or persistent subpopulations, we must include these species within the model.
We will now discuss some notable studies that include multi-strain models of bacterial
populations and consider the methods of differentiating between subpopulations.
Modelling heterogeneous populations
The focus of this project surrounds the growth of P. aeruginosa and the impact of the
morphological transition that occurs under the influence of β-lactam antibiotics. There
are multiple ways to model a transition between subpopulations and the term used will
37
depend on the system that is being described. If we consider models of persistence then
the wild-type bacteria may be able to transition to and from the persistent form. A simple
example can be seen in the persistence model used by Balaban et al. where the bacteria
will transition between a normal and persistent state at a constant rate [11]. A more
complex transition is used to model the transition to a peristent population in Cogan et
al. [25]. Here, the transition is dependent on both the antibiotic concentration and the
growth rate, which is modelled using Monod kinetics. This approach incorporates the
dependence of persister formation on the growth stage of the bacteria and the pressure
exerted onto the bacteria by antibiotic exposure. However, reversion from the persistent
population is dependent on the antibiotic concentration only. A later model of persister
formation by Cogan et al. [26] assumes that the transition from a normal to persistent
state is proportional to the concentration of a toxin that is produced in response to
environmental stress. Reversion back to the susceptible population occurs at a constant
rate and it is assumed that this is small in comparison to the transition to the persistent
form and negligible when considering constant doses.
Modelling the emergence of a resistant strain is similar to the methods used to model
persistence in that we must understand the mechanism through which bacteria gain re-
sistance and formulate a mathematical interpretation of the inter-population transition.
Acquisition of resistance genes can either be a result of genetic mutation or via HGT.
Lipsitch and Levin [64] developed a deterministic compartmental ODE model that de-
scribed the growth of an antibiotic-susceptible strain of bacteria and a strain with reduced
susceptibility. An additional equation was used to describe the dynamics of antibiotic
concentration. They incorporated the emergence of resistance due to mutation using a
stochastic component that modelled the appearance of resistant mutants using a Poisson
distribution every time the susceptible population replicated. Another way of integrating
a resistant mutant population could involve introducing the resistant population manu-
ally at a time point during the numerical simulation. It is possible to choose the size
of the initial resistant population and hence this approach can be used to simulate the
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appearance of a mutated bacterium or an influx of resistant bacteria, which could occur
in the case of cross contamination.
If a resistance mechanism is more likely to be passed via HGT then the number of
bacteria that transition from the susceptible to resistant population, BR, will no longer
only be dependent on the susceptible population, BS (as is the case with mutation models).
A frequency dependent term,




where β is the gene transfer rate and B = BS + BR, is commonly used in models of
HGT [10, 29, 110]. We notice that instead of using a typical mass action kinetics term,
the transmission rate, β, is normalised by the total population. By normalising the
transmission rate it is possible to preserve the expected behaviour of transmission when
one population is much larger than the other. Modelling HGT in this way fixes the gene
transfer rate as a constant, however, in Novozhilov et al. [81] the evolution of horizontally
transferred genes was investigated using a deterministic ODE model with an additional
stochastic counterpart.
In addition to acquiring resistance via HGT, it is also possible to lose the plasmid
and gain susceptibility. Some studies have assumed that plasmid loss occurs over such a
lengthy time frame that it need not be included within the model [10]. In D’agata at el.
plasmid loss is assumed to occur during replication and modelled using a reversion term
that depends on the replication rate and a probability parameter [29].
Biological processes and the speed that they occur will be individual to the strain and
phenotype of the bacteria. Therefore it is reasonable to assume that the rates used to
describe these processes may differ between subpopulations. Growth rates are especially
specific and will vary depending on the strain, phenotype and environment. For example,
some persistent bacteria enter a dormant state and do not proliferate. Additionally,
resistant bacteria are assumed to proliferate at a slower rate due to the fitness cost that is
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attached to carrying resistance. It is possible to model a fitness cost by including separate
growth terms for the susceptible and resistant strains ([64]), which we define as ηS and ηR
respectively. Alternatively, the fitness cost can be incorporated explicitly into the model
by introducing a fitness cost parameter, c. The resistant growth term becomes
ηR = (1− c)ηS, (1.10)
where c can take values between 0 and 1 [10, 64, 102]. By including a fitness cost parameter
we can easily explore different growth rates for the resistant strain as a proportion of the
growth rate of the susceptible bacteria.
In addition to the growth rate, each bacterial population will have distinctive rates of
death, whether that be natural death or antibiotic-induced death. Specifically, antibiotic-
resistance enables bacteria to survive antibiotic effects and in mathematical models this
effect is often identified by individual antibiotic-induced death rates or PD properties
[10, 29, 44, 102]. Other rates that may differ between phenotypes, including visibility
to immune cells and phagocytosis, can also be made individual to a subpopulation when
formulating a population dynamics model.
1.6 Project overview
We have provided a detailed overview of the methods used to formulate a population
dynamics model of a bacterial infection. Additionally, we have considered the terms that
are used to incorporate a treatment, host defences and heterogeneity within a population.
Throughout this thesis we will formulate various models for the growth of P. aeruginosa
with varying levels of complexity. For reference, we include Table 1.1, which includes a
brief description and the assumptions used to formulate the models herein. Our approach
will be to parametrise models using experimental data where possible, to obtain rates
that are specific to P. aeruginosa and the β-lactam antibiotic meropenem. If data is not
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available then we will explore the feasible parameter space to investigate the possible qual-
itative behaviour of the system. We will investigate novel treatment options by varying
the rates of key processes and investigate the optimisation of currently used treatments
using a genetic algorithm (GA).
In Chapter 2 we formulate a mechanistic model (Model I) to describe the growth
dynamics of P. aeruginosa in isolation with meropenem. The model is mechanistic in
the sense that carrying capacity is taken into account through the dynamics of nutrient
availability rather than via logistic growth. Using in vitro data of growth curves of P.
aeruginosa in the presence of varying concentrations of the antibiotic meropenem, we
obtain parameter estimates for the model that enable it to reproduce experimentally
observed behaviour. The analysis of two parameters sets, that produce different long
term behaviour, allows us to manipulate the system theoretically in order to explore
the advantages of the shape transition and simulate the effects of a combined dose of
meropenem and AMPs. The work in Chapter 2 has been published in [99].
In Chapter 3 we formulate Model II to describe the growth dynamics of P. aeruginosa
in isolation with meropenem and incorporate the possibility of efflux pump upregulation,
i.e. antibiotic resistance. Due to limited data, we obtain a parameter set using values
from our previous parametrisation attempts and literature. We explore the feasible pa-
rameter space to investigate the impact of the morphological transition on the growth of a
meropenem-susceptible and -resistant strain of P. aeruginosa and explore the parameters
associated with the resistance mechanism.
In Chapter 4, we extend Model II to formulate a mixed strain infection level model
(Model III). We analyse the potential impact of the immune response on the growth
of a P. aeruginosa infection during different treatment combinations. By altering the
immunogenic properties of the spherical cells in silico, we identify scenarios in which the
relationship between the immune response and the spherical population may determine
treatment success.
Finally, in Chapter 5 we apply a GA to Model IV to obtain optimised dosing regimens
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for a single antibiotic-susceptible strain of P. aeruginosa. Initially we assume that the
bacteria do not transition during antibiotic exposure to show that the GA chooses dosing
strategies that consist of a high initial dose that tapers off as the treatment progresses.
We then include the morphological transition to show that the presence of spherical cells
may impact the tailored treatment strategies suggested by the GA.
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Table 1.1: Review of mathematical models formulated to describe the growth of P. aerug-
inosa.
Model Description
I Model I describes the growth of a single meropenem-susceptible strain in
isolation with meropenem. Model assumptions include:
• only rod-shaped cells proliferate
• nutrient-dependent growth of rod-shaped cells
• bacteria transition freely between the rod and spherical shape (i.e. the
reverse transition occurs independently to antibiotic concentration)
• spherical cells evade the effects of meropenem
• all cells die naturally
II Model II describes the growth of a single strain in isolation with meropenem.
We include the possibility of resistance via active efflux. Model assumptions
include:
• only rod-shaped cells with no bound antibiotic proliferate
• bacterial growth described by logistic growth
• rod-shaped cells become internalised by antibiotic when the antibiotic
binds within the cell
• efflux reduces the rate of internalisation
• spherical cells are immune from antibiotic effects
• natural death of rod-shaped cells is negligible
• spherical cells only revert back to rods at low antibiotic concentrations
III Model III describes the growth of a mixed strain population at the site of
infection. We include antibiotic effects and host defences. The model is
formulated using the assumptions from Model II and the following:
• density-dependent immune response
• immunogenic properties may differ between cell morphologies
• immune cells are subject to natural clearance and bacteria-induced apop-
tosis
• resistant bacteria appear due to mutation or through cross contamination
IV Model IV describes the growth of a single meropenem-susceptible strain in
isolation with meropenem. Model assumptions include:
• only rod-shaped cells proliferate
• bacterial growth described by logistic growth
• spherical cells only revert back to rods at low antibiotic concentrations
• spherical cells evade the effects of meropenem
• spherical cells die naturally due to fragility
43
CHAPTER 2
MODELLING THE GROWTH OF P.
AERUGINOSA IN ISOLATION WITH
MEROPENEM
In [75] they attribute the survival of P. aeruginosa cells after exposure to meropenem
to a shape transition that results in the formation of viable yet fragile spherical cells.
In this chapter we develop a system of differential equations to describe the bacterial
growth of P. aeruginosa in the presence of the antibiotic meropenem with the inclusion
of a morphological transition that is activated by the presence of the antibiotic. Whether
this transition is a result of direct antibiotic action or attributable to an intrinsic survival
mechanism, we assume that the cell wall deficient spherical cells evade antibacterial effects,
as evidenced by the data in [75] and our own data. Using growth data we obtain estimates
for the parameters used in the model and analyse the results to changes in these parameter
values.
We note that our investigation in this chapter will focus solely on a meropenem-
susceptible strain of P. aeruginosa; initially our concern is not with the mechanisms of
resistance that are often attributed to P. aeruginosa, such as the upregulation of efflux
pumps. Rather, we wish to investigate a shape transition that permits meropenem-
susceptible strains of P. aeruginosa to tolerate the presence of antibiotics.
The work in this chapter has been published in PLOS Computational Biology [99].






Figure 2.1: Cells of the meropenem-susceptible P. aeruginosa PA1008 strain rapidly con-
vert to a spherical shape after adding (a) 0.5µg ml−1 and (b) 2µg ml−1 of meropenem
before reverting back to a bacillary form. Microscopy images were taken after 1, 6 and
22 hours. Left panels: transmitted light, right panels: fluorescence microscopy. In fluo-
rescence images, green and red colouring indicates viable and lysed cells respectively.
University of Birmingham and University of Texas Health Science Center at Houston.
Note that we have changed some variable notation from the paper for consistency with
the remainder of this thesis. In the published version of this work we refer to the spherical
cell population as S whereas in the following chapters we refer to this population as L.
2.1 Model formulation
The assumptions made for the model are based upon the results in [75], which we have
reproduced experimentally, with our results displayed in Figure 2.1 (see Appendix A.1 for
experimental Materials and Methods). The images indicate changes to cell morphology
shortly after exposure to the antibiotic; spherical shaped cells can be seen after only one
hour. After 22 hours we see rod-shaped cells that are in the process of dividing (Figure 2.1
(b)) and this indicates that the cells can revert back from the spherical form and continue
proliferation. Additionally, the fluorescence microscopy images support the results of [75];
most of the cells stained green, indicating that these spherical forms were viable.
In accordance with these findings, our compartmental model follows the interactions
described in Figure 2.2. We introduce variables (defined in Table 2.1) for rod-shaped
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bacteria (H) and spherical bacteria (L). Here, we assume that the rod-shaped cell pop-
ulation consists of all those cells that are susceptible to the antibiotic, this may include
cells that have shown signs of localised swelling or filamentation. In this model we will
refer to this population as rod-shaped whereas the spherical cell population is made up of
cells that have transitioned into this form due to antibiotic exposure. Experimental data
has shown that the spherical cells are susceptible to lysis due to internal turgor pressure
and that this causes the cells to expand before they lyse. For this model we will contain
















Figure 2.2: Schematic representation of the transitions of P. aeruginosa in response to
exposure to meropenem. The species shown are defined as follows: H are rod-shaped cells,
L are spherical cells and D represent dead cells. When the antibiotic, A, is introduced,
rod-shaped cells can make the reversible transition to a spherical shape. The antibiotic
is assumed to be effective at killing rod-shaped cells but not spherical cells due to a
depleted cell wall. Rod-shaped cells lyse naturally as do spherical cells. Rod-shaped cells
can proliferate if there is enough nutrient, N .
In addition to these variables we define the antibiotic concentration to be A and the
proportion of nutrient remaining in the system, N . Including a nutrient dependent growth
term, instead of the commonly used logistic growth term, will allow us to formulate a
mechanistic model. Figure 2.2 also includes a population of dead cells, however we do not
include this variable in the model or results. Any lysed cells will quickly disappear from
the culture, we can therefore assume that the contribution made to the optical density by
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the lysed cells can be considered negligible. This assumption is supported by Figure 2.1;
with only a minority of cells in the image fluorescing red (indicating a dead cell) we can
assume that the majority of dead cells have completely lysed and disappeared.
We assign parameters for the rates of growth, death and transition as defined in Table
2.2. Nutrient dependent growth will occur at the rate r and proliferation will concurrently
incur a decrease in nutrient that occurs at the rate r̃. Nutrient growth and depletion are
both modelled using a constant rate; we could use a monod expression to describe both
of these processes, however, we choose this linear term as the bacteria are growing in a
nutrient rich growth medium. For this model we assume that only rod-shaped cells can
proliferate. This assumption is based on existing literature, experimentally characterising
the proliferation of usually rod-shaped bacteria that have undergone conversion to spher-
ical cells as a result of shedding the cell wall [73]. The experiments demonstrated that
although proliferation of spherical cells was possible, it was only possible under specific
osmoprotective conditions and even then proceeds in only a very small subset of spherical
cells, with a doubling time 10-fold higher than that of the rod-shaped cells. Conventional
proliferation becomes impossible due to the compromised integrity of the spherical cell
wall; bacterial proliferation is heavily dependent on correct positioning of the cell wall
and without this it is unlikely that a cell will successfully divide. Although P. aeruginosa
was not included in these experiments, it was suggested that similar proliferation occurs
across all bacteria; due to the high doubling time we will assume that spherical growth is
negligible.
Meropenem is bactericidal hence its action is modelled via a death term distinct from
natural death [50]. This additional term differs from some models that absorb the antibi-
otic effects into the model by means of a reduction in bacterial growth, yet this approach
would be more suited to bacteriostatic antibiotics [8, 29]. The antimicrobial effects on the
rod-shaped population is modelled using a density dependent term to incorporate a satu-
rating effect. Attempts at using a linear term for this resulted in unsuccessful parameter
fits (results omitted) and a saturating term was found to be more suitable in describing
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the effects of the antibiotic; this is in keeping with previous models of antibiotic treated
bacteria [8, 10, 102]. We assume that the meropenem only inhibits rod-shaped cell survival
as experimental results indicate that transitioning to a spherical form mediates tolerance
to lethal β-lactam antibiotic concentrations for multiple bacterial species [73, 75]. We
assign ρ to be the maximum death rate of rod-shaped cells due to antibiotic and A50 to
be the antibiotic concentration needed for half maximal killing. For simplicity, we set the
Hill coefficient to 1 (i.e. n = 1 in (1.8)). We assume that the meropenem molecules will
enter the cell and bind to the PBPs in order to inhibit cell wall synthesis. In this model
we assume that this binding is irreversible due to the mode of action of β-lactams. The
antibiotic molecules covalently modify PBPs upon binding [112] and therefore when a
bacterium lyses, any bound antibiotic is unlikely to be released back into the extracellular
domain. The irreversibility of the antibiotic results in antibiotic decay and we will take
this to happen at a rate, ρ̃. Again, we choose not to have a specific Hill coefficient for
simplicity. Investigation into the value of ρ̃ has shown that relaxing this parameter and
setting ρ̃ = 0µg ml−1 OD−1 min−1 does not affect the results significantly (results omit-
ted) yet we include this assumption as it has an impact on long-term model predictions of
bacterial growth. In addition to this, we take antibiotic decay to follow first order kinetics
at a rate α. In concordance with [75], we assume that spherical cells evade the effects of
the antibiotic.
The primary objective of this model is to investigate whether we can describe the
population dynamics of P. aeruginosa in the presence of meropenem by including the
morphological transition witnessed in experimental data. We model this transition from
rod-shaped cells to spherical cells with a saturating term, similar to that used for the
bactericidal effects of the antibiotic on the rod-shaped cell population. Following exposure
to the meropenem the rod-shaped cells transition to a spherical form at a maximum rate
γ and T50 defines the concentration for which we get the half maximal transition rate and
again we assume that the Hill coefficient is 1. Following [73, 75] we include the process of
reversion within our model: antibiotic is removed from samples in order to experimentally
48
show that spherical cells can transition back to the bacillary form, implying that this
occurs independently from the presence of the antibiotic. Previous models of persister
populations have assumed that reversion does not occur when a constant dose of antibiotic
is administered [25, 26]. However, in our model, antibiotic may degrade out of the system
and even when present the spherical cells may not be directly exposed to antibiotic at all
times. Reversion will be independent from the antibiotic concentration and we define δ to
be the rate at which this occurs. Supported by the microscopy results in Figure 2.1, this
reverse transition also lends weight to the assumption that antibiotic decays as it suggests
that the pressure on the bacteria from the antibiotic has decreased.
Finally, following our own fluorescence microscopy data, we assume that both types
of cell will lyse naturally. In our microscopy results we witnessed lysed (red) rod-shaped
cells even in the absence of antibiotic, indicating that some level of natural death must
occur. Subsequently, we assume that spherical cells also lyse naturally due to the increased
fragility of the cell structure. Lysed cells degraded sufficiently quickly that we may assume
they do not contribute to the OD settings in our experimental set-up. The spherical cells
lyse at a rate ψ, whilst rod-shaped bacteria lyse at a rate φ. Due to the availability of
nutrient and general fitness of the rod-shaped cells we would expect φ to be small and
due to the compromised integrity of the cell wall in spherical cells we expect φ < ψ. We
also expect natural rod-shaped cell death to happen at a slower rate than death due to
antibiotic action.



































H(0) = H0, L(0) = 0, A(0) = A0, N(0) = 1. (2.5)
AsN is defined to be the proportion of initial nutrient remaining instead of a concentration
we can specify N(0) = 1. All variables and parameters are defined in Tables 2.1 and 2.2
respectively.
Table 2.1: Definitions and units for the variables in Model I, described by equations
(2.1)-(2.5).
Variable Definition Units
H Antibiotic-susceptible rod-shaped cells OD
L Spherical shaped cells OD
N Nutrient proportion of initial concentration dimensionless
A Antibiotic concentration µg ml−1
Table 2.2: Definitions and units for the parameters in Model I, described by equations
(2.1)-(2.5).
Parameter Description Units
α Antibiotic decay rate. min−1
r Growth rate of rod-shaped bacte-
ria.
min−1
r̃ Decay rate of nutrient due to con-
sumption by rod-shaped bacteria.
OD−1 min−1
γ Transition rate from rod to spher-
ical shape.
min−1
δ Transition rate from spherical to
rod shape.
min−1
ρ Death rate of rod-shaped bacteria
due to antibiotic.
min−1
ρ̃ Decay rate of antibiotic due to ir-
reversible binding to bacteria.
µg ml−1 OD−1 min−1
φ Death rate of rod-shaped bacte-
ria.
min−1
ψ Death rate of spherical bacteria. min−1
T50 Antibiotic concentration required
for half maximal killing effect
µg ml−1
A50 Antibiotic concentration required
for half maximal transition effect
µg ml−1
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2.2 Parametrisation data and methods
Parametrisation data
In order to successfully parametrise Model I we have used two sets of data, which we will
refer to as Data set 1 and Data set 2. Single colonies of the P. aeruginosa strain PA1008,
a meropenem susceptible isolate derived from a hospital burn unit [90], were inoculated in
LB broth and grown overnight. The following day, meropenem was added to the bacteria
culture at different concentrations. The optical density of each sample was recorded every
30 minutes for 24 hours to obtain growth curves for the population. A complete guide to
the materials and methods used to obtain this data can be found in Appendix A.2. The
first data set is used as parametrisation data; this consists of three biological replicates,
each with three technical repeats. The meropenem concentrations used for this data set
were 0µg ml−1, 2µg ml−1, 4µg ml−1, 10µg ml−1, 20µg ml−1, 40µg ml−1 and 200µg ml−1.
For each concentration we display the mean of the nine resulting growth curves. The
error bars are formulated by calculating the standard deviation of the means of the three
biological replicates.
Data set 2 is also referred to as the test data and includes one biological replicate with
three technical repeats; the meropenem concentrations used for Data set 2 were 0µg ml−1,
0.5µg ml−1, 1µg ml−1, 5µg ml−1, 50µg ml−1 and 100µg ml−1. For each concentration, we
calculate the mean value of the three resulting growth curves at each time point and the
standard deviation error bars for this data set represent the standard deviation over the
three technical repeats.
Parameter fitting methods
The parameter estimates were obtained using the MATLAB function fminsearch, which
uses the Nelder-Mead algorithm as described in [61]. The fminsearch function fits pa-
rameters that minimise a specified objective function given some initial estimates. We
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The vectors H and L are the solutions for rod-shaped and spherical cells respectively at
the time points used in the experiments. The vector y consists of the OD values obtained
in the experiment and n is the number of data values. This equation evaluates the mean
relative error of the difference between the data and the solution to the system at each
time point. We use the relative error in our objective function as unlike the absolute error
the relative error should not be skewed by large or anomalous data points. We note here
that the contributions of rod and spherical shaped cells to the OD differ in the objective
function. OD is a measurement of the absorbency of a material; it measures how much
light can pass through a sample and therefore reflects the total number of cells present in
the inoculum. Rod and spherical cells will contribute differently to the OD measurement
as they differ in size and absorbency. Therefore, rather than attempt to scale OD to obtain
a total cell number, we work in OD and based on our biological insight we have assumed
that spherical cells contribute half the absorbance of rod cells to the OD measurements.
When using the MATLAB function fminsearch to parametrise we also apply a con-
straint that restricts parameter values to non-negative values. To do this we apply a
penalty to the objective function that increases its value significantly if a parameter is
less than zero; we simply multiply the objective function value by 1000 (i.e. we make the
penalised objective function much larger than we anticipate the relative error using the





We first fit the non antibiotic-associated parameters that we expect to remain fixed in the
presence of antibiotic. By removing the antibiotic from the system we are left with the
following pair of equations
dH
dt





H(0) = H0, N(0) = 1. (2.9)
The initial guess for r is 1× 10−3 min−1 and for r̃ we choose 1× 10−1 OD1 min−1. The
natural death rate, φ, is assumed to happen at a slower rate than growth; a bacterial
population would not thrive if growth and death occurred at the same magnitude and
we therefore choose an initial parameter guess for φ of 1 × 10−5 min−1. Including the
initial condition, H0, in our estimation allows for the incorporation of error, whether it
be systematic or random, within the initial data values. The initial guess for H0 is chosen
to be the initial data value. We attain the results shown in Figure 2.3 parametrised by
the resulting final estimates,
[r, r̃, φ, H0] = [5.1× 10−3 min−1, 8.9× 10−3 OD−1min−1,
7.8× 10−6 min−1, 0.17 OD]. (2.10)
All parameters are given to two significant figures and the mean relative error is 7 ×
10−4. Figure 2.3 indicates that these parameters produce a good fit and that this model
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with nutrient dependent growth can describe the growth dynamics of the bacteria in the
experiment. We note that the model is unable to reproduce the slight lag phase (see papers
by, for example, Zwietering et al. and Biranyi et al. for developments of the logistic model
that can achieve this [13, 118]) and instead underestimates the initial condition; we do
not anticipate that this will alter any of the findings of this study and therefore choose
not to include further parameters to obtain the lag phase. We also notice that the death
rate is much lower than the growth rate; this supports the hypothesis that the natural




Figure 2.3: The solution to the system (2.7)-(2.9) using the parameters in (2.10), plotted
with the experimental data for the growth curve of P. aeruginosa (Data set 1). Data
points are plotted with errorbars representing the standard deviation of the means of the
three biological replicates.
Parametrisation with meropenem
Fixing the parameters given by equation (2.10), we use the killing curves to estimate
the remaining parameters that are attributed to the presence of antibiotic. This data
includes the addition of meropenem at multiple concentrations and therefore the full
system, equations (2.1)-(2.5), is used. Early parametrisation attempts provided initial
parameter guesses for the optimiser and these values are shown in Table 2.3 along with
the estimated parameter values obtained.
The optimiser estimated the values of all but two parameters, α and ρ̃, which were
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Table 2.3: Estimated parameter values (EPVs) for Model I. We define two parameter
sets, one that results in population elimination for all concentrations of meropenem (Θ1)
and another that displays population recovery of the bacteria when 2µg ml−1 is added, Θ2
(only α and ρ̃ differ between the two sets). Units for each parameter are shown in Table
2.2. R represents the sum of the relative errors for each of the data sets in Data set 1.










r 1× 10−3 5.1× 10−3 5.1× 10−3
r̃ 1× 10−3 8.9× 10−3 8.9× 10−3
φ 1× 10−5 7.8× 10−6 7.8× 10−6
α 1× 10−3 1.4× 10−8 5.5× 10−6
γ 3× 10−3 5.4× 10−3 5.4× 10−3
δ 1× 10−3 1.8× 10−3 1.8× 10−3
ψ 9× 10−5 1.2× 10−5 1.2× 10−5
ρ 1× 10−3 1.7× 10−3 1.7× 10−3
ρ̃ 1× 10−3 2.9× 10−3 8.2× 10−3
T50 0.5 0.47 0.47
A50 0.5 0.13 0.13
R - 3.47× 10−3 3.56× 10−3
OD when A0 = 2 at
t = 5000
0.069 0.37
determined to be unidentifiable. These two parameters represent the natural decay rate
and the rate of decay due to internalisation of the antibiotic; both are rates of decay
of a species for which we do not have data explicitly and thus it is unsurprising that
they cannot be identified. Latin hypercube sampling was used to investigate the possible
values of the two unidentifiable parameters and the results of this concluded that multiple
pairings of values can be used to successfully describe the population dynamics of all
concentrations. Further investigation into these feasible parameter pairings revealed two
qualitatively different predictions for population growth when the model is simulated over
a longer time period than used in experimental procedure. We choose two parameter sets
Θ1 and Θ2 to represent each of these outcomes, see Table 2.3. The estimated initial
condition H0 obtained for each parameter set can be found in Table 2.4.
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Table 2.4: Estimated initial condition H0 for each experimental data set in Data set 1.
Initial antibiotic concentration is fixed. The initial experimental data values are chosen
as the IPGs. EPVs obtained by treating the initial condition as a parameter and simul-








2 0.25 0.23 0.22
4 0.26 0.23 0.23
10 0.26 0.23 0.23
20 0.26 0.23 0.23
40 0.26 0.24 0.24
200 0.25 0.24 0.24
Using parameter sets Θ1 and Θ2 we obtain the results shown in Figure 2.4; both
parameter sets successfully fit the model to all of the experimental data in Data set 1.
The total errors of these data fits over all concentrations are 3.47× 10−3 and 3.56× 10−3
respectively and if taken as an indicator of goodness of fit, along with the visual fits shown,
we cannot distinguish between the two parameter sets when using Data set 1. However,
in future tests we find that there are slight differences in the ability of the two parameter
sets to describe the growth of the population at low antibiotic concentrations (in Data
set 2 and cell count data - see Section 2.3.2.
The qualitative differences between Θ1 and Θ2 emerge when we use the model to
predict the population growth over a longer time only for the case when 2µg ml−1 is added
(for higher concentrations population eradication occurs for both parameter sets). Figure
2.5 (a) displays the model solution for the predicted growth of the bacterial population
over a time of approximately 10 days using parameter set Θ1: the model predicts the
eventual elimination of the population due to antibiotic effects and an exhausted nutrient
supply. In contrast, if we simulate the experiment for this time using Θ2, we get the results
shown in Figure 2.5 (b). The results indicate that instead of the population dying out, we
would expect a large growth recovery period shortly after the time of the experiment, with
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Figure 2.4: The solution to the system (2.1)-(2.5) with Θ1 (blue dashed line) and Θ2 (green
dotted line). Initial conditions are taken from Table 2.4, for (a) 2µg ml−1, (b) 4µg ml−1,
(c) 10µg ml−1, (d) 20µg ml−1, (e) 40µg ml−1 and (f) 200µg ml−1 of meropenem. These
results are plotted along with the data points (red crosses) from Data set 1 with errorbars
displaying the standard deviation of the means of three biological replicates. Data values
are measured in optical density (OD); we formulate the solution for OD using the equation
OD(t) = H(t) + S(t)
2
.
the optical density levels surpassing those measured in the experiments. This is followed
by a slow, natural death phase caused by nutrient depletion. To explain this, we break
down the solution in Figures 2.6 (a)-(d). These single variable solutions show that when
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using Θ2, the antibiotic degrades at a higher rate than under parameter set Θ1. Due to
the higher antibiotic depletion rate, we predict that the antibiotic will be unsuccessful
in killing off the bacteria and growth resumes until around 5000 minutes when nutrient
supply depletes and slow natural death dominates. The nutrient levels predicted using
Θ1 indicate that the nutrient is almost completely used up before the antibiotioc has
fully degraded from the system. Consequently, bacterial growth cannot exceed death and
this results in the population being eradicated by the antibiotic. We also notice, when
modelling the system using Θ2, that the population of spherical cells depletes entirely,
shortly after the antibiotic is expended: the cells revert back to the native bacillary
morphotype, as witnessed in the results in [75] and our microscopy results in Figure 2.1.






















Figure 2.5: The long term solution to the system (2.1)-(2.5), using parameter sets (a) Θ1
and (b) Θ2 from Table 2.3, with A0 = 2. Parameter set Θ2 has a faster rate of antibiotic
loss due to internalisation and this results in the antibiotic degrading from the system
before it can sufficiently eliminate the bacteria. For higher concentrations of antibiotic
we see the bacteria being eliminated by the antibiotic for both parameter sets (results
omitted).
These qualitatively different characteristics result from varying values of only two pa-
rameters and indicate the sensitivity of the model solution to these parameters. Further-
more, the differences in parameter values indicate that it is the value of ρ̃ that determines
whether we predict population eradication or recovery. Θ1 has a slower rate of natural
antibiotic degradation, α, yet it is possible to use a higher value for this parameter and
this still results in the population dying out sooner (results omitted). The difference in
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Figure 2.6: The individual variable solutions to system (2.1)-(2.5) with A0 = 2. The
solution using Θ1 is represented with a blue dashed line and the green dashed-dotted line
represents the solution using Θ2 for (a) rod-shaped cells, (b) spherical shaped cells, (c)
antibiotic concentration and (d) nutrient. We note that these solutions are simulated
over a longer time series than the experiments. The results for higher concentrations of
antibiotic follow the trend of Θ1 for each variable when using either parameter set. The
only exception to this is the predicted growth of H when using Θ2; here the population
of H is eradicated to low OD values for all higher values of A0.
our values of ρ̃ is less significant numerically than that for α yet drastically changes the
estimated growth characteristics of the bacteria.
2.3.2 Parameter testing
Testing OD predictions
To test our parametrisation results, we use Data set 2 to examine whether the parameters
obtained can successfully fit the data acquired from an additional biological replicate, with
differing initial antibiotic concentrations. Initially we tested the parameters obtained
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using the growth curve in the absence of meropenem; by fixing these parameters yet
allowing the initial condition to be fitted to the new data, we are able to successfully
describe the growth curve of the new data. The results, shown in Figure 2.7, show that
although we are not able to capture all the detailed dynamics of growth, the growth rates
found for the initial data set are able to predict the overall behaviour of the new data set











Figure 2.7: The solution to the system (2.1)-(2.5) using the parameters in (2.10), plotted
with the additional test data for the growth curve of P. aeruginosa (Data set 2). Using
fminsearch we get a relative error value of R = 0.002 with an estimated initial condition
H0 = 0.2 when using growth rates (2.10).
After testing Θ1 and Θ2 against the new data set that includes the addition of antibiotic
we obtain the results displayed in Figure 2.8. Although both parameter sets are suitable
in describing the general trend of the curves for the higher concentrations of antibiotic
(≥ 2µg ml−1), Θ1 appear to describe the dynamics of the new kill curve data at the lower
concentration more successfully. Θ1 gives a relative error value of R = 0.014 and the
model captures the general trend of each curve at the earlier and later timepoints but
does miss some qualitative behaviour at intermediate timepoints (the dip in OD prior to
regrowth observed in Figures 2.8 (a)-(c) does not emerge). Nevertheless the model fits
the test data (including new concentrations) sufficiently well to proceed to the subsequent
analysis of the parametrised model. We note that the initial conditions have been fitted
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to the data; fixing the initial conditions results in a similar prediction for Θ1 and using
Θ2 the model overestimates growth.


































































Figure 2.8: The solution to the system (2.1)-(2.5) with Θ1 (blue dashed line) and Θ2 (green
dashed-dotted line). These results are plotted along with the data points from Data set
2 (along with standard deviation errorbars) with initial antibiotic concentrations of (a)
0.5µg ml−1, (b) 1µg ml−1, (c) 5µg ml−1, (d) 10µg ml−1, (e) 50µg ml−1 and (f) 100µg ml−1
meropenem. The initial conditions were estimated using the initial data points as initial
estimates. Data values are measured in optical density (OD); we formulate the solution
for OD using the equation OD(t) = H(t) + L(t)
2
.
Additionally, we notice that the experimental results using 0.5µg ml−1 and 1µg ml−1
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display periods of population regrowth at later timepoints, a result that is also seen in
the microscopy results at 22 hours (see Figure 2.1). The model predicts this behaviour
(over a longer timeframe) when using Θ2 for an initial concentration of 2µg ml
−1. Using
antibiotic concentrations from Data set 2, Θ1 can also successfully describe the post-
antibiotic regrowth phase for lower concentrations, as well as predicting the eradication
of the population using higher concentrations.
Testing the parameter sets against this new data suggests Θ1 may be a more viable
parameter set but importantly we reiterate the dependence of these fits on the values of
the unidentifiable parameters related to antibiotic decay. Furthermore, we shall see below
that when comparing against a different experiment, Θ2 may match the data better.
Using Data set 2 has enabled us to test the OD predictions of the model, however, the
OD measurements provide no insight into the proportions of rod-shaped and spherical
cells within the total population. In order to validate our model predictions further we
use microscopy results to estimate the contribution of each subpopulation to the overall
OD value.
Calibration against microscopy images
The images in Figure 2.1 give glimpses of the bacterial population at 3 time points of
the experiment and we can clearly see that a shape transition is occurring during the
experiment. The proportion of different phenotypes visible in further images under 3
conditions and at 3 timepoints were obtained using the cell counter plug-in for Fiji [96, 97].
Visible in many of the images were cells that were of an intermediate form or filamentous
and following the assumptions of the model, bacteria of all phenotypes that were not
completely spherical were contained in the rod-shaped population. For each concentration
and time point we obtained up to 7 images; Table 2.5 displays the mean proportions of
each of the subpopulations over the various images used.
To compare the cell count results to the model solutions, the model solutions must be
scaled from OD to cell number. We use the scaling given in [56] where an OD measurement
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Table 2.5: The average proportions of each bacterial subpopulation, obtained using the
microscopy images. The values in this table were obtained by counting the number of cells
in each subpopulation in each slide. The proportions were then calculated by dividing the
number of cells in a each subpopulation by the total number of cells in the image. The
mean proportion was then taken.
Antibiotic concentration Subpopulation
Time (Number of images)
1 hour 6 hours 22 hours
0µg ml−1
H 1 (5) 1 (6) 1 (7)
L 0 (5) 0 (5) 0 (5)
0.5µg ml−1
H 0.981 (6) 0.781 (6) 0.989 (6)
L 0.019 (6) 0.219 (6) 0.011 (6)
2µg ml−1
H 0.95 (5) 0.411 (5) 0.953 (6)
L 0.05 (5) 0.589 (5) 0.047 (6)
of 1 is given as equivalent to 2.04×108 cells. Comparing the model predictions to the cell
count data gives the results displayed in Figure 2.9. For the case when no antibiotic is
added we see that the microscopy results match the model predictions exactly; since no
antibiotic is in the system we would not expect the bacteria to transition and therefore we
only see and predict rod-shaped cells. As we add antibiotic, we find that the microscopy
counts match the model predictions well for the majority of timepoints, especially when
using Θ2. Qualitatively, for both parameter sets (and quantitatively for Θ2), we get a
good comparison for the lower concentration of 0.5µ g ml−1; less than half of the bacteria
transition to the spherical form over the first few hours of the experiment before the
population becomes almost entirely comprised of rod-shaped cells towards the end of the
experiment. As we increase the antibiotic concentration we get a very good comparison
over the first two timepoints but at the final timepoint we notice some disparity between
the cell counts and the model solutions. Qualitatively, the solution using Θ2 is equivalent
to the microscopy result. Θ1 predicts different qualitative behaviour with a long-term
persistent population of spherical cells. At higher concentrations of meropenem, both
parameter sets predict this and this is reflected in the killing curve data where significant
growth does not occur at these higher concentrations. Qualitatively the experimental
data shows the spherical cells transitioning back to rod-shaped more quickly than that
captured by Θ2. However, the fragility of the spherical cells will influence the experimental
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result: in [75] it was found that spherical cells would easily burst when placed directly
between the slide and coverslip. It is likely that this also would have occurred during our
experiments, thus leading to fewer spherical cells being visible in the images. It is therefore
possible that the population appears to transition back to fully rod-shaped quicker than
it actually would since many of the spherical cells in the sample could burst before the
image was taken.
Given the good qualitative and quantitative agreement between the data sets and
either Θ1 or Θ2 (depending on the type of data), we proceed our analysis using both
parameter sets. Recall that the difference between the two data sets results from two
unidentifiable parameters; continuing with both parameter sets we can ensure a compre-
hensive range of plausible qualitative behaviour is explored.
2.3.3 Manipulating the morphological transition
Our primary interest in formulating this model is to investigate the proposed morpholog-
ical change observed in our experimental data of P. aeruginosa. This shape transition
has been associated with the ability of the bacteria to withstand high levels of antibiotic
and using suitable parameters we can reproduce the bacterial regrowth witnessed in our
experimental data. We can now manipulate the system by changing parameters associ-
ated with the transition mechanism to investigate the impact the shape transition has on
bacterial susceptibility and produce predictions that could facilitate treatment design.
Figures 2.10 (a)-(f) display numerical simulations used for the analysis in this section.
We note here that the results using Θ1 are qualitatively the same regardless of the initial
antibiotic concentration and these are also similar to the results when using Θ2 with
initial antibiotic doses of > 2µg ml−1. The results for Θ2 differ for higher (> 2µg ml
−1)
and lower (2µg ml−1) antibiotic concentrations and therefore we only include simulations
using Θ2 for brevity (i.e. the Θ1 results are equivalent to the Θ2 results at 10µg ml
−1).
We have chosen to display simulations using the initial antibiotic dose of A0 = 2µg ml
−1
as the results in this case differ from the other concentrations and A0 = 10µg ml
−1 as this
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Figure 2.9: The variable solutions with respect to total population for H with (a) A0 = 0,
(c) A0 = 0.5, (e) A0 = 2, and L with (b) A0 = 0, (d) A0 = 0.5 and (f) A0 = 2. Solutions
were obtained by solving the system (2.1)-(2.5) using Θ1 (blue dashed) and Θ2 (green
dashed-dotted). The red markers show the proportion of each subpopulation with respect
to the total number of cells counted in the microscopy images. The errorbars indicate the
standard deviation over the multiple images used.
case represents a clinically relevant antibiotic concentration.
Inhibiting the change from rod-shaped to spherical cells
To propose that the morphological transition is a defensive mechanism that occurs due to
antibiotic exposure would imply that inhibition of this mechanism would be detrimental to
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Figure 2.10: The solution to the system (2.1)-(2.5) using Θ2 and varying the parameters
(a) γ for the case where A0 = 2, (b) γ for the case where A0 = 10, (c) δ for the case where
A0 = 2, (d) δ for the case where A0 = 10, (e) ψ, when A0 = 2 and (f) ψ when A0 = 10.
The default values, found via paramterisation, are depicted by the red solid lines. Values
for all varied parameters have units min−1.
the bacteria. By decreasing the transition rate γ we can examine whether inhibition may
lead to enhanced antibiotic action and scrutinise the impact of the transition mechanism.
Figures 2.10 (a)-(b) illustrate numerical simulations of the experiment varying γ using
Θ2 and initial antibiotic doses of 2µg ml
−1 and 10µg ml−1 respectively. At 10µg ml−1,
these simulations imply that inhibiting the transition to a spherical morphology would
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initially lead to higher OD levels but in all cases we ultimately achieve increased antibiotic
action with the bacterial population being eradicated faster than when we use the default
value of γ from the respective parameter set. The higher initial OD levels are a conse-
quence of having more rod-shaped cells in the system as they have a higher contribution
to the OD than the spherical cells.
A different result is obtained in Figure 2.10 (a). In this case we see that though a
decrease in γ will result in an increase in OD levels initially (as above), the population
will grow to the same value regardless of the decrease in transition rate. This population
value is reached once the antibiotic dose of 2µg ml−1 has been exhausted and the system is
reduced to equations (2.7)-(2.8). Bacterial growth once again becomes dependent on the
proportion of nutrient remaining in the system and as this depletes, bacterial growth is
unable to exceed bacterial death, resulting in a post-antibiotic, post-nutrient death phase.
Thus the transition to spherical cells may be considered a long-term defence mechanism
only at higher concentrations of antibiotic.
Inhibiting the reverse transition
Our microscopy results support the conclusion made by Monahan et al. that P. aeruginosa
bacteria are able to transition back to rod-shaped cells after transitioning to a spherical
form [75]. This reverse transition grants the bacteria the ability to resume growth and in
Figure 2.6 (a)-(b) we saw results that indicate the impact of this mechanism on restoring
the bacterial population size. Decreasing δ, the transition rate from spherical to rod-
shaped bacteria, from its estimated value illustrates how inhibiting this mechanism would
impact the survival of the bacteria.
Figure 2.10 (c)-(d) show the results of these simulations. Our variable solutions (omit-
ted) indicate that for all initial antibiotic concentrations and using both parameter sets,
decreasing the rate of the reverse transition predicts a higher population of spherical cells
and fewer rod-shaped cells, as might be anticipated. If we inhibit the transition sufficiently
(δ < 1 × 10−4 min−1), the model predicts similar overall population levels (OD600 values
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of around 0.2), that are made up entirely of spherical cells, regardless of the parameter
set used or the initial antibiotic concentration (compare the blue and pink lines in Figures
2.10 (c)-(d)). Since we have assumed that the spherical cells cannot proliferate but do
evade antibiotic effects, the larger spherical cell population results in prolonged antibiotic
and nutrient availability. Consequently, this predicts a system where though spherical
cells can transition back to a rod-shape at a much slower rate, in doing so they become
exposed to the effects of the unused antibiotic. Alternatively, they die naturally due to
their inherent fragility and this produces an extended death phase that ultimately leads
to population eradication, but over a much extended period of time than simulated. Con-
versely, if the level of inhibition is not sufficient then we predict lower population levels
initially than with default parameters, although behaviour is the same over the prolonged
period of time.
In cases where the antibiotic was previously unable to eradicate the population (for
example when we simulate the case of 2µg ml−1 using Θ2), inhibiting the transition at
which spherical cells can revert back to the bacillary form is advantageous to us as it
extends the efficacy of the antibiotic. This is reflected in Figure 2.10 (c) where we see
that the population level predicted through sufficient inhibition is less than that predicted
when using the default value. However, Figure 2.10 (d) displays the results when we use
parameter set Θ2 and let A0 = 10µg ml
−1; this represents a system that would have
previously predicted population eradication and by inhibiting the transition, we see that
the total population level achieved through sufficient inhibition is larger than we predicted
when using the default parameter value. Restricting the reverse transition interferes with
the antibiotic action and prevents the antibiotic from killing the bacteria. This result is
reiterated when using Θ1 for all initial concentrations and Θ2 for concentrations above
2µg ml−1.
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Investigating the use of antimicrobial peptides
In addition to investigating and establishing the existence of the transition mechanism,
Monahan et al. experimented with the use of antimicrobial peptides (AMPs) as an ad-
ditional antimicrobial agent. These AMPs are relatively inactive against rod-shaped P.
aeruginosa as they induce cell death by creating pores in the cytoplasmic membrane,
which remains unexposed in normal bacillary cells. However, they found that spherical
cells displayed large areas of exposed cytoplasmic membrane which gave reason to believe
that they would be more susceptible to the bactericidal effects of AMPs. This hypothesis
was supported by experimental data that saw a combination therapy of meropenem and
AMPs leading to lower bacterial load [75].
We can reproduce this theoretically by increasing the death rate of spherical cells, ψ.
Increasing the death rate ψ is equivalent to administering AMPs; these results are shown
in Figures 2.10 (e)-(f). An expected increase in spherical cell death and consequently a
decrease in rod-shaped cells results in faster population suppression for all concentrations
and both parameter sets. The depleted spherical cell population means that fewer cells
transition back to their native bacillary form and lower OD levels are achieved overall.
We note that for the case of 2µg ml−1 using Θ2 ψ must be increased from its default
value more than is required for the other cases for the AMPs to successfully assist the
meropenem in killing off the bacteria population, in comparison to cases with higher
initial antibiotic concentration or using Θ1. However, under all parameter conditions,
any increase in spherical cell death results in lower OD predictions and this reinforces
the results of Monahan et al. and advocates the use of meropenem in combination with
AMPs as a potential therapy for treating P. aeruginosa.
2.4 Discussion
Following the conclusions made by Monahan et al. [75] and supported by our own data,
we have formulated a model that describes the growth dynamics of P. aeruginosa in the
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presence of meropenem, with the inclusion of a subpopulation of cells with an incomplete
cell wall that results in an altered shape and size. We have made assumptions regarding
the inducement of this morphological shift and by successfully fitting it to experimental
data we obtained two parameter sets that successfully fit the data yet result in qualita-
tively different predictions of the long-term bacterial dynamics and different predictions
when we investigate the values of some of the model parameters. The values of the
antibiotic-attributed parameters were found to determine whether the bacterial popula-
tion survived antibiotic action when the initial antibiotic concentration was 2µg ml−1. We
notice that this is around the MIC value for meropenem when used to treat P. aerugi-
nosa and this could describe the system sensitivity to the antibiotic parameters at this
antibiotic concentration.
By formulating a mechanistic model we have obtained parameter values that are not
only potentially measurable but are also more meaningful and directly relate to the
amount of nutrient in the experiment. The model can successfully describe the over-
all trends witnessed in the growth curves and although the model does not capture the
growth dynamics over the first few hours of the experiment perfectly, the impact of this
on the applications of this model is arguable as our interests lie with the long term pre-
dictions of population growth, which are accurately predicted. The error over this region
increases for the higher antibiotic doses yet we note these are much higher than the rec-
ommended clinical dose of 10− 20µg ml−1, therefore any discrepancies obtained for these
concentrations should have no clinical relevance. We also take note of the large error bars
for the initial condition: the high level of variance between the measurements taken at
this time point means it could be difficult to achieve a fit of high confidence in this region
regardless. Furthermore, having parametrised the model from total bacterial load (OD
measurements) the model is then able to correctly predict the underlying dynamics of the
individual rod-shaped and spherical populations (calculated from the microscopy data).
Manipulation of the parameters obtained allows us to investigate the impact of inhibit-
ing the transition mechanism. Our results suggest that inhibiting the spherical transition
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would be detrimental to bacterial populations in most cases with inhibition leading to
faster depletion and lower OD levels over a long time scale. An exception to this is when
we use parameter set Θ2 and initial antibiotic concentration of 2µg ml
−1; in this case,
inhibition is only detrimental to growth in the short term, whereas long term predictions
are the same regardless of the level of inhibition. In most cases (including all antibiotic
concentrations for Θ1) the results imply that inhibition of the spherical transition would
be desirable in treating a P. aeruginosa infection and thus support the hypothesis that
this may be an intrinsic defence strategy of the bacteria.
When the transition to spheres was inhibited, the simulations also displayed a char-
acteristic of higher OD levels over the first few hours than with no inhibition; if these
results were to be directly translated to an in vivo infection, this could imply a higher
level of bacterial virulence. However, in order to formulate biological conclusions based
on these results we must consider the virulent properties of the different cell types we
include in the model. A higher OD value does not automatically signify a higher level of
virulence since we cannot assume that the virulence of spherical cells is half that of the
rod-shaped cells, an assumption we make for the OD. Virulence in P. aeruginosa is to a
large extent based on the Type III secretion system and secreted toxins; both of which
depend on outer membrane components for successful secretion. It is probable that the
spherical cells are less virulent than the rod-shaped cells due to their compromised outer
membrane. If this assumption is correct then although inhibition of the shape transition
predicts higher antibiotic action over the total time, a higher initial bacterial load would
not be a desirable effect of a treatment when these are predominantly rod-shaped cells.
Increased virulence could be threatening to a patient’s health and this would be especially
dangerous when treating immunocompromised patients.
An alternative strategy would be to target the reverse reaction and our results indicate
that this approach could be beneficial, depending on the virulent properties of the spher-
ical cells. By inhibiting this reaction we predict a higher proportion of spherical cells and
this enables successful suppression of a lower proportion of remaining rod-shaped cells
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without exhausting the antibiotic supply. Following this phase of rod-shaped cell death,
the model predicts that for sufficient inhibition, the bacteria attains similar spherical-only
population levels regardless of the parameter set used or initial antibiotic concentration.
Though in many cases the estimated population level is higher than we would predict
using the default parameter values, this would not be an undesirable outcome under the
assumption that spherical cells are not as virulent as rod-shaped cells due to the compro-
mised cell membrane.
Owing to the high proportion of spherical cells we predict when inhibiting the spherical
to rod transition, we could consider the combination therapy of meropenem and AMPs
with a drug that would inhibit the reverse transition. Simulations suggest that if we
sufficiently inhibit the reverse transition rate then any increase in spherical cell death
would result in faster killing of the bacterial population and extended antibiotic presence
regardless of the parameter set used or initial antibiotic concentration (results omitted
for brevity). Here we define sufficient inhibition of the reverse transition to be when we
choose a value for δ that predicts population levels comprised of mostly spherical cells.
If we do not attempt to inhibit the morphological transition and instead pursue the
application of a drug that increases the death rate of spherical cells alone, we predict lower
OD levels. This supports the results detailed in [75] that promote the use of AMPs as
a supplementary agent in combination therapy with the meropenem and empiric studies
have also found that β-lactam and AMPs act synergistically to inhibit growth [116]. In
Chapter 4 we extend the investigation into the use of AMPs in order to explore whether
they maintain a synergistic relationship with meropenem at the site of infection.
We have formulated a model to predict the growth dynamics of P. aeruginosa wit-
nessed in vitro. In order to make conclusions in a clinical setting we would have to
translate the model to an in vivo model and extend it to include antibiotic dosing instead
of the single antibiotic application used in our experiments. We would also need to con-
sider how nutrient availability would differ in vivo. Nutrient availability in vivo is likely
to be lower than in the nutrient rich growth media used in experiments, but it may be re-
72
plenished over time. Numerical simulations (omitted) indicate that if nutrient-abundance
is maintained for longer, the bacteria may withstand higher concentrations of antibiotic.
In conclusion, by formulating a model based on biological mechanisms, including a
morphological transition, into a mathematical model for population growth, we have suc-
cessfully obtained parameters values that describe the rates of the mechanisms involved.
Crucially, extending this model will allow for a better prediction of how these potential
therapies may impact the emergence and development of drug resistance and parameter
analyses could hint at strategies to combat the threat of resistance. Our analysis suggests
that inhibition of the morphological transition could be a suitable target for a treatment
strategy.
In the following chapter we extend Model I to include active efflux. By incorporating
the upregulation of efflux, we formulate a model that is capable of describing the growth
dynamics of a susceptible and a resistant strain.
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CHAPTER 3
MODELLING RESISTANCE TO MEROPENEM
VIA UPREGULATION OF EFFLUX PUMPS
P. aeruginosa infections can be remarkably hard to treat, along with other nosocomial
infections, due to the ability of P. aeruginosa to express intrinsic resistance mechanisms
and acquire further resistance via mutation or HGT.
Monahan et al. obtained experimental data that exhibited the population wide shape
transition of a meropenem-susceptible strain of P. aeruginosa. Using microscopy, we
reproduced these results with the meropenem-susceptible PA1008 strain (see Figure 2.1)
and the partially resistant PA1004 strain. The microscopy results for the PA1004 strain,
shown in Figure 3.1, indicate that the meropenem-resistant P. aeruginosa cells transition
from a rod to spherical shape (as the susceptible PA1008 strain does), yet the higher
number of viable cells in these images, compared to the images for PA1008, indicate
resistance to meropenem.
In Section 1.3 we discussed the main resistance mechanisms that are attributed to
resistance in P. aeruginosa. Along with restricted porin channels, the upregulation of
efflux and the overproduction of β-lactamase are the most commonly encountered resis-
tance mechanisms of P. aeruginosa. Whilst porin channel restrictions and active efflux
both reduce the intracellular uptake of antibiotic molecules, β-lactamases act to inactivate
antibiotic molecules that manage to translocate into the periplasmic space. These mecha-






Figure 3.1: Cells of the partially meropenem-resistant P. aeruginosa PA1004 strain
rapidly convert to a spherical shape after adding (a) 0.5µg ml−1 and (b) 2µg ml−1 of
meropenem before reverting back to a bacillary form. Microscopy images were taken
after 1, 6 and 22 hours. Left panels: transmitted light, right panels: fluorescence mi-
croscopy. In fluorescence images, green and red colouring indicates viable and lysed cells
respectively.
PBPs and enable P. aeruginosa populations to survive antibiotic exposure. Meropenem
resistance by PA1004 is assumed to be as a result of the action of efflux pumps and al-
though other mechanisms, such as β-lactamase production, may play a role in resistance,
we will focus on active efflux as being the primary resistance mechanism.
Mathematical models of antibiotic resistance often incorporate the effects of resistance
via a change in pharmacodynamic properties of the antibiotic. Often, these models de-
scribe the growth of a susceptible and resistant strain simultaneously. For example, in
[10], the resistant and susceptible bacterial populations are assumed to have different
MICs. A general approach is also taken in [29], with the different strains possessing dif-
ferent mortality rates depending on whether they bear a resistance plasmid. Similarly,
in [44, 102], antibiotic effects are modelled using a density dependent term, identical to
the term used in Model I; the effects of antibiotic resistance are modelled using different
maximum kill rates and half-maximal antibiotic concentrations for the two strains. Both
of these examples do not specify a resistance mechanism and instead focus more on the
resultant effects of resistance on bacterial growth or death.
Mechanistic representations of antibiotic resistance are somewhat rarer. In [74] a
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model was formulated to describe the efflux of a drug in and out of a cell. The intercellular
model comprises two ODEs and a PDE that incorporates efflux via facilitated diffusion.
The energy-dependent efflux mechanism is modelled using a PDE that explicitly depends
on binding between the drug substrate and energy levels within the cell; the enzyme
kinetics of this reaction produces an ODE model using Michaelis-Menten kinetics. In [33],
the finite difference method is applied to a reaction-diffusion model for biofilm growth.
Diffusion of β-lactamases into the extracellular domain is investigated and the results
suggest that the release of β-lactamases upon bacterial lysis should be considered as it
could decrease the extracellular antibiotic concentration and aid biofilm growth.
We wish to extend Model I to include efflux of intracellular antibiotic; we will extend
this model in later chapters to include a mixed population of susceptible and resistant
bacteria, similar to those in [10, 30, 44, 102].
3.1 Model formulation
We formulate a model that describes the growth of a single strain of P. aeruginosa in
isolation with meropenem in which efflux of meropenem can be accounted for. Following
the microscopy results we continue to include a shape transition and we extend Model I by
including the possibility of resistance via active efflux. Our model follows the interactions
described in Figure 3.2.
To include active efflux within our model we will differentiate between cells that have
internalised bound antibiotic and those that do not. Bacteria do not lyse due to antibi-
otic effects unless the antibiotic has successfully bound to the penicillin binding proteins
(PBPs) within the cell, and therefore we introduce a new variable I to represent the rod-
shaped cells with internalised bound antibiotic. Note that the term ‘internalised’ is used
throughout and refers to the antibiotic successfully entering and binding within the cell.
In accordance with this new variable, we amend the definition of H to be the pop-















Figure 3.2: Schematic representation of the transitions of P. aeruginosa in response to
exposure to meropenem with the inclusion of active efflux. The species shown are de-
fined as follows: H are rod-shaped cells with no bound antibiotic, I are rod-shaped cells
with bound internalised antibiotic and L are spherical cells. When the antibiotic, A, is
introduced, rod-shaped cells can make the reversible transition to a spherical shape. The
antibiotic can internalise within the bacteria and bind to the PBPs, causing the bacte-
ria to transition to the I population and quickly lyse. The antibiotic is assumed to be
effective at killing rod-shaped cells but not spherical cells due to a depleted cell wall.
Rod-shaped cells can proliferate but we assume that spherical cells cannot proliferate and
that proliferation of the I population will be negligible. Spherical cells can lyse naturally
due to the fragile nature of these cells. Active efflux results in a decrease in successful
binding of antibotic molecules within a cell and its effects are incorporated into the arrow
fom H to I. Note that we do not include natural death of the rod-shaped cells with no
internalised antibiotic as this is assumed to be negligible using the parametrisation results
in Chapter 2.
spherical cell population is described by L and we omit the equation for lysed cells. Bacte-
ria that lyse will disappear from the culture and we assume that their contribution to the
bacterial population will be negligible. The rod-shaped bacterial subpopulations are now
separated by whether they contain bound antibiotic and therefore we define the variable
A to be the concentration of unbound antibiotic. We wish to investigate total population
growth in addition to the growth of the bacterial subpopulations and hence we define B
to be the total bacterial population such that,
B = H + I + L. (3.1)
77
As we hope to extend this model in later chapters to include a host response it is
important to consider how nutrient availability would differ at a site of infection and in
vitro. Although we can assume that in vivo nutrient availability could be less abundant
than the nutrient rich broth used in vitro, it is also likely that there would be some
influx of nutrient at the site of infection. Subsequently, we may expect to see a low but
constant level of nutrient availability in vivo, compared to the nutrient rich broth used in
experiments. Following this, and since we have limited insight into nutrient availability,
a nutrient dependent growth term, similar to the term used in equation (2.1), would be
unsuitable to use. As nutrient levels in vivo are unknown, and would ultimately depend
on the site of infection, we choose here to model growth using a term that does not depend
explicitly on nutrient availability. It is expected that bacterial growth would saturate over
time, due to limitations of space and nutrient and therefore we use a logistic term to model
bacterial growth as this provides the model with a means of growth that is not dictated
by an unknown level of substrate. We use the growth function,






where G(H) defines the growth of the rod-shaped bacteria with no internalised antibiotic,
r is the maximum growth rate, k is the carrying capacity and c is the fitness cost. The
upregulation of efflux, along with the expression of multiple resistance mechanisms, can
compromise bacterial growth. Hence we attach a fitness cost to the bacterial growth term
so that we can consider the effects of resistance on bacterial growth when modelling a
resistant strain. It is possible to model a fitness cost by including separate growth terms
for the different strains or by incorporating a fitness cost explicitly into the model by
introducing a fitness cost parameter, c, that can take values between 0 and 1 [10, 64, 102].
By including a fitness cost parameter we can easily explore different growth rates for the
resistant strain as a proportion of the growth rate of the susceptible bacteria. Introducing
a fitness cost parameter will incur a penalty to the growth that can be set equal to zero
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when modelling a susceptible strain and vary when simulating a resistant strain.
Note that our growth term is specific to the population of rod-shaped cells with no
internalised antibiotic. We assume that following successful internalisation, the antibiotic
molecules will inhibit cell wall synthesis, which will disrupt the proliferation process. We
assume that proliferation of the bacteria with bound antibiotic will be severely limited by
the antibiotic and successful proliferation will be negligible in comparison to the rate of
antibiotic-induced death. Following from Chapter 2, we assume that the cell wall deficient
spherical cells lack the machinery needed to successfully proliferate and subsequently we
only include proliferation of the rod-shaped cells with no internalised antibiotic within
the model.
Antibiotic internalisation is modelled using the function,
B(A,H) = (1− ω) νA
A+ A50
H, (3.3)
where B(A,H) defines the internalisation of the antibiotic in the rod-shaped cells, ν
is the maximum internalisation rate, A50 is the concentration needed for half maximal
internalisation and ω is defined as the efflux pump upregulation parameter.
We use a density-dependent term as attempts at using a linear term to model inter-
nalisation were unsuccessful (results omitted) and it is likely, due to the inherently low
membrane permeability of P. aeruginosa, that antibiotic molecule translocation across
the cellular membrane would saturate quickly. We assume that prior to the antibiotic
successfully binding, the bacteria will not be susceptible to antibiotic-induced death and
hence the population of internalised bacteria, I, are assumed to have bound antibiotic
within the cell.
We choose to model the upregulation of efflux via a decrease in internalisation (i.e.
we assume that antibiotic is effluxed sufficiently rapidly that it can be assumed to be
effectively instantaneous) and hence the efflux upregulation parameter, ω, can take values
between 0 and 1; as ω increases the internalisation rate will decrease. Modelling resis-
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tance via a decrease in internalisation differs from the models in [10, 30, 44, 102], where
resistance results in a direct effect on antibiotic action. We assume that efflux will affect
antibiotic-induced death indirectly; once an antibiotic molecule has bound within the cell,
bacterial lysis will occur at the same rate regardless of efflux. Efflux directly decreases
the intracellular antibiotic concentration and thus decreases the rate of antibiotic binding.
Hence by including the internalisation term within the model and assuming that efflux
affects the binding process, a more mechanistic approach is used. Furthermore, this ap-
proach facilitates future model developments that will include regulation of the genetic
network involved in efflux.
Before the antibiotic successfully internalises, the bacteria may transition to a spherical
shape. We define the transition of the rod-shaped bacteria with no internalised antibiotic





A density dependent term is used to describe the morphological transition, with maximum
transition rate γ and antibiotic concentration needed for half maximal transition, T50.
We continue to assume that the bacteria can transition back to the rod-shape but we
now assume that the reverse transition only occurs when the concentration of unbound












with slope parameter b, critical antibiotic threshold Ac and maximum reverse transition
rate, δ. Once the antibiotic concentration reaches the critical threshold, the cell wall
deficient bacteria will transition back to the rod shape and resume proliferation.
Our parametrisation results in Chapter 2 indicated that the rate of natural death
of the rod-shaped cells with no internalised antibiotic may be low. Here, we assume
that natural death of the H population will be negligible when compared to the rates of
80
internalisation and transition and hence we do not include a separate natural death term
for these rod-shaped cells. If we wished to include natural death then this could easily
be absorbed into the logistic growth term. Similarly, we assume that natural death of
the rod-shaped cells with bound antibiotic will be negligible when compared to the rate
of antibiotic-induced death. We continue to assume that whilst in the spherical form,
the bacteria will completely evade antibiotic effects. However, the spherical cells may lyse
naturally, due to fragility, at a rate ψ. Additionally, the rod-shaped cells with internalised
antibiotic may lyse due to antibiotic effects and we model antibiotic action using a linear
death term with death rate, ρ.
Antibiotic decay is modelled using a natural degradation term that follows first order
kinetics, with decay rate α. Additionally, we include a degradation term for the antibiotic
that is lost due to successful binding within bacteria. We define ν̃ as rate of antibiotic loss
due to internalisation and this is assumed to be proportional to the rate of internalisation,
ν.

























= (1− ω) νA
A+ A50





















H(0) = 104 I(0) = 0 L(0) = 0 A(0) = A0. (3.10)
Variable definitions are given in Table 3.1 and parameter definitions and default parameter
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values are shown in 3.2 (these choices will be justified in Section 3.2), although a range
of values are used throughout. Unless otherwise specified, we use an initial antibiotic
concentration of 10µg ml−1 as this represents a clinically relevant in vivo meropenem
concentration [77, 103]. We choose a relatively small initial population of 104 cells and
assume that no bacteria will transition to the spherical form prior to treatment.
Table 3.1: Definitions and units for the variables in Model II, described by equations
(3.6)-(3.10).
Variable Definition Units
B Total bacterial population cells cm−3
H Rod shaped cells with no bound antibiotic cells cm−3
I Rod shaped cells with internalised bound antibiotic cells cm−3
L Spherical shaped cells cells cm−3
A Unbound antibiotic µg ml−1
It is worth noting here that by separating the bacterial populations into those that
do contain antibiotic and those that do not, we find that antibiotic-induced cell death is
represented by a term that does not explicitly depend on the level of unbound antibiotic.
Whilst this may appear surprising at first, the unbound antibiotic concentration does
affect cell death indirectly via the presence of internalised antibiotic. This differs from
Model I; now only the transitions from H to I and H to L depend explicitly on the
external antibiotic concentration.
3.2 Results
3.2.1 Modelling limited or no antibiotic treatment
Figure 3.3 displays the model solutions using the default parameters for the case when no
antibiotic is added and when we simulate the administration of one dose of meropenem.
Note that we are simulating the growth of a susceptible strain and hence we set both the
efflux pump upregulation parameter and fitness cost to 0. When no antibiotic is added, we
see bacterial growth of the rod-shaped population until it reaches carrying capacity; since
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r maximum growth rate of rod-
shaped cells
day−1 3 [94]
c deduction in growth due to fit-
ness cost attached to carrying
resistance
dimensionless 0.15 [100, 109]
k carrying capacity of rod-
shaped bacteria
cells cm−3 106 [94]
ν maximum antibiotic internal-
isation rate
day−1 1.57 -
ω decrease in internalisation due
to upregulation of efflux
dimensionless 0.5 -
A50 antibiotic concentration
needed for half maximal
internalisation
µg ml−1 0.47 Chapter 2




needed for half maximal
transition
µg ml−1 0.47 -
ρ antibiotic-induced cell death
rate for rod-shaped cells
day−1 100 -
ψ spherical cell death rate day−1 0.017 Chapter 2
δ transition rate from spherical
to rod shape
day−1 10 -
Ac critical antibiotic concentra-
tion threshold for reversion of
spherical cells
µg ml−1 0.5
b smoothed step function slope
parameter
µg ml−1 1 -
α antibiotic decay rate day−1 10 [77, 103]






the transition is antibiotic-dependent we see no spherical cells and clearly no antibiotic
becomes internalised. When one dose is administered we see some bacteria transitioning
to the cell wall deficient state, resulting in an increase in L, and the antibiotic internalises
within some rod-shaped bacteria, resulting in an increase in I. Once the antibiotic is
exhausted the spherical bacteria transition back to the rod shape, the internalised bacteria
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From equation (3.11) we find two steady states: the trivial unstable bacteria-free steady
state,
(H∗, I∗, L∗, A∗) = (0, 0, 0, 0) , (3.12)
and the stable steady state with the bacterial load at carrying capacity,
(H∗, I∗, L∗, A∗) = (k, 0, 0, 0) . (3.13)
In the absence of antibiotic we would expect to reach the stable steady state if the initial
population size is nonzero. Similarly, if any bacteria remain after a dose of antibiotic
has degraded, we would also expect the population to reach the stable steady state. The
true values of the parameters in the model may vary from those in our default parameter
set and it is likely that these parameter values will vary by bacterial strain and site of
infection. However, it is unlikely that one dose of antibiotic would cause the bacterial
population to reach a level at which it would die off completely, especially with the
initial population size used in our simulations. Therefore, in agreement with the model
predictions, we expect that if a single dose of antibiotic was added, the population would
still reach the carrying capacity steady state. If we use the resistant strain parameters
then the results are in agreement with the susceptible strain; a single dose is ineffective
and the population would grow to the steady state (results omitted).
3.2.2 Modelling a constant infusion of antibiotic
The model suggests that the effects of one dose of antibiotic would be insignificant and
this is in line with typically used dosing strategies; it is unlikely that one bolus dose
of antibiotic would be given as we would not expect this limited amount of antibiotic
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Figure 3.3: The solution to the system (3.6)-(3.10), using default parameter values shown
in Table 3.2, with A0 = 0µg ml




exposure to eradicate a bacterial population. Instead a number of repeated doses or a
continuous infusion of meropenem is more likely to be administered. For this model we
focus on the latter case, of a continuous dose and we continue to use a clinically relevant
steady state antibiotic concentration of 10µg ml−1 [77, 103].
If the constant antibiotic concentration is higher than the critical antibiotic threshold,
Ac, then we would expect the spherical cells to remain dormant for the duration of the
dosing regimen. Our microscopy images suggest that the bacteria transition when A0 =
0.5µg ml−1, but we do not know whether the transition would occur at lower antibiotic
concentrations. Therefore, we use Ac = 0.5µg ml
−1 as an upper bound for the critical
threshold value for the reverse transition. The continuous infusion dose of 10µg ml−1 is
much greater than the default critical threshold antibiotic concentration and therefore
we assume that the effects of the reverse transition on the population solutions will be















= (1− ω) νA
A+ A50











H(0) = 104 I(0) = 0 L(0) = 0 A(0) = A0. (3.18)
Solving this system, with the default parameter values produces the solutions shown
in Figure 3.4. The rod shaped cell population with no internalised antibiotic decreases
over time as the bacteria become internalised by the antibiotic or transition to spheres.
We have assumed that the bacteria will not transition back from the spherical form whilst
the antibiotic is present and hence we see the spherical population increases over time.
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As the population of rod-shaped cells decreases, the spherical population reaches a peak
and following this we see a decline due to spherical cell death. Similarly, we see the same
behaviour in the population of rod-shaped cells with internalised antibiotic. A sharp
increase occurs until the H population depletes and the antibiotic-induced death term
dominates the behaviour and causes a decrease in I until the steady state is reached.
Solving equations (3.14)-(3.17) at steady state, we obtain the bacteria-free steady
state,
(H∗, I∗, L∗, A∗) = (0, 0, 0, A0) , (3.19)
and a second steady state,
























We see that the second steady state is dependent on the value of (3.21). For all values of
X < 0 we find that only one non-negative steady state is possible; this is the bacteria-free
steady state (3.19) and it is stable in this region. When X = 0 we find that there is a
transcritical bifurcation and two steady states exist for values X > 0. Firstly we have
(3.19), which now becomes unstable, and secondly we have (3.20), which is stable for all
X > 0 (e.g. see results in Figures 3.5-3.6, which were generated using XPPAUT v8.0).
Using these steady state expressions we are able to gain insight into suitable values
for the estimated parameters for which we do not have any prior information. Firstly,
note that we initially set the fitness cost, c, and upregulation of efflux, ω, parameters
to 0 to represent an antibiotic-susceptible strain. All of the subpopulation steady state
87

















































































Figure 3.4: The solution to the system (3.14)-(3.18), using default parameter values shown
in Table 3.2, with A0 = 10µg ml
−1.
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expressions depend on the value of (3.21), which is dependent on the growth rate, r, and
the internalisation and transition parameters: γ, A50, ν and T50.
Firstly, the growth rate and carrying capacity, k, were chosen from a suitable range of
values obtained via parametrisation attempts in [94] where a bacterial growth model of P.
aeruginosa was fitted to in vivo experimental data taken from burn wounds in rats. We
would expect a continuous infusion of antibiotic to suppress the population of rod-shaped
bacteria with no internalised antibiotic and result in a low steady state value. In order
to obtain a positive steady state value we require a positive value of X and from this we
can infer that,
r > νY + γZ. (3.24)
For simplicity, we assume that A50 = T50 and choose T50 = 0.47µg ml
−1, following the
parametrisation results in Chapter 2. Subsequently, by substituting the chosen values of
A50, T50 and r into (3.24), along with the initial antibiotic concentration A0 = 10µg ml
−1,
we can deduce the following inequality,
3.141 > (ν + γ) . (3.25)
From condition (3.25), we can infer biologically feasible values for the maximum rates of
internalisation and transition for a nonzero steady state to be feasible. This inequality
is obtained using the default parameter values, yet a similar inequality could be found if
the growth-attributed parameter values were to vary. The parameters used to obtain this
inequality are potentially all measurable and provide us with insight into the combined
rates of internalisation and transition. For our default parameter set, for simplicity we
will assume that the maximum rate of transition, γ, is equal to the maximum antibiotic
internalisation rate, ν.
Using the steady state expressions, we can explore the parameter values used and
confirm that changes to the parameter values result in the expected biological result.
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Firstly, we investigate changes to the two death rates: the natural death rate of the
spherical cells, ψ, (which could be altered using AMPs) and the antibiotic-induced death
rate of the rod-shaped cells, ρ (which would change for different antibiotics). By inspection
of (3.20), increasing either death rate results in a decrease in the respective population.
The steady state values of the non-affected populations remain unchanged.
We recall that the carrying capacity, k, defines the maximum size to which the popula-
tion can grow and illustrates the limitations of resource availability on population growth.
If, for example, nutrient availability increased, we would expect the carrying capacity to
increase, allowing for higher population levels. Similarly, if resources were further re-
stricted, the carrying capacity may decrease from the default value and we would expect
lower population levels. The steady state expressions are in accordance to the expected
results with k featuring in the numerator of each of the population expressions.
Next, we investigate the effects that changes to the growth rate have on the steady state
population levels. Figure 3.5 displays the results when we vary the growth rate, r (note
that we have omitted the solution for antibiotic concentration as this remains unchanged).
We vary the growth rate over a range of values taken from parametrisation efforts in [94].
Figure 3.5 indicates that an increase in growth rate would result in higher populations
for all subpopulations, as we would expect. An increase in growth rate would lead to
more rod-shaped cells that are able to transition and evade antibiotic effects, resulting in
a higher total population. In contrast, we find that even a small decrease in growth rate
from the default value leads to predictions of the population dying off completely. Since
we have chosen default values for the rate of transition, ν, and internalisation, γ, based
on the default growth rate, the model solution then becomes dependent on the condition
that X > 0. If the inequality is not met then the system reaches the bacteria-free steady
state.
Following the results of changes to the growth rate, we obtain similar results if we
make changes to the internalisation rate, ν, or the transition rate, γ. Figure 3.6 displays
the steady state values when we vary the internalisation rate; as expected, a decrease
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Figure 3.5: The steady state solutions to the system (3.14)-(3.18) using the default pa-
rameter values shown in Table 3.2, with A0 = 10µg ml
−1 and varying the growth rate, r,
from the default value of 3 day−1. The solid lines represent the region in which the steady
state is stable and the dotted lines show where the steady state is unstable. B is the total
number of bacteria, such that B = H + I + L.
in the internalisation rate leads to higher populations of rod-shaped cells that have no
internalised antibiotic. Subsequently, a higher H population leads to more spherical cells.
The interesting results seen in Figure 3.6 (c) occur due to a balance between the growth
rate of the antibiotic-free bacteria and the internalisation rate. The results indicate that
if we decrease the internalisation rate from the default value then we would expect a
higher steady state for the population of bacteria with bound antibiotic. This could
seem counter-intuitive as we would expect to have fewer bound bacteria if the antibiotic
internalises less efficiently. However, as fewer bacteria have antibiotic binding within
them, there is a larger population of rod-shaped cells that can proliferate and this causes
the higher steady state value for I∗. Decreasing ν sufficiently eventually has the more
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Figure 3.6: The steady state solutions to the system (3.14)-(3.18) using the default pa-
rameter values shown in Table 3.2, with A0 = 10µg ml
−1 and varying the internalisation
rate, ν from the default value of 1.57 day−1. The solid lines represent the region in which
the steady state is stable and the dotted lines show where the steady state is unstable. B
is the total number of bacteria, such that B = H + I + L.
intuitive effect of lowering I∗.
If we increase the internalisation rate, even by a small amount, we see the system
reaches the bacteria-free steady state. This is similar to the effects of decreasing the
growth rate, r, and occurs due to the inequality condition, (3.25), not being met. If the
internalisation rate is increased then bacterial growth no longer outweighs the effects of
the antibiotic and the population will die out.
Varying the transition rate, γ, gives similar predictions to those obtained when we
vary ν (results omitted for brevity); the internalisation and transition rates have similar
effects on the system and this is supported by their relative contributions to the steady
state expressions. Following from these results, we find that if we increase the transition
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rate, from the default value, then we would expect the population to die out. If the
transition rate increases then higher numbers of bacteria transition to the spherical form
and the remaining rod-shaped cells do not proliferate at a rate that would outweigh
antibiotic effects. As the spherical cells do not contribute to population growth, the total
population will die out.
Rather than varying the transition and internalisation rates individually, as previously
shown, we can also investigate the relative sizes of these parameters. Figure 3.7 displays
the results when we consider different parameter pairings for the two rates of internali-
sation and transition; for each parameter pairing, the combined sum of the two rates is
fixed to be 0.314. As the combined value of ν and γ does not differ, the population of
rod-shaped cells with no bound antibiotic does not change. As we increase the internal-
isation rate we witness an increase in the number of bound bacteria, as expected, since
the numerator of the steady state expression increases. Subsequently, we predict fewer
spherical cells as an increase in ν results in a decrease in the transition rate γ. As a result
of the model set up and (3.25), we would expect to obtain nonzero steady state values for
all of the parameter pairings considered. However, our results suggest that the population
would be significantly affected if we set the transition rate to 0 as we predict a very small
steady state population (≈ 300 cells cm−3).
The parameter surveys performed have indicated the dependency of the steady state
expressions, and hence the model solutions, to the expression (3.21). We have used some
parameter estimates in the analysis which could, of course, vary in reality. However, our
analysis indicates a method that can be used to obtain relative parameter values required
for a trivial or nontrivial steady state and is easily adaptable for alternative parameter
choices.
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Figure 3.7: The solutions to the system (3.14)-(3.18) using the default parameter values
shown in Table 3.2 with ω = 0 and A0 = 10µg ml
−1. We vary the maximum rate of
internalisation, ν, and the maximum rate of transition, γ, whilst keeping the combined
sum of these rates to be 0.314. Both ν and γ have a default value of 1.57 day−1 and hence
the default solution is represented by the blue-dotted lines.
3.2.3 Investigating parameter values attributed to a resistant
strain
We have used the model, described by equations (3.14) - (3.18) to describe the growth
dynamics we would expect from a susceptible strain of P. aeruginosa and we have explored
how changes to the parameter values affect bacterial growth. We now wish to investigate
how changes to the parameters attributed to resistance affect the model solutions.
Firstly, we investigate whether we can produce the growth dynamics we would expect
from a resistant strain by increasing the efflux pump upregulation parameter, ω. Efflux
pumps remove antibiotic molecules from the cytoplasm and periplasm of the bacterium
and cause a lower antibiotic concentration within the cell. Subsequently, the effects of
efflux pump upregulation result in a decrease in successful antibiotic internalisation.
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Figure 3.8: The solution to the system (3.14)-(3.18) using the default parameter values
shown in Table 3.2, with A0 = 10µg ml
−1 and varying the efflux pump upregulation
constant, ω from the default value of 0.5.
Increasing the efflux efficacy parameter, ω, produces the results displayed in Figure
3.8. It is clear to see that even a small increase in ω causes significant increases in all of
the bacterial subpopulations. If the bacteria are able to inhibit the successful binding of
the antibiotic by just 10% then we see the total population exceed values of the carrying
capacity. It is possible for the population to exceed the carrying capacity as logistic
growth is only limited by the rod-shaped population with no internalised antibiotic since
we have assumed that neither of the remaining subpopulations proliferate.
Figure 3.7 indicated that the susceptible population would be significantly reduced
if the rod-shaped cells were unable to transition to spheres. Figure 3.9 shows a similar
investigation into the relative sizes of the transition and internalisation rates. We see
that the resistant bacterial population successfully survives antibiotic exposure with each
parameter pairing, including the case when the transition rate is set to zero. If we compare
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Figure 3.9: The solution to the system (3.14)-(3.18) using the default parameter values
shown in Table 3.2 with ω = 0.5 and A0 = 10µg ml
−1. We vary the maximum rate
of internalisation, ν, along with the maximum rate of transition, γ, whilst keeping the
combined sum of these rates to be 0.314. Both ν and γ have a default value of 1.57 day−1
and hence the default solution is represented by the blue-dotted lines.
the cases of γ = 3.14 day−1 (red dashed lines, no internalisation) and ν = 3.14 day−1 (pink
lines, no transition), the results suggest that the resistant strain could benefit from not
utilising the morphological transition. During a constant dose of antibiotic, the resistant
spherical bacteria are still susceptible to natural death whereas the rod-shaped cells are
susceptible to internalisation yet they can proliferate. However, due to the upregulation
of efflux, the rate of internalisation is decreased and hence the benefits of maintaining the
cell wall could outweigh the benefits of transitioning to the spherical form.
Finally, we investigate how including a fitness cost to the growth of a resistant strain
would affect the model predictions. It has been shown that various resistant plasmids can
incur a fitness cost to the host bacteria that can vary from 0.09 to 0.25 as a proportion
of non-plasmid bearing growth [100]. We assume that the energy costs associated with
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Figure 3.10: The solution to the system (3.14)-(3.18) using the default parameter values
shown in Table 3.2, with ω = 0.5 and A0 = 10µg ml
−1 and varying the fitness cost, c,
from the default value of 0.15.
the overexpression of efflux would incur similar fitness costs. Figure 3.10 displays the
results when we vary the fitness cost parameter c; an increase in c results in a reduction
of the growth rate of the rod-shaped cells. As the growth rate decreases, we predict lower
population levels, as expected. As the fitness cost reaches 0.25, population growth is
significantly inhibited and the population reaches similar levels to the susceptible strain.
However, the effects of a high fitness cost could be countered with a sufficiently high
increase in efflux (results omitted).
3.3 Discussion
The models, described by equations (3.6)-(3.10) and (3.14)-(3.18) are able to successfully
produce the population dynamics of a susceptible and resistant strain of P. aeruginosa
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after exposure to a single dose or constant infusion of antibiotic respectively. Using
a suitable parameter set, the models predict that both strains would survive a single
dose of antibiotic and grow to the carrying capacity. Whilst the susceptible strain relies
on the morphological transition to flourish, the results suggest that the transition could
potentially obstruct bacterial growth in a resistant strain. If the efflux pumps are suitably
effective then we predict that the benefits of efflux pump upregulation could outweigh the
potential benefits of the morphological transition and the burden of the fitness cost that
could occur as a result of expressing the resistance mechanism.
In the following chapter we extend Model II to an infection level model. We investigate
the growth of a multi-strain infection, the effects of the host response and the role of the
morphological transition in vivo.
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CHAPTER 4
AN INFECTION LEVEL MODEL
Throughout Chapters 2-3, we have only considered the growth of a single strain of P.
aeruginosa in isolation with the antibiotic meropenem. In Chapter 3, we introduced an
efflux parameter and chose a suitable parameter set to successfully predict the growth
dynamics of an antibiotic-susceptible and -resistant strain. By extending Model II, to
include an immune response, we can formulate a model to investigate the role of the
shape transition during the growth of an infection in vivo and to explore the effects of
the immune system on the different bacterial subpopulations. Additionally, we can model
a susceptible and resistant strain simultaneously and explore the conditions in which a
resistant strain would emerge.
Mixed strain models have been used to investigate the emergence of resistance under
different antibiotic regimens ([29, 64]) and to explore how the immune response can affect
the resistant population [44]. In [102] a general model was developed to describe the
population dynamics of a local bacterial infection. The model was used to investigate the
effects of a single antibiotic treatment and a combined antibiotic and antivirulence treat-
ment. Suitable treatment strategies were discovered that could eliminate the bacterial
population and prevent the emergence of resistance, thus providing support for research
into antivirulence drugs. We will conduct a similar investigation but with the inclusion
of morphological heterogeneity within the bacterial population.
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4.1 Model formulation
The model will describe the growth dynamics of a multi-strain P. aeruginosa population
with the influences of antibiotic action and an immune response. The compartmental
model follows the interactions described in Figure 4.1. In accordance with Model II, we
introduce the variable (defined in Table 4.1) Hi, where i = {S,R}, for rod-shaped bacteria
with no internalised bound antibiotic; the subscripts S and R refer to the susceptible and
resistant strains respectively. Similarly, we define Ii and Li, with i = {S,R}, to be the
populations of rod-shaped bacteria with internalised bound antibiotic and spherical cells
respectively, for the susceptible and resistant strains. We define the concentration of
unbound antibiotic, A, and introduce the phagocyte population, P .
As we are modelling growth in vivo we continue to use the logistic growth term,
with maximum growth rate r and carrying capacity, k. We choose to use logistic growth,
instead of nutrient dependent growth as nutrient availability is unknown and likely to vary
between infection types. Therefore we choose a growth term that will describe growth
yet does not depend explicitly on nutrient levels. Following from Model II we assume
that only rod-shaped bacteria with no internalised bound antibiotic will proliferate. As
soon as the antibiotic binds within the cell, proliferation will be inhibited and become
negligible compared to the high antibiotic death rate. Similarly, as bacteria shed the cell
wall and transition to spheres, they may lack essential machinery needed to successfully
proliferate. Since we are using a logistic growth term we do not include a separate natural
death term for the rod-shaped cells with no bound antibiotic. Additionally, we assign a
fitness cost parameter, c, to the growth of a resistant strain.
We assume that the resistant strain is only partially resistant to the antibiotic effects
and hence the antibiotic can bind to penicillin-binding proteins (PBPs) in both strains; we
model internalisation using a non-linear saturating term with maximum transition rate,
ν, and antibiotic concentration needed for half-maximal internalisation, A50. We continue
to assume that resistance to meropenem will occur via efflux pump overexpression. Resis-













Figure 4.1: A diagram representing the transitions of a susceptible and resistant strain
of P. aeruginosa in the presence of (a) meropenem and (b) host defences. The species
are defined as follows: Hi are rod-shaped cells with no internal bound antibiotic, Ii
are rod-shaped cells with internalised bound antibiotic, Li are spherical cells, A is the
external antibiotic concentration and P is the population of phagocytes. A subscript S
or R indicates that the bacteria are susceptible or partially-resistant to the meropenem
respectively. The effects of the antibiotic and the transitions between cell types are
detailed in (a). We assume that proliferation is negligible if the antibiotic is bound
within the cell or if the cell wall has been shed. In the presence of the antibiotic, rod-
shaped cells transition to spherical cells or become have antibiotic internalised within the
cell. Spherical cells can lyse naturally due to fragility and bacteria that have internalised
antibiotic can die due to the effects of the meropenem. The effects of the immune response
are detailed in (b). Phagocytes are recruited in response to all bacterial subpopulations,
albeit at individual rates for the rod-shaped cells and spherical cells (here, B represents
the bacterial population and the dashed arrow represents the influence of the bacteria
on phagocyte recruitment). All bacterial species are susceptible to phagocytosis and
phagocytes are removed via natural clearance and bacteria-induced apoptosis.
and a lower successful binding rate of the antibiotic within the cells. Therefore as before
we model efflux pump upregulation as a decrease in the internalisation rate, ν, and define
ω to be the efflux pump upregulation parameter that can take values between 0 and 1.
Rod-shaped bacteria with internalised antibiotic will lyse due to antibiotic effects as
the antibiotic inhibits cell wall synthesis. We define ρ to be the death rate of rod-shaped
cells due to antibiotic effects and assume that this death rate is the same for both strains
since we are modelling resistance via a decrease in internalisation. We assume that natural
death of the rod-shaped cells with bound antibiotic will be negligible when compared to
the rate of antibiotic-induced death and therefore we do not include a separate natural
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death term.
Following the microscopy images in Figures 2.1 and 3.1, we assume that both strains
transition to spherical cells following exposure to the antibiotic. The transition is modelled
using a saturating nonlinear term with maximum transition rate, γ, and concentration
needed for half-maximal transition, T50. We continue to assume that bacteria in both
strains can transition back to the rod-shape once the extracellular antibiotic concentration
depletes to a low critical threshold concentration. We model the reverse transition using
a hyperbolic tangent function with slope parameter b and critical antibiotic threshold Ac.
Once the antibiotic concentration reaches the critical threshold, the cell wall deficient
bacteria will transition back to the rod shape and resume proliferation. If the spherical
cells do not transition back to the rod shape they are susceptible to lysis due to their
inherent fragility and we model this using a linear term with death rate, ψ.
To model an immune response, we assume that all bacterial subpopulations are sus-
ceptible to phagocytosis; the rate at which phagocytosis occurs will depend on the number
of phagocytes available and the type of bacteria. The immunogenic properties of L-forms
remain relatively unknown [35, 36, 83]. However, the cell envelope is highly immuno-
genic: both the outer membrane and peptidoglycan layer have constituents that act as
pathogen-associated molecular patterns (PAMPs). These molecules are recognisable to
the immune system and phagocytes will respond accordingly. Therefore, since the cell
wall is disrupted in the spherical cells it is not clear whether or not the spherical cells
will incur the same immune response as cells that harbour an intact cell wall. Follow-
ing [98, 102], we model phagocyte recruitment using logistic growth and assume that
the morphology of a bacterium could affect its immunogenic properties. We define the
maximum recruitment rate κi, where i = {H,L}, with subscripts H and L referring to
the rod-shaped and spherical bacteria respectively. The carrying capacity of phagocytes
is defined as PMAX . We assume that all bacteria, regardless of shape, are susceptible to
phagocytosis. Similarly, since phagocytosis may depend on the outer membrane being
intact, we assume that the susceptibility of the spherical cells to phagocytosis could vary
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from that of the native rod shaped bacteria. Hence we introduce the parameter φi, where
i = {H,L}, to be the phagocyte-induced death rate of rod-shaped bacteria and spherical
bacteria respectively.
P. aeruginosa bacteria can produce toxins that induce apoptosis of neutrophils and
other immune cells [108]. We model bacteria-induced apoptosis using a linear density
dependent term with rate, µ. For simplicity, we assume that bacteria produce toxins at
the same rate regardless of the strain or shape and hence apoptosis occurs at the same rate
for all bacterial subpopulations. Additionally, we define the clearance rate of phagocytes,
ξ.
Throughout our results we consider the introduction of resistance into the environe-
ment via gene acquisition or cross contamination. Bacteria can acquire resistance through
HGT or as a result of mutations during proliferation. Overexpression of the genes that
regulate efflux is thought to occur as a result of mutations and therefore for simplicity,
we assume that this is the only way that a bacterium may gain reduced susceptibility
[67]. Alternatively, through cross contamination, a population of resistant bacteria could
appear within the environment. Throughout the simulations we incorporate the emer-
gence of resistance into the model by introducing a resistant population at some point
over the course of the simulated treatment. If we are considering a resistant population
that has arisen due to mutation then our initial population size would be small, whereas
a population that appears from cross contamination could be much larger. Our aim is to
understand the conditions under which a resistant population would grow and to inves-
tigate how treatments could work in conjunction with the host response to control the
emergence of resistance and clear the population.
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Table 4.1: Definitions and units for the variables in Model III, described by equations
(4.1)-(4.9).
Variable Definition Units
HS Antibiotic-susceptible rod-shaped cells with no inter-
nalised bound antibiotic
cells cm−3
IS Antibiotic-susceptible rod-shaped cells with internalised
bound antibiotic
cells cm−3
LS Antibiotic-susceptible spherical cells cells cm
−3
HR Antibiotic-resistant rod-shaped cells with no inter-
nalised bound antibiotic
cells cm−3
IR Antibiotic-resistant rod-shaped cells with internalised
bound antibiotic
cells cm−3
LR Antibiotic-resistant spherical cells cells cm
−3
P Phagocytes cells cm−3
A Extracellular antibiotic concentration µg ml−1



































































LR − φHHRP, (4.4)
dIR
dt
= (1− ω) νA
A+ A50















LR − ψLR − φLLRP, (4.6)
dP
dt















(HS + (1− ω)HR) , (4.8)
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with initial conditions,
HS(0) = HS0, IS(0) = 0, LS(0) = 0, HR(0) = HR0, IR(0) = 0,
LR(0) = 0, P (0) = 0, A(0) = A0. (4.9)
Definitions for all variables and parameters are displayed in Tables 4.1 and 4.2 respectively.
A default parameter set was chosen using suitable literature, the parametrisation results
in Chapter II and the analysis in Chapter III. The default parameter values are also shown
in Table 4.2, although a range of values is used throughout.
To produce the simulations in the remainder of this chapter we include the assumption
that bacterial growth will cease when the population reaches a low critical threshold. It
is likely that environmental pressure and the stochasticity of biological processes would
cause the rod-shaped population to die out if the population decreased to a low level.
When solving the model we include the assumption that growth will stop once the rod-
shaped population reaches 50 bacteria and further assume that the rod-shaped bacteria
will no longer transition to the spherical form. We assume that the reverse transition
is still possible, as are the interactions of the immune system and antibiotic with the
remaining cellular populations.
4.2 Bacterial growth in the absence of antibiotic
4.2.1 Single strain infection
Initially, we consider bacterial growth of a susceptible strain, prior to treatment, such
that the initial conditions are,
HS(0) = 10
4, IS(0) = 0, LS(0) = 0, HR(0) = 0, IR(0) = 0,
LR(0) = 0, P (0) = 0, A(0) = 0. (4.10)
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Table 4.2: Definitions, units and default values for the parameters used in Model III,
described by equations (4.1)-(4.9). We define i = {H,L} where H and L imply that the







r Rod-shaped bacterial growth rate. day−1 3 [94]





k Carrying capacity of rod-shaped bacteria
with no internalised bound antibiotic.
cells cm−3 106 [94]
ν Maximum antibiotic internalisation rate. day−1 1.57 -
ω Efflux pump upregulation parameter. dimensionless 0.5 -





γ Maximum transition rate from rod to spheri-
cal shape.
day−1 1.57 -





δ Transition rate from spherical to rod shape. day−1 10 -
Ac Critical antibiotic concentration threshold for
reversion of spherical cells.
µg ml−1 0.5 -
b Smoothed step function slope parameter. µg ml−1 1 -
κi Maximum recruitment rate of phagocytes by
bacteria.
day−1 0.5 -
PMAX Carrying capacity of phagocytes. cells cm
−3 1.8× 105 [98]
ψ Death rate of spherical cells. day−1 0.017
Chapter
3
ρ Death rate of rod-shaped bacteria due to an-
tibiotic.
day−1 100 -













ξ Natural clearance rate of phagocytes. day−1 1.512 [98]
α Extracellular antibiotic decay rate. day−1 15 [77]
ν̃ Extracellular antibiotic decay due to internal-






A suitable phagocyte recruitment rate, κH , is chosen to reflect an infection that cannot
be cleared by the immune system alone. Figure 4.2 (a) displays the solutions of the model
using the default parameter set with A(0) = 0. Since the immune response cannot clear
the infection we see that both populations of rod-shaped bacteria and phagocytes reach
nonzero steady state values.
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Figure 4.2: The solution to the system (4.1)-(4.8), using the default parameter values
found in Table 4.2 and the initial conditions (a) (4.10) and (b) (4.11).
If we consider a single strain that is partially-resistant to the antibiotic and solve the
model using the initial conditions,
HS(0) = 0, IS(0) = 0, LS(0) = 0, HR(0) = 10
4, IR(0) = 0,
LR(0) = 0, P (0) = 0, A(0) = 0, (4.11)
then we obtain the results in Figure 4.2 (b). Before the antibiotic is added, the suscep-
tible and resistant populations have similar growth dynamics and identical immunogenic
properties as no bacteria transition to the spherical form. The only assumed difference
between the two strains prior to antibiotic exposure is the fitness cost attributed to carry-
ing resistance genes. The effects of the fitness cost are observed in the lower steady state
value reached by the resistant population.
4.2.2 Investigating the emergence of resistance
It is possible that a resistant population may emerge via mutation or due to cross-
contamination prior to treatment and hence the initial number of resistant bacteria that
appear in the population, HR0, could vary. In addition to the initial condition, the time
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that the resistant population appears, which we refer to as TR, could affect the size of the
resistant population. Figure 4.3 displays the population levels of the resistant population
when we vary the fitness cost against the initial condition. We note that the graphs show
the size of the resistant population (not the steady state population sizes) at the specified
time after introducing the resistant population at time t = 0. The results indicate time-
dependent behaviour; the resistant population could survive with reduced fitness but the
length of time that it can continue to grow will depend on the size of the fitness cost. The
population will inevitably die out eventually unless the fitness cost is very low; further
investigation indicates that if the fitness cost is less than 1×10−5 then we could expect the
resistant population to persist for an extended time period. Fitness cost values of this size
are extremely small in comparison to the interval of realistic values provided in [100, 109]
and although these values are related to plasmid-mediated resistance, we can use them
as an indication of the potential size of a fitness cost. This indicates that fitness costs of
less than 1× 10−5 could be considered as negligible and thus we conclude that unless the
resistant strain has a negligible fitness cost, then we would not expect a resistant strain
to emerge. If there is a negligible fitness cost then Figures 4.3 (a)-(b) indicate that the
initial condition will determine the size of the resistant population.
Similarly, we can explore the effects of the time that the resistant population appears
on whether a resistant population can establish itself. Figure 4.4 indicates that TR does
not significantly affect the population size of the resistant population when compared to
the effects of the fitness cost and initial condition.
4.3 Introducing the antibiotic
In Chapter 3 we considered the effects of a single dose of antibiotic and predicted that the
amount of antibiotic simulated would not successfully clear either a susceptible or resistant
population. After incorporating an immune response we attain similar results using the
default parameter set and conclude that even with the additional effects of an immune
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Figure 4.3: The population levels of resistant bacteria for varying values of fitness cost,
c, and initial condition, HR0. Note that these figures show the total resistant population
after (a) 50 days and (b) 1000 days. Population growth is simulated by solving the
equations (4.1)-(4.8), using the default parameter values found in Table 4.2 and initial
conditions (4.10) with HR(0) = HR0, for the desired time frame. The total population
of resistant bacteria, R, is calculated such that R = HR + IR + LR. The total number
of susceptible bacteria is not significantly affected, regardless of the characteristcs of the
resistant population (results omitted).
response, a single dose of antibiotic would not be effective in clearing either a susceptible
or resistant infection (results omitted for brevity). Furthermore, a similar investigation
into the emergence of a resistant population indicates that as soon as the antibiotic is
exhausted the conditions at the site of infection would return to the antibiotic-free state.
If a resistant population emerges during the treatment then following from the results in
Figure 4.3, the survival of this population after antibiotic exposure will be determined by
the fitness cost. Unless there is a negligible fitness cost then we would expect the resistant
population to die out following exhaustion of the antibiotic. A single dose treatment would
be clinically irrelevant and consequently we continue to consider the effects of a continuous
dose of antibiotic on the bacterial population.
For the following analysis we will consider a constant dose of antibiotic and assume
that antibiotic exposure will prevent the spherical bacteria from rebuilding the cell wall
for the duration of the treatment. After considering a constant dose of antibiotic and
assuming that there is no reverse transition, we amend Model III and obtain the constant
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Figure 4.4: The population levels of resistant bacteria for varying values of (a) fitness
cost and (b) initial condition against the time of population appearance, TR. In (a), the
initial resistant population size was taken as 100 bacteria and in (b) it was assumed that
the resistant bacteria had no fitness cost. After simulating the emergence of the resistant
population, the simulation is continued until (a) 5000 days (as the steady state is reached
on a unrealistically long timescale) and (b) the steady state is reached; after this, the
number of resistant bacteria, R, is calculated such that R = HR + IR + SR. The total
number of susceptible bacteria is not significantly affected, regardless of the characteristics












































= (1− ω) νA
A+ A50






HR − ψLR − φLLRP, (4.17)
dP
dt
















HS(0) = HS0, IS(0) = 0, LS(0) = 0, HR(0) = HR0, IR(0) = 0,
LR(0) = 0, P (0) = 0, A(0) = A0. (4.20)
Using the continuous dose model, we will investigate the population growth of both
single strain infections and a mixed strain infection during multiple treatment combina-
tions. We also consider varying immunogenic characteristics for the spherical populations.
Table 4.3 is given at the end of this chapter and details the results obtained throughout;
this can be used as a guide to the predictions made using the continuous dose infection
level model.
4.3.1 Single strain infection
Initially, we consider a population of susceptible bacteria and assume no cross-contamination
or breakthrough mutations occur during the time course of the treatment. We solve the
model (4.12)-(4.19) using the default parameter set, with initial conditions,
HS(0) = 10
4, IS(0) = 0, LS(0) = 0, HR(0) = 0, IR(0) = 0,
LR(0) = 0, P (0) = 0, A(0) = 10, (4.21)
and obtain the solutions displayed in Figure 4.5 (green dashed lines). Within the first
few days we see a rapid decrease in rod-shaped bacteria with no bound antibiotic as
the antibiotic binds within the bacteria or they shed the cell wall. The presence of the
bacterial population initiates an immune response and we see a rise in phagocytes. As
the antibiotic treatment continues we see all subpopulations decrease until the infection
is cleared, albeit after a lengthy treatment period. We note that our results in Chapter
2 suggested that the morphological transition could enable the population to survive a
constant dose of antibiotic (see Figure 2.6); the results in Figure 4.5 suggest that the
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Figure 4.5: The solutions to the system (4.12)-(4.19) using the default parameter values
in Table 4.2 and the initial conditions (4.21) (green dashed lines) and (4.22) (blue dashed-
dotted lines).
additional effects of the immune response could aid the antibiotic and clear an antibiotic-
susceptible infection.
We have predicted that the immune response could be a critical factor when predicting
treatment success. This result can be directly related to the study by Ankomah et al. [7]
in which they suggest that the presence of a subpopulation with phenotypic resistance (i.e.
persister cells) would not cause treatment failure in cases where the rate of phagocytosis is
sufficiently high. These results highlight the importance of acknowledging hosts defences
when considering mechanisms of antibiotic evasion including the morphological transition.
We also consider the effects of a continuous dose of antibiotic on an infection that
comprises a single antibiotic-resistant strain. Solving equations (4.12)-(4.19), with initial
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conditions,
HS(0) = 0, IS(0) = 0, LS(0) = 0, HR(0) = 10
4, IR(0) = 0,
LR(0) = 0, P (0) = 0, A(0) = 10, (4.22)
gives the results displayed in Figure 4.5 (blue dashed-dotted lines). As expected, the
results suggest that the resistant bacteria would reach a non-zero steady state, even after
continued exposure to the antibiotic and in the presence of an intact immune response.
Active efflux enables the bacteria to resist antibiotic effects and an alternative treatment
would be required in order to successfully clear the infection.
4.3.2 Investigating the emergence of resistance
In Section 4.2.2 we concluded that in the absence of antibiotic, a resistant population could
only emerge if the fitness cost was small enough. Antibiotic effects will undoubtedly place
pressure on the susceptible population and it is likely that this pressure will impact the
conditions needed for a resistant population to emerge. There are four parameters that
could affect the resistant population; we previously considered the fitness cost, c, initial
condition, R0, a time of emergence, TR. In the presence of antibiotic, the efflux parameter,
ω, must also be considered.
We assume that a resistant population could emerge, due to mutation, and avoid an-
tibiotic exposure until the population has grown to the size of approximately 100 bacteria
and therefore use an initial condition of HR(0) = 100 (unless we are investigating the
initial population size). Similarly, it is possible that a contaminant population of resis-
tant bacteria could be of this size, or greater. Additionally, it is possible that a resistant
population may already be present before the treatment is administered; following from
the previous section we note that this will only occur if there is no fitness cost attributed
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to carrying resistance. Thus we obtain the initial conditions,
HS(0) = 10
4, IS(0) = 0, LS(0) = 0, HR(0) = 100, IR(0) = 0,
LR(0) = 0, P (0) = 0, A(0) = 10. (4.23)
Note that we have chosen an initial condition for the susceptible population that is much
lower than the antibiotic free steady state. This initial condition was chosen to reflect
an infection that was caught before the population reached its steady state value. In a
hospital environment, it is possible that a P. aeruginosa infection could be detected and
treated whilst in the early stages of infection.
Following from Figure 4.5 we find that a constant dose of antibiotic will clear the
susceptible population in the absence or presence of a resistant subpopulation. Hence we
only investigate changes to the steady state population of the resistant bacteria. Figure
4.6 (a) displays the steady state values for the resistant population when we vary the time
of emergence against the initial number of resistant bacteria. The results indicate that
neither variable has an effect on the steady state population. In an antibiotic free envi-
ronment we predicted that the initial condition would affect the steady state population
(see Figure 4.4 (b)), however, we now find that neither variable impacts the population
size when a constant dose of antibiotic is added. After further investigation we find that
neither TR nor R0 has any impact on the steady state population level when compared
with the fitness cost, c, or the efflux parameter, ω (see Figure 4.6 (c)-(f)).
Figure 4.6 (b) displays the results if we vary the population determining parameters:
the fitness cost, c, and efflux upregulation parameter, ω. Two clear regions of behaviour
emerge for low and high values of c. When we have a low fitness cost (c < 10−2), we find
that changes to the efflux parameter have a large impact on the steady state whilst the
fitness cost has little effect. For higher fitness costs (c > 10−2), we find that the efflux
parameter has less of an effect on the steady state compared to the fitness cost. For the
highest values of the fitness cost and lowest values of the efflux parameter we find that
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Figure 4.6: Steady state values of the resistant bacterial population after solving the
system (4.12)-(4.19), with initial conditions (4.23) and default parameter values shown
in Table 4.2. We vary the following parameter pairings: (a) initial condition, HR0, and
emergence time, TR, (b) fitness cost, c, and efflux parameter, ω, (c) initial condition and
efflux parameter, (d) initial condition and fitness cost, (e) efflux parameter and emergence
time and (f) fitness cost and emergence time.
the population is cleared regardless of the size of the other parameter.
Note that Figure 4.6 (d) and (f) both suggest that bacteria with lower fitness can
still establish a population in the presence of antibiotic compared to the antibiotic-free
environment (see Figure 4.3). The higher allowance for reduced fitness in resistant bacteria
arises due to the niche created by the mass killing of the susceptible bacteria by the
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antibiotic. These results suggest that antibiotic exposure causes a selective pressure that
could enable resistant populations to emerge that would not survive in an antibiotic-free
system.
4.4 Considering alternative treatments
The results in Figure 4.5 predicted that a constant dose of antibiotic could successfully
clear an antibiotic-susceptible strain infection with the support of the immune response.
However, we are considering a parameter choice that requires a lengthy treatment time
of around 200 days. A treatment of this length is clinically infeasible as not only would
it be costly, it would provide an ideal environment for resistance to develop and leave the
patient vulnerable to more threatening infections.
In [75] antimicrobial peptides were suggested as a suitable therapy to target cell wall
deficient bacteria (CWDB) and our results in Chapter 2 supported the use of antibiotics
and AMPs when the bacteria was in isolation with the antibiotic. Additionally, the
combined use of antibiotics and an antivirulence drug was considered in [102]. We will
continue to explore the effects of AMPs and an antivirulence drug on the growth of a
single and mixed strain infection.
4.4.1 AMPs
Firstly, we do not consider the use of AMPs as a single treatment for a P. aeruginosa
infection. AMPs target the spherical cells that form during antibiotic exposure; if no
antibiotic is added then AMPs can have no effect. Rather, we still consider the use of
AMPs in conjunction with antibiotics. We recall that the use of AMPs is simulated by
increasing the death rate of the spherical cells.
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Antibiotic-susceptible infection
Figure 4.7 displays the results when we simulate a combined treatment of antibiotic and
AMPs on an antibiotic-susceptible infection. The model predicts that an increase in
the spherical death rate, caused by the AMPs, would result in fewer spherical cells. The
effect this has on the total population consequently depends on whether the decrease in the
spherical population causes a substantial difference in the number of phagocytes recruited.
These results suggest that there is a non-monotonic relationship between the effectiveness
of the AMPs and the success of this combined treatment. If the AMPs increase the
spherical cell death rate by approximately 5-fold (ψ = 0.1 day−1, green dashed-dotted
lines) then the persistent population of spherical cells is cleared faster without impacting
the initial immune response. However, a more substantial increase in spherical cell death
(ψ = 10 day−1, cyan solid lines), from the default value, causes a substantial decrease
in spheres and subsequently significantly fewer phagocytes are recruited initially. With
fewer phagocytes at the site of infection, the rod-shaped cells are able to proliferate and
grow to greater numbers. As the rod-shaped population increases, the immune response
reacts accordingly and eventually the rod-shaped population is cleared but the treatment
duration is no less than if we were to use the antibiotic alone.
If the antibiotic is administered alone (red dashed lines) then we predict that the
population comprises only spherical cells towards the end of the treatment. Therefore, the
application of the antibiotic at the later stages is not necessary for bactericidal purposes
but instead as a requirement to keep the spherical cells from reverting back to rods. The
remaining spherical cells are then cleared through natural clearance and phagocytosis.
The AMPs have the ability to clear this population of spherical cells’ faster, if their
effectiveness does not significantly impact the immune response. However, if the AMPs
are too potent then they have little impact on the overall population and instead they
alter the composition of the population because of the indirect effect they have on the
immune response. For higher values of ψ, the population towards the end of the treatment
comprises mostly rod-shaped cells with no internalised antibiotic and the antibiotics are
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Figure 4.7: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.21), default parameter values shown in Table 4.2 and varying the spherical cell death
rate, ψ, from the default value of 1.7 × 10−2 day−1. An increase in ψ represents the
addition of antimicrobial peptides.
necessary for bactericidal purposes. We recall that due to the compromised cell membrane
the spherical cells could be less virulent than the rod-shaped cells. If so, an increase in the
proportion of rod-shaped cells would be an undesirable outcome and using AMPs could
result in a more threatening infection.
Overall we predict that there could be a synergistic relationship between the AMPs
and the antibiotic but this ultimately depends on the AMPs having a specific level of
effectiveness. If we consider the parameter space for the spherical cell death rate, ψ,
then we can attempt to find an optimal value of ψ, for which we predict the shortest
necessary treatment time. If we vary the value of ψ and calculate the minimum time
needed to eradicate the population then we obtain the results in Figure 4.8. We estimate
the optimal death rate of the spherical cells to be ψ ≈ 0.25 day−1, which relates to an
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eradication time of approximately 61 days for our default parameter set. Beyond this
synergistic potency level, the AMPs could become ineffective and possibly detrimental to
treatment efforts.










Figure 4.8: The time taken to clear an infection for various values of the spherical cell
death rate, ψ. These results represent the administration of a continuous dose of antibi-
otics and AMPs; an increase in ψ represents an increase in the addition of AMPs. The
variable solutions to the system (4.12)-(4.19), with initial conditions (4.22), default pa-
rameter values shown in Table 4.2 were calculated with various values of the spherical cell
death rate, ψ. The time taken to clear the total bacterial population was then obtained
and plotted against the values of ψ.
Antibiotic-resistant infection
If we simulate a combined dose of antibiotics and AMPs as a treatment for an antibiotic-
resistant strain then the results, detailed in Figure 4.9, suggest similar findings to those
obtained for the susceptible strain. As we increase the spherical cells death rate from the
default parameter value we predict fewer spherical cells and a larger rod-shaped bacteria
population. Overall, the total population is not altered substantially and the steady state
of the total population is similar, regardless of the efficacy of the drug and its influence
on the immune response. Using AMPs in addition to the AB does not affect the total
population but instead alters the composition of the population. If we use antibiotics
alone then we predict that the largest subpopulation will be the spherical cells. If we
add the AMPs then the rod-shaped bacteria make up the dominant subpopulation. The
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antibiotic alone was unable to treat the resistant infection and we find that the use of
AMPs does not change the treatment outcome.
























































Figure 4.9: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.22), default parameter values shown in Table 4.2 and varying the spherical cell death
rate, ψ, from the default value of 1.7 × 10−2 day−1. An increase in ψ represents the
addition of antimicrobial peptides.
Mixed strain infection
Finally, we consider the use of the antibiotic and AMP combination on a mixed strain
infection. From the results in Figure 4.6 we concluded that the initial condition and time
that the resistant population first appears does not affect the steady state population
for the resistant bacteria. Following these results, we only consider an initial population
of 100 resistant bacteria in the following simulations and assume that this population is
present at time t = 0.
Figure 4.10 displays the results if we simulate a combined dose of antibiotic and AMPs
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on a mixed population. The results are similar to those obtained for the resistant strain
infection; the AMPs alter the composition of the infection but do not alter the outcome
of the treatment. Overall we find that the susceptible population is cleared marginally
faster if we use the combined treatment. However, a large resistant population remains and
grows to the same steady state for all tested values of ψ. Furthermore, by adding AMPs
we could expect a more threatening resistant infection due to the increased proportion of
rod-shaped cells.
4.4.2 Antivirulence drugs
Administering the antivirulence drug as a single treatment
Antivirulence drugs work by disarming the pathogen of a specific virulent property and
each pathogen will display an array of these factors. Therefore we must specify a target
virulence factor in order to suitably incorporate the administration of an antivirulence
drug within the model. Some antivirulence drugs will increase the efficacy of the host
immune system by weakening pathogenic properties that counteract immune effects. In
[102], the effect of the antivirulence drug was modelled by an increase in the phagocytosis
rate; a saturating term was used to incorporate the concentration of the drug and its PK
properties. We will assume that a continuous dose of antivirulence drug is added and
hence the increase in the rate of phagocytosis can be modelled as constant. It is unclear
how an antivirulence drug would affect the spherical cells and hence we assume that only
the rod-shaped bacteria are affected.
Initially, we consider the use of an antivirulence drug on its own. In Figure 4.11
the model predictions suggest that using a single antivirulence treatment could clear a
bacterial infection (of both rods and spheres) in a few days if sufficiently potent. Further
investigation indicates that a 60-fold increase in rod-shaped cell phagocytosis, from the
default value of φH , would be required for an antivirulence drug to clear the infection in
a week if used as a single treatment. Note that a similar increase in phagocytosis would
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Figure 4.10: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.23), default parameter values shown in Table 4.2 and varying the spherical cell death
rate, ψ, from the default value of 1.7 × 10−2 day−1. An increase in ψ represents the
addition of antimicrobial peptides.
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Figure 4.11: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.20), default parameter values shown in Table 4.2 and varying the rod-shaped cell phago-
cytosis rate, φH , from the default value of 2.4 × 10−4 (cells cm−3)−1 day−1. An increase
in φH represents the addition of an antivirulence drug that increases susceptibility of the
rod-shaped bacteria to host defences. It is assumed that the antivirulence drug is the only
treatment and hence A0 = 0.
be needed for an antivirulence drug to clear a single antibiotic resistant strain of bacteria
(results omitted).
If we consider a mixed strain infection then our results suggest that the antivirulence
drug would have the same effect on a mixed and single strain population. Furthermore, we
conclude that the antivirulence drug would require the same level of effectiveness to clear
the susceptible subpopulation in the absence and presence of a resistant subpopulation.
As we previously predicted, the fitness cost could prevent the emergence of the resistant
population if no treatment is administered. By adding an antivirulence drug, we are able
to clear the resistant population faster than without treatment.
Antivirulence drugs are still being investigated and sufficient data is not available to
obtain pharmacodynamic properties. Therefore it is not possible to quantify their efficacy
using experimental data and we cannot conclude whether an antivirulence drug would be
effective enough to clear an infection when used as a single therapeutic agent (though
in the majority of in vivo studies, antivirulence drugs have attenuated but not cleared
infections [27, 46, 52, 65, 92]). However, if the level of efficacy achieved by the antivirulence
drug was sufficiently high that it could clear an antibiotic susceptible strain then our
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results also suggest that it could clear an antibiotic resistant infection (unsurprisingly
since the only difference here is that the resistant strain grows more slowly). Conversely,
if the antivirulence drug was found to have limited efficacy when used alone (a 60-fold
increase in the phagocytosis rate is likely to be unrealistic), it could be considered as a
potential component of a combined treatment.
Administering the antivirulence drug in combination with the antibiotic
Following from Figure 4.11, we predict that the rod-shaped phagocytosis rate, φH , would
need to increase above 10−2 in order to clear the infection using the antivirulence drug
alone. In the following simulations and subsequent sections we consider the combined use
of an antibiotic-antivirulence drug pairing. We limit the parameter space for the phago-
cytosis rate of rod-shaped cells to φH ∈ [0 10−2] so that we only consider antivirulence
drugs that cannot be used alone.
Firstly, we consider the use of the antibiotic and an antivirulence drug for the treatment
of an antibiotic-susceptible infection. The results shown in Figure 4.12 indicate that as
the effectiveness of the antivirulence drug increases, the rod-shaped population is cleared
faster and subsequently a smaller population of spherical cells appears. Once the rod-
shaped population has been cleared, the remaining spherical population enters a slow
death phase where the cells are susceptible to natural death and phagocytosis (recall that
the antivirulence drugs are assumed to not have any effect on the phagocytosis rate of
the spheres). Since the rod-shaped cells are cleared faster using the antivirulence drug,
the spherical cells enter the death phase sooner and are subsequently cleared faster than
if the antibiotic was added alone. Antibiotic exposure is crucial during the death phase
as it prevents the spherical cells from transitioning back to the rod-shape.
If we simulate the growth of an antibiotic-resistant strain with the antibiotic-antivirulence
treatment we obtain a similar result to the antibiotic-susceptible strain. The results, dis-
played in Figure 4.13 indicate that if the antibiotic is used alone (φH = 2.4× 10−4 (cells
cm−3)−1 day−1, red dashed lines) then we would expect the rod-shaped populations to
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Figure 4.12: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.21), default parameter values shown in Table 4.2 and varying the rod-shaped cell phago-
cytosis rate, φH , from the default value of 2.4× 10−4 (cells cm−3)−1 day−1. An increase in
φH represents the addition of an antivirulence drug.
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Figure 4.13: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.22), default parameter values shown in Table 4.2 and varying the rod-shaped cell phago-
cytosis rate, φH , from the default value of 2.4× 10−4 (cells cm−3)−1 day−1. An increase in
φH represents the addition of an antivirulence drug.
reach nonzero steady state values. If we increase the rod-shaped cell phagocytosis rate
from the default value, our results suggest that using an antivirulence drug could help
clear the rod-shaped population and increase the success of the antibiotic treatment. As
with the susceptible-only strain, the spherical population enters a death phase, once the
rod-shaped population has cleared and it is crucial that we clear this population in order
to achieve treatment success.
If we simulate the effects of the combined antibiotic and antivirulence drug treatment
on the growth of a mixed strain infection then our predictions are congruent to the
single strain predictions (results omitted). The antivirulence drug enables clearance of all
the rod-shaped cell subpopulation and the remaining spherical cells enter a slow death
phase. Thus by combining antibiotics with an sufficiently potent antivirulence drug, the
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model predicts that an antibiotic-susceptible (but persistent) infection can be cleared
more quickly and an antibiotic-resistant infection can also be cleared.
4.4.3 Triple combinations
Our results thus far suggest that we could expect a lengthy treatment duration if antibi-
otics are used alone to treat a susceptible infection. If a resistant population is present
then antibiotics become ineffective and cannot clear the infection. After considering two
combination strategies we find that we could still expect a very lengthy treatment dura-
tion if we use a combination of antibiotics along with either AMPs or an antivirulence
drug. The AMPs were found to help clear the spherical population whilst the antiviru-
lence drugs support the immune system in clearing the rod-shaped cell population. If we
simulate a triple drug combination treatment of the antibiotic, AMPs and an antiviru-
lence drug then it may be possible to clear the infection in a much shorter time frame. If
we simulate a triple combination of drugs on the single strain antibiotic-susceptible and
antibiotic-resistant infections then we obtain the results displayed in Figure 4.14 (a) and
(b) respectively. The graphs display the total population size after 14 days of continuous
treatment and we predict that it could be possible to clear both infections within this
clinically relevant time frame by using a combined therapy of antibiotic, antimicrobial
peptides and an antivirulence drug. We notice two distinct regions in both plots of Figure
4.14. For low rod-shaped cell phagocytosis rates (φH < 1×10−3 (cells cm−3)−1 day−1) the
population cannot be cleared in the two week time period, regardless of the effectiveness
of the AMPs. For faster rates of rod-shape cell phagocytosis (φH > 1×10−3 (cells cm−3)−1
day−1) we find that the effectiveness of the antivirulence drug determines the population
size but total clearance is only possible if the spherical cell death rate if sufficiently high
(ψ > 0.05 day−1). We note that a discontinuity arises in Figure 4.14 (b) and we see a
rapid change in solution occurs around the region when φH < 1 × 10−3 (cells cm−3)−1
day−1. We attribute this behaviour to a previous assumption regarding the behaviour
of the population at low cell numbers; we have assumed that the bacteria will cease to
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Figure 4.14: The population levels of (a) susceptible bacteria and (b) resistant bacteria
after 14 days for varying values of the rod-shaped cell phagocytosis rate, φH , and spherical
cell death rate, ψ. Increasing these parameters from their default values (marked with a
star) simulates the effects of an antivirulence drug and antimicrobial peptide treatment
respectively on the single strain infections. The total population of susceptible, S, and
resistant bacteria, R, is calculated such that S = HS + IS + LS and R = HR + IR + LR
respectively.
proliferate once the population reaches 50 bacteria.
We also simulate the triple combination on the mixed population and conclude from
Figure 4.15 that if the AMPs and antivirulence drug can clear the susceptible strain then
the resistant strain will also be cleared due to its small initial condition and fitness cost.







































Figure 4.15: The population levels of (a) susceptible bacteria and (b) resistant bacteria
after 14 days for varying values of the rod-shaped cell phagocytosis rate, φH , and spherical
cell death rate, ψ. Increasing these parameters from their default values (marked with a
star) simulates the effects of an antivirulence drug and antimicrobial peptide treatment
respectively on the mixed strain infection. The total population of susceptible, S, and




Until now we have assumed that the spherical bacteria have identical immunogenic prop-
erties to the rod-shaped cells and our default parameters were chosen such that the re-
cruitment rate, κ and the phagocytosis rate, φ, are the same regardless of cell shape.
It has been suggested that the immunogenic properties of the spherical cells could
differ to those of the rod-shaped bacteria [35, 36, 83]. Both the outer membrane and
peptidoglycan layers have constituents that act as PAMPs and activate immune responses.
If peptidoglycan is lost, spherical cells may actually be less immune stimulatory. With
regards to phagocytosis, if the outer membrane is not intact then phagocytosis could
also occur at a different rate for the spherical cells. By varying these parameters we
can investigate how different immunogenic properties could affect the total bacterial load
during treatment.
We begin by considering the case where phagocytosis rates differ between rod-shaped
and spherical bacteria and assume that recruitment of phagocytes is the same regardless
of the state of the cell wall.
4.5.1 Antibiotic-susceptible infection
Initially, we consider the impact of different phagocytosis rates for different cell types in
an antibiotic-susceptible strain infection during a continuous treatment of antibiotic. The
properties of the spherical cells suggest that phagocytosis may occur at a different rate to
rod cells due to the damaged cell wall. It is unknown how well immune cells phagocytose
spherical cells. Phagocytosis may occur at a faster rate since the cells have a depleted
cell wall. However, the depletions may incur loss of targets for the immune cells and
therefore phagocytosis could occur at a slower rate. Investigation into faster phagocytosis
rates for the spherical cells indicated that in all cases the bacteria would be cleared faster
for all treatment combinations (results omitted). Following this, we choose to investigate
the casse where the spherical cell population has a slower phagocytosis rate than the
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rod-shaped cells. If we decrease the spherical cell phagocytosis rate, φL, we obtain the
results in Figure 4.16. As expected, we predict larger populations of spherical cells as we
decrease the phagocytosis rate from the default value. The larger spherical population
causes the total population of bacteria to increase and this initiates a stronger immune
response as more phagocytes are recruited. Additionally, since fewer spherical cells are
phagocytosed, fewer phagocytes undergo apoptosis. Consequently, due to the higher
number of phagocytes, we predict that the rod-shaped populations would be cleared faster
if the phagocytosis rate of the spherical cells decreases. The spherical cells are susceptible
to natural death and replenishment depends on the size of the rod-shaped population.
Hence we see a decline in the spherical population as soon as the rod-shaped population
has depleted.
The qualitative result for the total population remains the same regardless of the
phagocytosis rate; we predict total bacterial clearance, even if we assume that the spher-
ical cells are immune to phagocytosis (φL = 0 (cells cm
−3)−1 day−1, cyan solid lines).
The treatment duration needed to clear the infection increases as the phagocytosis rate
decreases and we could expect a higher bacterial load over the course of the treatment.
After further investigation we find that the qualitative results of the combination
therapies are the same regardless of the phagocytosis rate. The success of using AMPs
alongside the antibiotic will be dependent on the effectiveness of the AMPs and using an
antivirulence drug with the antibiotic could decrease the treatment time by a few days.
We omit the results for the dual treatment combinations (which are qualitatively equiv-
alent to those in Sections 4.4.1-4.4.2) but compare the results for a triple combination
when φH > φL. Using Figure 4.16 we predicted that the rod-shaped population could die
out faster if the spherical cell phagocytosis rate decreases. Consequently, when φH > φL
the antivirulence drug does not need to be as effective to clear the infection, compared
to the case when φH = φL - see Figure 4.17. Additionally, we observe a higher popu-
lation at the end of the 14 day treatment for many of the parameter pairings in Figure
4.17 (b) compared to those in Figure 4.17 (a). The higher populations represent the
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Figure 4.16: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.21), default parameter values shown in Table 4.2 and varying the spherical cell phago-
cytosis rate, φL, from the default value of 2.4× 10−4 (cells cm−3)−1 day−1.
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φL = 1× 10−5
Figure 4.17: The population levels of total susceptible bacteria after 14 days for varying
values of the rod-shaped cell phagocytosis rate, φH , and spherical cell death rate, ψ.
Increasing these parameters from their default values (marked with a star) simulates the
effects of an antivirulence drug and antimicrobial peptide treatment respectively. We
have assumed that the spherical cell phagocytosis rate is (a) equal to the rod-shaped
phagocytosis rate, (b) slower than the default rod-shaped phagocytosis rate (1× 10−5).
higher spherical cell population that occurs as we decrease the spherical cell phagocytosis
rate; this indicates that a longer treatment period may be necessary if the spherical cell
phagocytosis rate is lower than the default value.
4.5.2 Antibiotic-resistant infection
If the immunogenic properties are the same for all bacterial subpopulations then the
model predicts that a partially antibiotic-resistant infection would be untreatable using
antibiotics alone (see Figure 4.5). Figure 4.18 displays the model solutions if we vary the
phagocytosis rate of the spherical cells, φL, assuming that φL < φH . The results suggest
similar findings to the susceptible strain; as the spherical cell phagocytosis rate decreases
from the default value, the spherical population increases and initiates a stronger immune
response. If the bacterial infection is susceptible to the antibiotic then the increase in
phagocytes results in faster clearance of the rod-shaped population. However, in the case
of an antibiotic-resistant infection, the increase in phagocytes could kill off the rod-shaped
population that would otherwise survive if the immunogenic properties were identical for
all cell types. Therefore, we predict that a resistant strain infection could become treatable
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Figure 4.18: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.22), default parameter values shown in Table 4.2 and varying the spherical cell phago-
cytosis rate, φL, from the default value of 2.4× 10−4 (cells cm−3)−1 day−1.
with antibiotics if the spherical cell phagocytosis rate is slower than the rod-shaped cells.
The results in Figure 4.18 are counter-intuitive and it is only through consideration of
the immune response that we are able to obtain these predictions. The results suggest that
it may not be beneficial for the resistant bacteria to activate the morphological transition
at a site of infection if the spherical cells are phagocytosed slower than the rod-shaped
cells. If the resistant population suffers as a result of transitioning to the spherical form
then it is possible that they may not utilize this mechanism; we will consider this in the
discussion section of this chapter.
If the model solutions do convey the true behaviour of a resistant only population
then antibiotics alone could be sufficient to clear the infection if the spherical cells are
phagocytosed slower than the rod-shaped cells. However, we continue to explore combined
treatments with the view to cut down the lengthy treatment time needed to clear the
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spherical population.
If we assume that the immunogenic properties between cell types are identical then our
previous results suggested that the use of AMPs in conjunction with the antibiotic would
not change the steady state value of the resistant population compared to the antibiotic-
only treatment strategy (see Figure 4.9). If we assume that the spherical cell phagocytosis
rate is lower than that for rods and simulate the use of AMPs along with the antibiotic we
obtain the results in Figure 4.19. The AMPs initially cause a decrease in spherical cells and
therefore there are fewer phagocytes recruited than when the antibiotic was added alone.
Consequently, the rod-shaped population is not overwhelmed by the immune response
and the population survives treatment. These results suggest that AMPs could provide
a more favourable environment for the rod-shaped population and prove detrimental to
treatment success.
If we simulate the use of an antivirulence drug alongside the antibiotic to treat a resis-
tant infection with a low spherical cell phagocytosis rate then we predict identical results
to those obtained for the susceptible infection when assuming identical immunogenic prop-
erties between bacterial phenotypes (see Figure 4.12). If we add an antivirulence drug
then we decrease the time it takes to clear the rod-shaped population using the antibiotic
alone. Consequently, the spherical populations enter a slow death phase and the time
until total clearance marginally decreases as the effectiveness of the antivirulence drug
increases.
To decrease the treatment duration we can investigate the administration of a triple
drug combination. We find that the region of parameter pairings needed to clear the
infection within 14 days are similar for both cases: when immunogenic properties are
identical and when the phagocytosis rates of the cell types are different (see Figure 4.14
(b)).
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Figure 4.19: The variable solutions to the system (4.12)-(4.19), with initial condi-
tions (4.21), default parameter values shown in Table 4.2, with φL = 1 × 10−5 (cells
cm−3)−1 day−1 and varying the spherical cell death rate, ψ, from the default value of
1.7 × 10−2 day−1. The rate of spherical cell phagocytosis, φL, is slower than the default
rate as we are investigating the possiblity that spherical cells are less susceptible to phago-




We now consider a mixed strain infection and assume that the spherical cells are phagocy-
tosed slower than the rod-shaped cells. If we vary the phagocytosis rate for the spherical
cells in a mixed strain infection then we obtain the results in Figure 4.20. For both
strains, the results indicate similar findings to those obtained when considering single
strain populations. As we decrease the spherical cell phagocytosis rate we predict a larger
spherical population that comprises mostly antibiotic-susceptible spherical cells. The in-
creased spherical population initiates a stronger immune response and subsequently the
rod-shaped subpopulations die out faster as we decrease the spherical cell phagocyto-
sis rate from the default value. Eventually the susceptible population is cleared after
continued antibiotic usage. As previously witnessed in Figure 4.18, the rapid morpho-
logical transition could potentially suppress the emergence of resistance by boosting the
phagocyte population. Whilst having a lower phagocytosis rate could be favourable for
the spherical populations initially, it may be unfavourable for the other bacterial sub-
populations. This result could potentially suggest an opportunity to exploit this natural
suppression. However, we still estimate a lengthy treatment period and conclude that a
successful treatment would need to clear the spherical populations to prevent either strain
recovering after the treatment is stopped.
If we simulate the use of AMPs along with the antibiotic, we obtain the results in
Figure 4.21. The effects of the AMPs cause a decrease in susceptible spherical cells
and therefore there are fewer phagocytes recruited. When only antibiotics are used, the
large phagocyte population (recruited due to the large susceptible spherical population)
showed potential to delay the emergence of the resistant population. By adding AMPs
we are providing a more favourable environment for the resistant strain and we see the
resistant rod-shaped cell population flourish for sufficiently large ψ. The increase in
spherical cell death should negatively impact both of the spherical populations but the
rod-shaped resistant population becomes so large that the AMPS do not prevent growth
of the resistant population. Our predictions indicate that in the case of a multi-strain
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Figure 4.20: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.23), default parameter values shown in Table 4.2 and varying the spherical cell phago-
cytosis rate, φL, from the default value of 2.4× 10−4 (cells cm−3)−1 day−1.
infection with a spherical population that is less susceptible to phagocytosis, the use of
AMPs could be detrimental and would not pose a suitable treatment in combination with
antibiotics.
Instead of considering a combination therapy of antibiotics and AMPs, we consider
the combined use of an antivirulence drug with the antibiotic in order to clear the mixed
infection faster. Simulating the use of this drug combination indicates the results shown
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Figure 4.21: The variable solutions to the system (4.12)-(4.19), with initial condi-
tions (4.23), default parameter values shown in Table 4.2, with φL = 1 × 10−5 (cells
cm−3)−1 day−1 and varying the spherical cell death rate, ψ, from the default value of
1.7× 10−2 day−1 to mimic the addition of AMPs. The rate of spherical cell phagocytosis,
φL, is slower than the default rate as we are investigating the possiblity that spherical
cells are less susceptible to phagocytosis than rod-shaped cells.
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in Figure 4.22. If we increase the rod-shaped cell phagocytosis rate, φH , then both the
susceptible and resistant rod-shaped cell populations are cleared faster. Subsequently, as
we increase the rod-shaped cell phagocytosis rate, fewer spherical cells form. The length of
treatment required to fully clear the infection (i.e. rods and spheres) is not substantially
decreased as a result of adding the antivirulence drug. However, the antivirulence drug
shows potential to further exploit the suppression of the resistant population, caused by
the effects of the transition-inducing antibiotic, and decrease the time required to clear
the rod-shaped cells, which may have increased virulence to the spherical cells.
If we simulate a triple combination therapy we can infer that as long as the additional
drugs are effective enough to clear the susceptible population then they will also clear
the resistant population (see Figure 4.23). If we compare Figure 4.23 (b) to Figure 4.14
(a) (where the immunogenic properties are assumed equal), we find that the resistant
population becomes more susceptible to the antivirulence drug if the phagocytosis rate is
slower for the spherical population.
4.6 Recruitment rate
As the outer membrane may still be intact in the spherical cells, it could be more reason-
able to assume that shedding the cell wall is more likely to affect the recruitment rate.
PAMPs are often found in the peptidoglycan layer of the cell membrane and the outer
membrane and therefore it is very likely that the spherical cells will have fewer PAMPs
and be less immune stimulatory.
4.6.1 Antibiotic-susceptible infection
If we decrease the recruitment rate of the spherical cells, κL, in an antibiotic-susceptible
strain, we obtain the results in Figure 4.24. In the initial stages of treatment, the lower
recruitment rate of the spherical cells causes fewer phagocytes to be recruited by the
infection. As a result of the smaller phagocyte population, all bacterial subpopulations
139



















































































Figure 4.22: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.23), default parameter values shown in Table 4.2, with φL = 1 × 10−5 (cells cm−3)−1
day−1 and varying the rod-shaped cell phagocytosis rate, φH , from the default value of
2.4× 10−4 (cells cm−3)−1 day−1. The rate of spherical cell phagocytosis, φL, is slower than
the default rate as we are investigating the possiblity that spherical cells are less suscep-
tible to phagocytosis than rod-shaped cells. An increase in φH represents the addition
of an antivirulence drug that increases susceptibility of the rod-shaped bacteria to host
defences.
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Figure 4.23: The population levels of (a) susceptible bacteria and (b) resistant bacteria
after 14 days for varying values of the rod-shaped cell phagocytosis rate, φH , and spherical
cell death rate, ψ. Increasing these parameters from their default values (marked with a
star) simulates the effects of an antivirulence drug and antimicrobial peptide treatment
respectively. We have assumed that the spherical cell phagocytosis rate is slower than
the rod-shaped phagocytosis rate (1× 10−5). The total population of susceptible, S, and
resistant bacteria, R, is calculated such that S = HS + IS + LS and R = HR + IR + LR
respectively.
increase as the recruitment rate of the spherical cells decrease. If the spherical cell re-
cruitment rate decreases to κL = 1 × 10−3 day−1 then we could expect the qualitative
result of the treatment to change as the antibiotic treatment fails to clear the infection.
For Figures 4.25-4.27 we assume that the phagocyte recruitment rate of the spherical
cells is φL = 1× 10−3 (cells cm−3)−1 day−1, since using this value we have predicted that
the antibiotic treatment would become ineffective in clearing the antibiotic-susceptible
infection alone. We investigate whether we can clear the infection using a combination
therapy of antibiotic with AMPs or an antivirulence drug. We simulate the AMPs by
varying the spherical cell death rate, ψ, and obtain the results in Figure 4.25. The
results suggest that the addition of AMPs could lead to fewer spherical cells. However,
as the AMPs only target the spherical cells and the spherical cells have a low phagocyte
recruitment rate, we find that the remaining subpopulations are unaffected by the addition
of AMPs. Adding AMPs could potentially help clear the infection but we predict that
this could take over 200 days of constant therapy and hence we conclude that this would
not be a suitable treatment strategy.
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Figure 4.24: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.21), default parameter values shown in Table 4.2 and varying the spherical cell phago-
cyte recruitment rate, κL, from the default value of 0.5 day
−1.
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Figure 4.25: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.21), default parameter values shown in Table 4.2, with κL = 1 × 10−3 day−1 and
increasing the spherical cell death rate, ψ, from the default value of 1.7 × 10−2 day−1 to
mimic the use of antimicrobial peptides. The rate of phagocyte recruitment by spherical
cells, κL, is slower than the default rate as we are investigating the possiblity that spherical
cells are less immune-stimulatory than rod-shaped bacteria.
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Figure 4.26: The variable solutions to the system (4.12)-(4.19), with initial condi-
tions (4.21), default parameter values shown in Table 4.2, with κL = 1 × 10−3 day−1
and varying the rod-shaped cell phagocytosis rate, φH , from the default value of
2.4 × 10−4 (cells cm−3)−1 day−1. An increase in φH represents the addition of an antivir-
ulence drug that increases the susceptibility of the rod-shaped bacteria to host defences.
The rate of phagocyte recruitment by spherical cells, κL, is slower than the default rate as
we are investigating the possiblity that spherical cells are less immune-stimulatory than
rod-shaped cells.
Similarly, we investigate the effects of an antibiotic-antivirulence drug pairing. Figure
4.26 suggests that a combined dose of antibiotics and antivirulence drug could be suc-
cessful in clearing the infection, if the antivirulence drug was sufficiently effective. The
antivirulence drug enables the phagocytes to limit bacterial growth and this prevents as
many rod-shaped bacteria from transitioning to the spherical form. However, neither the
antibiotic nor the antivirulence treatment directly affects the fitness of the spherical cells
so we predict a slow death phase.
If we investigate a triple treatment combination we get the results in Figure 4.27. The
results indicate that a combination therapy of all three drugs could clear the infection in
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Figure 4.27: The population levels of susceptible bacteria after 14 days for varying values
of the rod-shaped cell phagocytosis rate, φH , and spherical cell death rate, ψ. Increasing
these parameters from their default values (marked with a star) simulates the effects of an
antivirulence drug and antimicrobial peptide treatment respectively. We have assumed
that the spherical cell recruitment rate (1 × 10−3) is slower than the rod-shaped cell
phagocytosis rate.
as little as 14 days if the drugs are sufficiently effective. We note that a higher level of
efficacy is needed for the antivirulence drug in comparison to the results in Figure 4.17,
where we have assumed that the phagocytosis rate is slower for the spherical cells but
immune cells are recruited at the same rate to all types of cell. If the immune system is
not as responsive to the spherical population then it is still possible to clear the infection
if we boost the ability of the immune cells to kill the rod-shaped bacteria.
4.6.2 Antibiotic-resistant infection
Using the model we find that the consequences of the spherical cells having a lower
phagocyte recruitment rate than the rod-shaped cells causes identical changes in both
the antibiotic-susceptible and -resistant infections. For brevity we do not include the
corresponding simulations but instead provide a short overview of the results.
A decrease in the spherical cell recruitment rate from its default value could result
in higher populations for all types of bacteria. A combined dose of antibiotic and AMPs
would only influence the spherical cell subpopulation and hence the treatment would re-
main unsuccessful. An alternative treatment of an antivirulence drug and the antibiotic
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could help decrease all subpopulations and the results are akin to those obtained through
simulating the same treatment on a resistant infection with identical immunogenic prop-
erties (Figure 4.13).
4.6.3 Mixed strain
We have shown that if the population consists of a single strain and the phagocyte recruit-
ment rate of the spherical cells is slower than that of the rod-shaped cells then we could
expect a more threatening infection that could evade antibiotic effects. If we consider the
recruitment rate of the spherical cells and suppose that the population consists of both
strains then we obtain the predictions in Figure 4.28. In a mixed strain infection, the
model predicts similar dynamics to the single strain up to around day 20; all susceptible
subpopulations grow to higher levels as we decrease spherical cell recruitment. Due to
the lower recruitment rate, we initially predict a weaker immune response and as a result
we see faster growth of the resistant population. However, as the resistant population
grows, the immune response increases in response to the higher resistant rod-shaped cell
population. Consequently, the antibiotic and increased immune response can clear the
susceptible population that previously persisted in the single strain simulations. This
predicted behaviour suggests that if recruitment is lower for the spherical cells then we
could expect the presence of a resistant strain to impact the survival of the susceptible
strain negatively whilst promoting the growth of the resistant strain.
If we simulate the combination of AMPs and antibiotics then we obtain the predictions
in Figure 4.29. As expected, the AMPs are successful in clearing the spherical cells,
however, they do not affect the rod-shaped cell populations and therefore we could still
expect a dominant resistant population to emerge. The results indicate that an additional
drug is necessary if we wish to clear the resistant population.
If we consider the use of an antivirulence drug in combination with the antibiotics then
we obtain results similar to the single strain results. We predict that the antivirulence
drug would lower the rod-shaped cell populations and consequently we also predict fewer
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Figure 4.28: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.23), default parameter values shown in Table 4.2 and varying the spherical cell phago-
cyte recruitment rate, κL, from the default value of 0.5 day
−1.
spherical cells. The spherical population takes some time to clear but it is possible to
completely clear the infection eventually (results omitted). Finally, Figure 4.30 indicates
that it is possible to clear the mixed strain infection within 14 days if the spherical cells
recruit phagocytes at a slower rate than the rod-shaped cells. Following from our previous
results we conclude that this would only be possible using both a triple combination of
the antibiotic, AMPs and antivirulence drug.
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Figure 4.29: The variable solutions to the system (4.12)-(4.19), with initial conditions
(4.23), default parameter values shown in Table 4.2, with κL = 1 × 10−3 day−1 and
increasing the spherical cell death rate, ψ, from the default value of 1.7 × 10−2 day−1
to mimic the addition of antimicrobial peptides. The rate of phagocyte recruitment by
spherical cells, κL, is slower than the default rate as we are investigating the possiblity
that spherical cells are less immune-stimulatory than rod-shaped cells.
4.7 Discussion
Following from Model II, we have formulated a model that describes the growth dynamics
of a multi-strain population of P. aeruginosa at the site of infection with the inclusion
of a morphological transition, immune response and multiple treatment combinations.
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Figure 4.30: The population levels of (a) susceptible bacteria and (b) resistant bacteria
after 14 days for varying values of the rod-shaped cell phagocytosis rate, φH , and spherical
cell death rate, ψ. Increasing these parameters from their default values (marked with a
star) simulates the effects of an antivirulence drug and antimicrobial peptide treatment
respectively on the single strain infections. The total population of susceptible, S, and
resistant bacteria, R, is calculated such that S = HS + IS + LS and R = HR + IR + LR
respectively.
We summarise our results for all treatment combinations and all explored immunogenic
characteristic settings in Table 4.3.
If we assume that the immunogenic properties are identical between cell types then
the results suggest that antibiotic treatment could clear a P. aeruginosa infection only if
it was purely susceptible to the antibiotic. In Chapter 3 we predicted that a continuous
dose of antibiotic would not clear an infection and after including an immune response
within the model we see that treatment success is now predicted. This result supports the
conclusions in [7] and emphasises the importance of including the immune response when
considering persistent populations as host defences may help determine the treatment
outcome. If a resistant strain is present then we predict that the antibiotic treatment
would fail, as expected.
After considering an antivirulence drug we conclude that it could be used as a single
treatment and clear all infections if the drug is sufficiently potent. Whilst this conclusion
strongly supports the use of antivirulence drugs we would require further experimental
evidence to hint towards feasible levels of efficacy. As with any antivirulence strategy, the
selective pressure placed on the population by the antivirulence drug would need to be
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Table 4.3: A review of the results for treatments considered in Chapter 4. A single tick,
4, indicates that treatment success is possible but the duration required is clinically
infeasible. A double tick, 44, infers that treatment success is possible in a clinically
feasible time frame. A cross, 8, indicates that treatment is not possible and if followed
by (R) then the remaining infection is resistant to antibiotics. We highlight the effects of
using an antivirulence treatment alone with a k to note that bacterial clearance is possible
but will depend on the effectiveness of the antivirulence drug. For the drug combinations
we have assumed that the level of antivirulence efficacy is below the level needed to clear
the infection in a feasible time frame.
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analysed in order to anticipate resistance developing to the drug.
Our investigation into the effects of the different immunogenic cell properties has been
extensive but not exhaustive. We also undertook preliminary investigations into the case
where both of the immune-related rates are lower for the spherical cells (not included
here). Whilst this is a plausible and likely scenario, we find that many of the results
we obtained under this assumption were congruent with the results obtained in Sections
4.5 and 4.6 combined. Using the results in these sections we are able to make suitable
predictions regarding bacterial growth and treatment success if both the spherical cell
phagocytosis rate and phagocyte recruitment rate were both lower than the rod-shaped
cells rates. Considering both of the immunogenic properties simultaneously requires the
evaluation of a vast parameter space and hence predictions could be inconclusive; further
investigation would benefit from experimental evidence that could hint towards suitable
parameter values.
The varied results in Table 4.3 indicate that the immunogenic properties of the spheri-
cal population could affect the survival of an infection and change the treatment outcome.
If we examine the predictions for bacterial growth during a single antibiotic treatment
and vary the immunogenic properties then we recognise two interesting scenarios. Firstly,
we predicted that the susceptible population could become untreatable with antibiotics
alone if the recruitment rate was slower for the spherical cells but subsequent results
showed that in this case we could apply additional treatments to increase the likelihood
of treatment success.
Secondly, we found that a resistant infection could become treatable with antibiotics
alone if the phagocytosis rate of the spherical cells is lower than the rod-shaped cells. The
rapid transition of many of the resistant bacteria causes a large influx of phagocytes that
enable total bacterial clearance. This compelling result seems counter-intuitive and leads
us to question whether the resistant bacteria would utilise the morphological transition if
it was detrimental to the overall population. It is likely that the resistant bacteria would
adapt and remain as bacillary cells if the selective pressures of the immune response caused
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by the antibiotic-induced morphological transition negatively impacted bacterial fitness.
However, it is unclear whether the increased immune response explicitly causes a decrease
in individual bacterial fitness. The morphological transition permits a bacterium to evade
antibiotic effects, thus increasing its individual bacterial fitness. It could be argued that
the increase in immune cells, caused by the large spherical population, damages the total
bacterial population but not individual cell fitness.
If the resistant bacteria were to adapt and remain as bacillary cells in order to limit
the immune response then they could once again become untreatable by antibiotics alone.
If they do not transition to the spherical form then we would not consider the use of
AMPs but we may still consider the use of an antivirulence drug in combination with
the antibiotic; the success of this treatment would depend on the effectiveness of the
antivirulence drug (see Figure 4.13).
Our results suggest that a susceptible strain could be cleared using antibiotic alone but
our results suggest that a lengthy treatment period would be necessary. After considering
the dual treatment combinations we can formulate conclusions about the clinical potential
for both AMPs and the antivirulence drug. In Chapter 2 we produced results that strongly
supported the combined use of meropenem and AMPs to clear an antibiotic-susceptible
bacterial population in vitro when growing in isolation with the treatment. Whilst we
do not have experimental data to indicate the analogous result for a resistant strain,
it is feasible that a resistant population could also be cleared with the antibiotic and
AMPs in isolation. However, after including host defences and a combination of strains
we find that the results do not strongly support the use of AMPs when used as part
of a combined continuous therapeutic strategy. Our results suggest that the success of
a combined treatment of an antibiotic and AMPs would depend on the effectiveness of
the AMPs and the composition of the infection. For an antibiotic-susceptible infection
with identical immunogenic properties, the combination of antibiotics and AMPs could
decrease the treatment time needed to clear the infection by half compared to an antibiotic
treatment alone if the AMPs could increase the spherical cell death 5-fold. However, a
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treatment time of 100 days is still significant and could be threatening to the patients
health. If the AMPs are too potent or if the phagocytosis rate of the spherical cells is
slower than the corresponding rate for the rod-shaped population then we find that AMPs
may only alter the composition of the population and have little impact on the treatment
time. Similarly, we predict that the use of AMPs in conjunction with the antibiotic merely
alters the composition of the resistant population and has no effect on bacterial load or
on the treatment time.
We see that in the case of the spherical cells having a low phagocyte recruitment
rate, the failed antibiotic-only treatment becomes successful if we add AMPs for both
the susceptible and resistant populations. What we observe as a success for the AMPs is
soon discounted as we remind ourselves that the predicted treatment period needed for
clearance was extensive and not clinically feasible. Furthermore, as formerly mentioned,
the effect of varying phagocytosis rates on the resistant population is unclear and we
would need to know how resistant bacteria would adapt in response to immunogenic
characteristics in order to know whether AMPs would be necessary or helpful. If the
bacterial population is mixed and the phagocytosis rate of the spherical cells is low then
it is possible that the use of AMPs could be detrimental and cause treatment failure.
Overall, our results do not imply positive or conclusive hypotheses to support the use
of AMPs as part of a combined treatment with antibiotic. Whilst our results do not
condemn the use of AMPs they do emphasise the need for further investigation into their
use. The results of the triple combination simulations unanimously support the potential
of AMPs when used in a triple drug combination and we acknowledge the ability of the
AMPs to clear the persistent spherical population. As with the antivirulence drug, we
would need to obtain pharmacodynamic properties of AMPs for P. aeruginosa before
convincing conclusions can be made regarding their use.
Throughout the results in this chapter, the antivirulence drug has shown potential
as a single treatment, therapeutic aid of the antibiotic and as a component of the triple
drug combination. However, in many cases we have observed long predicted treatment
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times due to the spherical cell population that remains after the rod-shaped bacteria
have been cleared by the antivirulence drug. If the antibiotic is withdrawn before this
spherical population is cleared (via phagocytosis and cell lysis) then this could propose
a hindrance to treatment success as we may expect the infection to regrow once the
antibiotic is removed. We note that these predictions were obtained under the assumption
that the antivirulence drug could only affect the rod-shaped cells. It is possible that the
antivirulence drug could also increase the phagocytosis rates of the spherical cells. After
further investigation, we can confirm that in all cases (single and mixed infections) the
infection could be completely cleared within a week using the combined treatment of
antibiotic and an antivirulence drug if the latter affected spherical cell and rod-shaped
cell phagocytosis equally (results omitted). However, if experimental evidence suggested
that the antivirulence drug only targeted the rod-shaped cells then we may still face long
treatment periods unless it is possible to clear the spherical population faster. We propose
that the need to reduce long treatment times could present an opportunity to use AMPs
strategically in a more effective manner. If we can identify the time at which a combined
dose of antibiotic and antivirulence drug clear the rod-shaped population, then it may
be possible to predict a suitable time to add AMPs as part of a sequential drug strategy.
The antibiotic and antivirulence drug could quickly remove the rod-shaped population
and the AMPs could subsequently initiate rapid clearance of the remaining spherical cells
and reduce the treatment time. We will consider this treatment strategy in the following
chapter where we consider the impact of a persistent spherical population during the




TRANSITION OF P. AERUGINOSA TO
OPTIMISE ANTIBIOTIC USAGE
In the foregoing chapters we have formulated mathematical models of P. aeruginosa in
order to consider how the morphological transition could impact bacterial growth when
treated with meropenem. The majority of our results thus far have examined the growth
of the population during a constant dose of antibiotic. Simulating a constant dose enables
us to obtain the long term dynamics of the population more simply and in some cases has
provided the opportunity for analytical analysis. Exploring the parameter space using a
constant dose model has allowed us to investigate novel treatments and drug combina-
tions. However, novel treatments may take years before becoming clinically available and
combination strategies are not always financially feasible. It is crucial that we optimise
the current use of available antibiotics in order to extend their life span.
Traditional treatment regimens usually consist of a fixed amount of antibiotic given
at specific intervals. This type of treatment strategy offers practicability, due to the con-
stant dose, but often lacks optimality and could help facilitate the spread of resistance.
Mathematical modelling is increasingly being used to explore antibiotic dosing strategies
and the effects of dosing on antibiotic resistance [17, 29, 39]. After formulating a mathe-
matical model it is possible to simulate multiple doses of antibiotic by solving the model
and adding antibiotic via a change in antibiotic concentration at prescribed time points.
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Using this “manual” approach provides valuable insight into the effects of different dosing
strategies. However, the antibiotic dose and duration is chosen by the person simulating
the program and a disadvantage of this is that there is a limit to how many strategies can
be explored.
Paterson et al. [86] explored a novel approach of using a genetic algorithm (GA) to
search for optimal dosing strategies. In the study it was suggested that in user-controlled
studies the person undertaking the investigation may only find “an optimal solution from
a selection of sub-optimal treatments”, due to the limits on how many dosing strategies
can be explored. Using a GA makes it possible to explore a vast space of possible dosing
strategies automatically in order to obtain the most optimal treatment regimen. In the
study the authors analysed the effectiveness of traditional treatment regimens and com-
pared them to the treatment regimes that were identified using the GA. A deterministic
population dynamics model was formulated to describe the growth of a susceptible and a
resistant strain of bacteria in isolation with an antibiotic treatment. Resistance was as-
sumed to arise through HGT; as this process could result in small population densities a
deterministic model may not always provide an accurate approximation. At low bacterial
densities the randomness of biological processes can determine the survival of a population
and therefore a stochastic framework was developed alongside the deterministic model to
analyse bacterial growth during the dosing strategies. The stochastic model was used to
obtain success rates, with confidence intervals, for each dosing strategy, in order to choose
the most efficient. In addition to success rates, they also analysed the time taken to clear
the infection and the amount of antibiotic in the system.
In [86], a traditional treatment regimen was initially investigate and simulated for 10
days. It was found that the antibiotic concentration fell between the MIC values for the
susceptible and resistant bacteria for the first three days of treatment. Whilst the antibi-
otic concentration is within these two figures, the susceptible bacteria perish and leave
the resistant bacteria in a favourable environment, thus facilitating their development.
The GA then identified suitable treatment strategies that increased the success rate of
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the treatment and decreased the treatment time. The optimal dosage vectors were found
to exhibit the characteristics of a high dose followed by tapering lower doses. We will refer
to this type of strategy as a high dose, tapered doses (HDTDs) strategy. The initially
high dose causes the antibiotic concentration to quickly reach the MIC of the resistant
bacteria and stop the initial facilitation of resistant bacteria that was found to occur in the
traditional regimen. Additionally, the optimal treatment strategies often required a lower
total amount of antibiotic over the course of the treatment compared to the traditional
regimen. Overall, the GA found suitable treatments that were shorter, more effective and
less toxic.
In this chapter we will explore optimal dosing strategies for P. aeruginosa by applying
a similar methodology to that used in [86]. Instead of considering the emergence of
resistance within a population, we will turn our focus to how the morphological transition
could impact the results of the GA. We assume that antibiotic exposure will trigger an
en masse transition within the bacterial population and therefore a deterministic model
will provide a suitable approximation to the system.
5.1 Model formulation
In keeping with our previous models, we formulate a system of equations to describe the
dynamics of a population of rod-shaped cells (H) and spherical cells (L). Additionally, we
describe the concentration of antibiotic (A). We are interested in the role of the spherical
population and its effects on treatment strategies; therefore, we do not include a resistant
population or a population of rod-shaped cells with bound antibiotic and return to the
simpler set-up from Chapter 2.
The mechanisms included in this model are similar to those in Model I and Figure 2.2
can be used for reference of the interactions in this model. The only distinctions that can
be made between Model I and the current model is a change to the method used to describe
bacterial growth and the reverse transition of the bacteria. For mathematical simplicity
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we choose to model bacterial growth using a logistic term, with carrying capacity k and
growth rate r. Natural cell death was found to be negligible in the parametrisation results
in Chapter 2, we omit it from this model.
Following from Models I-III, we assume that the spherical bacteria cannot proliferate
but can die naturally at a rate, ψ. We model the transition to the spherical shape
using a saturating term with maximum rate γ and concentration needed for half maximal
transition T50. We assume that the reverse transition will only occur at low antibiotic
concentrations and model this transition using a hyperbolic tangent function with slope
parameter b and critical threshold concentration Ac.
We maintain the assumption that the spherical cells evade antibiotic effects completely
and model the effect of the antibiotic on the rod-shaped cells using a nonlinear term
with maximum death rate ρ and concentration at which half maximal killing occurs A50.
Following from [86] we assume that antibiotic doses are added to the system daily and
we introduce the dosage vector, D = (D1, D2, ..., D10), where at time t̂i the antibiotic is
replenished with an amount Di (i ∈ (1, 2, ..., 10)). Finally, we assume that antibiotic decay
follows first order kinetics. In Chapter 2 we also included antibiotic degradation due to
bacterial death within the model yet we found both antibiotic-associated parameters to
be unidentifiable. Therefore, we choose to simplify the mechanisms involved in antibiotic
decay.


















































Dnδ(t− t̂n)− αA, (5.3)
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with initial conditions
H(0) = 103, L(0) = 0, A(0) = 0. (5.4)
Variable definitions are given in Table 5.1 and parameter definitions and default parameter
values are displayed in Table 5.2. We note that the initial condition for the antibiotic,
A(0) = 0, as we choose to add the first initial antibiotic dose on day 1.
Table 5.1: Definitions and units for the variables in Model IV, described by equations
(5.1)-(5.4).
Variable Definition Units
H Antibiotic-susceptible rod-shaped cells cells cm−3
L Spherical shaped cells cells cm−3
A Antibiotic concentration µg ml−1
Parameters were chosen following the previous models where possible. Some param-
eters have been chosen as to suitably predict the dynamics required. In [86], the MIC
values of the susceptible and resistant strain were used to model antibiotic death and
having these parameter values allowed for analysis of the predicted antibiotic concentra-
tion over the time course of the treatment. As the parameters in our model are not all
parametrised using experimental data, they are not all specific to a strain of bacteria
and antibiotic. Therefore we will not aim to suggest MIC values and thereon formulate
conclusions based on the antibiotic concentration. Instead we focus on the total amount
of antibiotic used and the time taken to clear the infection.
5.2 Detail of the genetic algorithm
The tailored treatment methods were obtained using the built-in MATLAB function ga,
which uses a GA to find a local minimum to a function. By choosing a suitable objective
function that relates to the number of bacteria and the amount of antibiotic used over a
10 day dosing period, we can use the GA to find local minima that represent the optimal
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Table 5.2: Definitions and units for the parameters in Model IV, described by equations
(5.1)-(5.4).
Parameter Description Units Default value
α Antibiotic decay rate. day−1 1
r Growth rate of rod-shaped bacte-
ria.
day−1 2
k carrying capacity of rod-shaped
bacteria
cells cm−3 106
γ Transition rate from rod to spher-
ical shape.
day−1 1
δ Transition rate from spherical to
rod shape.
day−1 1
Ac critical antibiotic concentration
threshold for reversion of spher-
ical cells
µg ml−1 0.5
b smoothed step function slope pa-
rameter
µg ml−1 1
ρ Death rate of rod-shaped bacteria
due to antibiotic.
day−1 5
ψ Death rate of spherical bacteria. day−1 0.017
T50 Antibiotic concentration required
for half maximal killing effect
µg ml−1 0.47
A50 Antibiotic concentration required
for half maximal transition effect
µg ml−1 10








This represents a multicriteria objective function. The first term in our objective function
represents the sum of doses over a 10 day dosing period. We wish to minimise the total
amount of antibiotic in order to reduce antibiotic exposure (and hence the likelihood that
resistance may emerge). Following from [86], we constrain the antibiotic concentration
at any given time to be less than 60µg ml−1 due to the toxicity of antibiotic and we test
maximum daily doses of 40, 50 and 60µg ml−1.
Whilst we wish to minimise the amount of antibiotic used, if less antibiotic is added
then the bacterial population may increase. Therefore we also choose to minimise the
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total bacterial load to ensure treatment success; the second term in our objective function
calculates the total bacterial load from the day before the inital dose (t = 0 days) to just
under 3 weeks after the final dose (t = 30 days). Note that we calculate the total bacterial
load over the extended period after the dosing regimen is complete as we wish to consider
regrowth of the infection within our minimising function. By including the possibility of
regrowth we hope to reject treatment strategies that result in failed treatment in the long-
term. Weighting coefficients were used in [86]. We choose to balance the terms equally by
scaling appropriately: we normalise both terms in the objective function using the scaling
factors, n1 and n2, that scale the terms to values that are approximately O(1). To scale
the total amount of antibiotic we choose a scaling factor equal to a typical total amount
of antibiotic allowed over the dosing regimen. For example, for a typical daily antibiotic
dose of 14µg ml−1, the scaling factor is n1 =
1
140
. Similarly, we scale the total bacterial
load over the 30 day time period using the total bacterial load achieved with a dosing
strategy that minimises the second term in the fitness function, with the constraint that
the total antibiotic used cannot exceed 140µg ml−1; this gives n2 =
1
7.5×103 . This approach
roughly balances the two terms in the fitness function. Varying this balance would lead
to either unnecessarily large quantities of antibiotic being used or treatments that don’t
eradicate the bacteria. The default options in Matlab for ga were used meadning that
new generations were produced from a combination of elite children, crossover children
(recombination) and mutation children. The GA was implemented with a population size
of 100, for 200 generations and repeated 10 times.
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5.3 Results
5.3.1 Investigating antibiotic dosing regimens for a rod-shaped
population
Initially we assume that the bacteria do not transition to spherical cells during exposure
to antibiotics to attempt to reproduce some of the results obtained in [86] (where no



















Dnδ(t− t̂n)− αA, (5.7)
with initial conditions
H(0) = 103, A(0) = 0. (5.8)
Traditional treatment regimens
Following [86] we begin by looking for a traditional treatment regimen that is able to clear
the infection within a 10 day treatment period. For the traditional regimen we assume
that the antibiotic doses are equal such that D1 = D2 = ... = D10. If we simulate a 10
day traditional treatment strategy of a constant dose then we predict that a minimum
dose of 14µg ml−1 per day would be required to clear the population in 10.97 days (Figure
5.1).
Tailored treatment regimens
To clear the infection we have shown that a total of 140µg ml−1 must be administered
over a 10 day period if the doses are equal. The most effective solutions chosen by the
GA are displayed in Table 5.3. In agreement with [86], the GA selects dosage vectors
that have a high initial dose followed by lower doses that taper off towards the end of
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Figure 5.1: The solution to the system (5.6)-(5.7), with initial conditions (5.8) with dosing
vector D = (D1, D2, ..., D10), with Di = 10 ∀i ∈ [1, 10]. In (a) the bacterial concentration
is given and in (b) the antibiotic concentration.
the treatment (HDTDs). The total amount of antibiotic can be reduced from 140µg ml−1
in the traditional regimen to as low as 124µg ml−1 in R1 and the time it takes to clear
the infection can also be decreased. Previously we found that it would take 10.97 days
to eradicate the population and with the tailored treatments we find that it is possible to
clear the infection in as little as 6.35 days (R3).
Table 5.3: Dosage vectors chosen by the GA to treat an infection of rod-shaped bacte-







R1 (40, 19, 16, 18, 15, 16, 0, 0, 0, 0) 124 7.31
R2 (50, 18, 19, 11, 18, 12, 0, 0, 0, 0) 128 7.10
R3 (50, 17, 21, 26, 15, 0, 0, 0, 0, 0) 129 6.35
R4 (46, 18, 13, 19, 21, 9, 0, 0, 0, 0) 126 7.04
R5 (50, 17, 11, 24, 13, 13, 0, 0, 0, 0) 128 7.04
R6 (56, 15, 14, 14, 15, 16, 0, 0, 0, 0) 130 7.2
R7 (51, 11, 17, 13, 19, 13, 4, 0, 0, 0) 128 7.56
We have obtained similar predictions to those in [86] and would support the use of a
HDTDs treatment regimen for a population of rod-shaped cells that cannot transition.
Our aim is to now consider whether a HDTDs strategy is advisable for an infection that
utilises the shape transition.
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5.3.2 Investigating antibiotic dosing regimens for a population
that utilises the antibiotic-induced morphological transi-
tion
Traditional treatment regimen
The full model, described by equations (5.1)-(5.4), is used if we assume that the bacteria
can employ the morphological transition. Following from Section 5.3.1 we attempt to find
a traditional regimen that could clear the infection within 10 days. Figure 5.2 displays
the populations of rod-shaped spherical cells one day after the final dose of antibiotic is
administered (Figures 5.2 (a) and (b)) and three weeks after the final dose is administered
(Figures 5.2 (c) and (d)) with varied antibiotic doses. The day after we add the final dose
we find that the rod-shaped population is cleared for repeated doses of 6µg ml−1 and
higher (Figure 5.2 (a)) but a spherical population remains regardless of the antibiotic
dose.
After three weeks of no antibiotic exposure we see changes to both populations of
cells. For all antibiotic concentrations we find that most of the spherical cells will return
to the rod-shape and resume proliferation. Regardless of the dose used for the tradi-
tional treatment regimen, we would expect the population to regrow to the steady state
population.
We note that the range of doses tested is large and that for the higher concentrations
it is likely that the antibiotic concentration within the body at the end of the treatment
could be high and potentially toxic.
Applying the GA
Our results suggest that it is not possible to clear the infection using a traditional 10 day
dosing regimen with equal doses. Therefore we do not have a total amount of antibiotic
to use as a constraint in the GA. To obtain the GA results we set the maximum daily
dose to 40µg ml−1 and do not limit the total amount of antibiotic used over the treatment
or the concentration of antibiotic during the treatment. The dosage vectors chosen by
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Figure 5.2: The populations of rod-shaped cells ((a) and (c)) and spherical cells ((b) and
(d)), the day after ((a)-(b)) and two weeks after ((c)-(d)) the final dose of a traditional
treatment for a fixed dose for 10 days with varied dose, Di.
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the GA are displayed in Table 5.4. The most efficient dosage vectors exhibit a trend of a
high initial dose and high final dose but between these doses there is no significant trend.
If it is not possible to clear the infection during the 10 day treatment period then
the population will grow to the carrying capacity once the antibiotic has degraded. The
contribution of population growth to the total bacterial load term post-antibiotic exposure
becomes very large. Therefore, we find that any change to the bacterial load term, caused
by alterations in the dosage vector over the first 10 days, will have a negligible effect on
the objective function compared to the bacterial load that grows in the remainder of time
after the treatment. As a result, we find that the GA chooses treatment strategies that do
not utilise the total amount of antibiotic available as it attempts to minimise the objective
function by reducing the second term of (5.5) that corresponds to the total amount of
antibiotic used. If we amend the objective function to only minimise the bacterial load or
add in constraints to the total amount of antibiotic used and the antibiotic concentration
during treatment we still find that the GA does not predict the HDTDs strategy we
predicted for the infection that can be cleared within 10 days.
Table 5.4: Dosage vectors chosen by the GA to treat an infection that utilises the morpho-
logical transition (γ = 1 day−1). The total amount of antibiotic available is unconstrained
and we employ the objective function (5.5). The concentrations of both bacterial popula-





Concentration at t = 12
H S
R1 (11, 4, 4, 3, 3, 4, 3, 3, 2, 11) 48 788 0.95× 104
R2 (12, 3, 3, 3, 4, 3, 4, 2, 3, 11) 48 877 1.02× 104
R3 (12, 3, 3, 4, 3, 3, 4, 3, 2, 11) 48 822 0.98× 104
R4 (12, 3, 4, 4, 3, 4, 2, 3, 2, 12) 49 853 0.902× 104
R5 (11, 3, 3, 5, 2, 4, 3, 3, 3, 10) 47 827 1.08× 104
Our results suggest that if a bacterial infection cannot be cleared using a traditional
treatment strategy that the GA will not advise towards a HDTDs strategy as the algorithm
struggles to substantially minimise the total bacterial load. The same result is obtained
if we use the GA to identify the most effective dosing strategy for a population with no
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spheres that is not cleared using the prescribed traditional dosing regimen. For example,
if we apply a 12µg ml−1 dose each day for 10 days then, following from our results in
Section 5.3.1, we would not clear the bacterial population and the GA would not suggest
the HDLDs strategy (results omitted).
If the population of spherical cells is not cleared then we do not obtain a clear trend
within the most effective treatment strategies suggested by the GA. This result highlights
the importance of considering phenotypic variants when using this method to choose
treatment strategies. The spherical population and the reverse transition enable the
population to survive high dosage treatment strategies and therefore the GA finds it
hard to substantially minimise the objective function. If we can successfully remove
the persistent population then it may be possible to once again get a strong conclusion
regarding suitable treatment strategies using the GA.
Considering the use of AMPs
In Chapter 4 we analysed the effects of using AMPs in conjunction with the antibiotic
and concluded that the use of AMPs may not be beneficial during treatment. We briefly
considered that they could propose a suitable treatment option once the rod-shaped pop-
ulation has been cleared. Here, we assume that the spherical population that persists
and enables population recovery after the antibiotic dosing strategy has finished, can be
cleared using AMPs alone using a sequential treatment strategy. To simplify investigating
this we set the reverse transition rate δ = 0 day−1. By removing the reverse transition
we provide the GA with the chance to optimise clearance of the rod-shaped population
without being affected by the spherical population that previously enabled population
regrowth after the treatment period. We assume that AMPs will subsequently be added
to eradicate the remaining spherical population following the final dose of antibiotic.
We find that the rod-shaped population can be cleared using a traditional strategy
with a 10 day repeated dose of 7µg ml−1 (results omitted). This is a lower dose than
estimated was necessary for the population of cells that do not alter their morphology
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(Figure 5.1) but we note that the bacteria are transitioning to spheres and being killed by
the antibiotic so the rod-shaped population will decrease faster and as a result are cleared
faster. If we subsequently apply the GA with the total amount of antibiotic as 70µg ml−1,
using the objective function (5.5), we obtain the tailored treatment strategies shown in
Table 5.5. The GA chooses treatment strategies that exhibit the HDTDs trend and the
amount of antibiotic and time taken to clear the infection decreases from the traditional
treatment regimen.
Table 5.5: Dosage vectors chosen by the GA to treat an infection that utilises the morpho-
logical transition but does not revert back to the rod-shape in the absence of antibiotic.







R1 (27, 7, 8, 8, 7, 0, 0, 0, 0, 0) 59 6.34
R2 (29, 7, 8, 8, 7, 0, 0, 0, 0, 0) 60 6.17
R3 (32, 4, 10, 9, 5, 0, 0, 0, 0, 0) 59 6.89
R4 (28, 5, 8, 9, 5, 4, 0, 0, 0, 0) 59 6.24
R5 (28, 9, 9, 7, 6, 0, 0, 0, 0, 0) 59 6.1
Whilst the GA has suggested suitable treatment strategies, recall that there will be
a large spherical population present during and after the antibiotic treatment. If we
simulate a sequential treatment strategy of antibiotic dosing regimen R1 from Table 5.5
followed by a constant dose of AMPs, administered for 5 days starting from the day after
the last nonzero antibiotic dose, we obtain the results in Figure 5.3. Previously we set the
reverse transition rate δ = 0 day−1 in order to apply the GA to the population with rod-
shaped and spherical cells. To simulate the chosen strategies we do not need to maintain
this assumption and we reset the reverse transition rate to its default value, δ = 1 day−1.
The results suggest that the AMPs could quickly clear the spherical population before
they transition back to rod-shaped cells and resume proliferation. As the antibiotic has
not degraded fully from the system we see that the spherical cells may not transition back
to the rod-shape before the AMPs are added. The spherical population is rapidly cleared
and total clearance occurs before the antibiotic has fully degraded.
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Figure 5.3: The individual variable solutions to the system (5.1)-(5.3) with initial con-
ditions (5.4). For t ∈ [1, 5] we simulate the antibiotic dosage vector D = (27, 7, 8, 8, 7).
For t ∈ [6, 11] we change the death rate of the spherical cells, ψ from its default value of
0.017 day−1 to ψ = 5 day−1 to simulate the addition of AMPs. For t > 11 we return to
the value of ψ = 0.017 day−1 in order to simulate the removal of the AMPs.
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5.4 Discussion
In this chapter we have shown that the presence of phenotypic variants, such as the
spherical cells, could impact the dosing strategies obtained using a GA. As the cells lie
dormant and possess the ability to transition back to the rod shape, a HDTDs strategy
would not clear the infection. It is likely that this result would be similar for populations
that include persister cells and highlights the need to consider these phenotypes when
searching for optimal treatment strategies.
The model formulated for this chapter was simplified in order to observe the basic
impact of morphological heterogeneity on optimal dosing strategies. We could apply the
genetic algorithm to a more complex model such as Model III to see if the HDTDs strategy
is optimal in the presence of an immune response. Using Model III we could attempt
to reproduce the results in [86] using the mixed strain model and include a stochastic
framework to evaluate treatment success.
If the morphological transition facilitates treatment failure then we predict that it
may still be able to obtain a successful treatment strategy if we include addition of AMPs
following the final antibiotic dose. In Chapter 4 we found that AMPs could be ineffective
if used simultaneously with antibiotic to treat an in vivo infection but here we highlight
their potential as part of a sequential treatment strategy. Further optimisation attempts
could be made to predict the optimal dosing frequency (we only considered one dose
each day) and at which time to add the AMPs. We note that we have only considered a
constant dose of AMPs; we could extend the model to incorporate the AMP concentration
in order to optimise the dosage and number of doses required to effectively remove the
spherical population. Finally, we could apply the GA to optimise the simultaneous use of
antibiotics and an antivirulence drug and investigate the use of the triple drug combination




This thesis has comprised a number of mathematical models that have been formulated to
investigate the role of the antibiotic-induced morphological transition witnessed in popu-
lations of P. aeruginosa. We have investigated the potential threat of the cell wall deficient
forms that are observed in populations of P. aeruginosa but whose characteristics, clinical
significance and cause have not yet been established.
Research suggests that the formation of spheroplasts, with a depleted peptidoglycan
layer and unstable osmotic properties, may be the final structural change witnessed before
lysis, implying that the transition may be due to antibiotic effects and not an intrinsic
mechanism. However, the results in [75], which we were able to reproduce experimen-
tally, show a clear indication of the reverse transition and its ability to replenish the
population after antibiotic exposure, suggesting that it is in fact a purposeful evasion
mechanism, induced by antibiotic exposure, yet ultimately implemented by a responsive
cellular mechanism.
Using Model I (to describe the in vitro growth of a single susceptible strain) we can
attempt to address the ambiguity surrounding the cause of structural changes to the
bacterial population. By assuming that the change in bacterial morphology occurs due
to the presence of antibiotic exposure, whether the transition is an intrinsic internal
response of the bacteria or a result of antibiotic action, the model formulated allows for
both of these possibilities. The death rate of the bacillary cells due to antibiotic can be
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seen to represent those cells that are eliminated by the antibiotic before any significant
changes in morphotype occur. Those that do display changes in their ultrastructure
undergo transition into the spherical population and are then subject to a higher death
rate; however this mechanism is not explicitly dependent on antibiotic. Another way
of looking at this would be to suggest that if the shift in population structure is solely
the result of peptidoglycan inhibition, induced by the antibiotic, then once a bacterium
has converted into a spherical form the bactericidal damage has already been induced
and lysis is no longer dependent on antibiotic presence. Similarly, allowing for a reverse
transition would suggest that the damage made by the antibiotic is reversible.
Much of our results in Chapter 2, however, support the hypothesis proposed by Mon-
ahan et al. [75] that this transition is in fact a purposeful mechanism used to evade
antibiotic effects. Under the assumption that spherical cells are immune to antibiotic
effects, and by using suitable parameters, we have shown that the transition may lead
to the recovery of population levels in the absence of meropenem, which we have seen in
both our microscopy results and growth curves using low antibiotic concentrations. Al-
though these results are restricted by limited data, the repercussions of this theory could
give insight into the persistent characteristics of P. aeruginosa and explain its ability to
sometimes withstand high levels of carbapenems.
Our experimental results provide evidence for the morphological transition when the
bacteria are grown in isolation with the antibiotic. Following from our results in Chapter
2, we extended Model I to formulate Model II, which was used to describe the growth of
a single strain of P. aeruginosa and included the possibility of efflux pump upregulation.
We subsequently developed Model III to further investigate the potential threat of the
morphological transition in vivo. By including host defences, we recognised the significant
contribution of the immune response to treatment; the presence of a persistent subpopu-
lation did not always hinder treatment success due to the efforts of the immune response.
However, after further investigation into the immunogenic properties we proposed that
the persistent spherical population could be the cause of treatment failure if they are
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less immunogenic. Following from [7, 40], we find that our results highlight the need to
include population heterogeneity and the immune response within infection level models
to truly explore novel treatment approaches.
Related cell morphologies have been shown to play a role in in vivo infections, for
example, L-forms have been detected in the urine and blood of patients suffering from
recurrent renal diseases and urinary tract infections [35, 36]. Our results have detailed the
impact that a population of spherical cells would have on a P. aeruginosa infection and
led to multiple hypotheses regarding novel treatments and potential treatment strategies.
To better our predictions we would require further evidence of the characteristics of the
spherical cells, including their immunogenic and virulence properties and their growth
capabilities. We have assumed throughout that a cell with a disrupted cell wall would be
unable to grow. It has been suggested that the spherical cells may be able to proliferate
through blebbing or explode in order to produce membrane vesicles that can contribute to
biofilm formation and virulence [73, 106]. If so then our results here would possibly present
the best case scenario as it is likely that additional proliferation would only exaggerate
the potential threat of the spherical cells.
Using Models I-IV we have been able to test an array of treatment strategies in silico.
In Chapter 2 we hypothesised the use of two novel treatments that could inhibit either the
forward or reverse transition. We predicted that a drug that could inhibit the transition
to spherical cells could cause higher bacterial loads but would leave the population more
vulnerable to the antibiotics resulting in fast clearance of the population. It is also worth
noting here that if the morphological changes witnessed are a result of antibiotic action
then inhibiting the transition mechanism could be counter-productive to the application
of meropenem. Envisaging a drug that could inhibit the bacterium from shedding the cell
membrane, thus keeping it intact, could work directly against the mechanism of action of
the antibiotic. Furthermore, if a resistant bacteria emerged that could evade the effects
of the transition-inhibiting drug then the resistance genes could be directly selected for
as the resistant bacteria would be able to transition to the spherical form and have an
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increased chance of survival.
Alternatively, we simulated the use of a drug that could inhibit the reverse transition.
Whilst the viability of this type of drug is unclear, the results suggested that a drug of
this type may not help to eradicate the population but could instead prevent the bacteria
from regrowing by forcing the bacteria to remain as spheres. Additionally, we proposed
that the reverse transition inhibiting drug would work synergistically with AMPs and
help decrease the treatment time needed to clear the population.
The use of AMPs as a supporting drug for antibiotics has been investigated through-
out this thesis. In vitro results supported the theory that AMPs could clear spherical
populations when added with antibiotics and using Model I we were able to simulate
their use and reinforce the potential of AMPs [75]. Using Model III we simulated the
combined use of AMPs and antibiotic as a treatment for an infection of P. aeruginosa at
a site of infection. By including host defences we produced results that differed from our
previous conclusions. If used simultaneously with the antibiotic we predicted that AMPs
could decrease treatment times. However, this result was dependent on specific levels of
drug effectiveness and the strain of bacteria. For higher levels of potency we predicted
that the AMPs could be ineffective at best, and in the worst case scenario, they could lead
to higher levels of virulence and a more resistant infection. In vivo testing of AMP usage
could be performed to examine whether the results of the drug combination are congruent
to the in vitro or in silico predictions and could determine their potential. Nonetheless,
our results indicate that we should not disregard the potential for using AMPs to re-
move cell wall deficient subpopulations. We previously mentioned the combined use of
antibiotics and AMPs with a drug that could inhibit the reverse transition. In addition,
we have estimated that a triple combination of antibiotics, AMPs and an antivirulence
treatment may clear bacterial infections within a clinically feasible time frame regardless
of the immunogenic properties of the spherical cells and the presence of resistance. Fur-
thermore, in Chapter 5 we appraised the use of AMPs as a sequential treatment after a
tailored antibiotic dosing regimen. By implementing the GA with an infection level model
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we could test whether the immune response impacts the synergism between the antibiotic
and AMPs, as we previously found in Chapter 4.
As with all potential treatment options, further investigation into the resultant impact
that AMP usage may have on the emergence of resistance would be needed. The use of
AMPs would impose a direct fitness cost on the spherical cells that could impact selection
for resistant phenotypes. However, due to the already-depleted cell wall and lowered
natural survival rate of the spherical cells, it is uncertain whether imposing a further
fitness cost on the bacteria would impact the possible emergence of resistance.
The final treatment tested was an antivirulence drug that could prevent the bacteria
from evading host defences and increase their vulnerability. We incorporated the effects
of an antivirulence drug into Model IV by increasing the susceptibility of the rod-shaped
cells to immune cells and found that in all cases the antivirulence drug helped clear the
rods faster than using antibiotic alone. If used alone, our predictions suggested that the
antivirulence drug may be able to clear the infection yet we acknowledge that a high
potency level is needed to achieve this. Furthermore, our predictions were obtained under
the assumption that only the rod-shaped cells were targeted by the antivirulence drug; if
all cell types were affected by the drug then its effects would be drastically increased.
Resistance to an antivirulence drug could develop and we discussed antivirulence drug
resistance in Section 1.4.3. To consider resistance to a drug that increases bacterial
vulnerability to host defences would require knowledge of the specific mechanism that
the drug inhibited. There are multiple ways in which bacteria evade host defences and
resistance would only emerge if the inhibited mechanism had a direct impact on bacterial
fitness.
In Chapter 5 we investigated the impact of a spherical subpopulation on the optimised
treatment strategies chosen by the GA. As the threat of resistance develops and the need
to optimise antibiotic usage increases, tailored treatment regimens may become a viable
option. As we have shown, treatment strategies that are suggested for non-transitioning
populations may not be successful in clearing populations that include spherical cells.
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The presence of any persistent subpopulation would need to be considered when obtaining
tailored treatment strategies; if we ignore persistence then tailored treatment regimens
may be ineffective. Furthermore, the results in Chapter 4 indicate that a slight change to
the immune response could significantly impact treatment success and therefore patient
immunity must be considered when choosing a personalised treatment strategy.
If we wish to combat the threat of antibiotic resistance then we must gain a complete
understanding of bacterial species, virulence and the mechanisms that enable antibiotic
evasion. In this thesis we have detailed how mathematical modelling can be used to
simplify complex biological systems and describe bacterial growth in order to obtain pre-
dictions that could be used as a basis for experimental investigation. The presence of cell
wall deficient P. aeruginosa cells could enable antibiotic evasion and increase the threat of
recurrent infection that comes along with phenotypic persistence. By exploring parameter
spaces we have investigated novel treatment strategies and using a genetic algorithm we
have shown that the presence of a spherical population could change treatment strategies
chosen by the algorithm. We have highlighted the importance of including host defences
in mathematical models of bacterial growth as the contribution of the immune response
and the interplay between the persistent population and immune cells could have seri-
ous consequences for personalised medicine approaches. To further investigate tailored
treatments, the GA could be applied to the infection level model, Model III. It is possible
that the GA could successfully select optimal treatments (without AMPs) for an infection
with a spherical cell subpopulation if host defences are incorporated. It would be vital to
investigate weak immune responses and the immunogenic properties of the spherical cells
to gauge a better understanding of the viability of tailored antibiotic regimens. Further-
more, experimental validation of spherical cell properties would be integral to establish




A.1 Staining and fluorescence microscopy
Single colonies of the P. aeruginosa strain PA1008, a meropenem susceptible isolate de-
rived from a hospital burn unit [90], were inoculated into LB broth and grown for around
16 hours at 37◦C , shaking at 200 rpm.
A.1.1 Microscopy images for displaying transition
Cultures were normalised to an optical density at 600 nm (OD600) of 0.2 in 20 ml LB
broth containing the desired concentration of meropenem. Cultures were incubated at
37◦C, 200 rpm in between time points.
At each time point, 1 ml of bacteria was removed from each flask and the OD600
measured. A sample from each flask was then normalised to an OD600 of 1 by centrifuging
the sample and re-suspending in the appropriate volume of PBS. 500µl of each sample
was stained with 1.5µl of LIVE/DEAD BacLight stain mixture and incubated for 15
minutes at room temperature, in the dark. Samples were centrifuged and re-suspended
in 4% PFA for 10 minutes at room temperature to fix the samples. Samples were washed
three times with PBS to remove the fixative, and re-suspended in 500µl of PBS following
the final wash.
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5µl of stained culture was loaded onto a microscope slide and allowed to air dry. Once
dry, one drop of antifade gold mounting solution was loaded onto the sample and covered
with a cover slip. These were left overnight to set in the dark. Microscope slides were
examined using a Zeiss Axio Observer microscope. Images were taken using the 63× oil
immersion objective and exposure to transmitted light, red and green fluorescence. For
fluorescence an exposure of 500 ms was used.
A.1.2 Microscopy images for parameter testing
Cultures were normalised to an optical density at 600 nm (OD600) of 0.4 in LB broth
after 16 hours of growth. Meropenem dilutions were made at twice the desired final
concentration in LB. 50µl of the normalised PA1008 culture was added to a 96-well plate
followed by 50µl of the meropenem dilution. For each condition, 6 wells were prepared
so that the contents could be pooled together to increase the yield of cells. Between time
points the 96-well plate was incubated in a plate reader, shaking at 200 rpm, 37◦C. OD600
was measured from the samples every 10 minutes to allow the OD of the samples to be
monitored over the course of the experiment (thus ensuring bacterial load is comparable
to that of our growth curves – see below).
At each time point, the contents of the appropriate wells were removed and pooled
together for each concentration in separate microcentrifuge tubes. 600µl of 4% PFA was
added directly and incubated for 30 minutes at room temperature to fix the samples.
Samples were washed three times with PBS to remove the fixative, and re-suspended in
50µl of PBS following the final wash. Each sample was stained with 3µl of LIVE/DEAD
BacLight stain mixture and incubated for 15 minutes at room temperature, in the dark.
Samples were washed three times with PBS to remove excess stain, and re-suspended in
50µl of PBS following the final wash.
5µl of stained culture was loaded onto a microscope slide and allowed to air dry. Once
dry, one drop of antifade gold mounting solution was loaded onto the sample and covered
with a cover slip. These were left overnight to set in the dark. Microscope slides were
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examined using a Zeiss Axio Observer microscope. Images were taken using the 63× oil
immersion objective and exposure to transmitted light, red and green fluorescence. For
fluorescence an exposure of 100 ms was used. At least 5 images were obtained for each
condition.
A.2 Growth curves for model parametrisation
Single colonies of the P. aeruginosa strain PA1008 were inoculated into 5 ml of LB broth
and grown overnight at 37◦C, shaking at 200 rpm. The following day, the cultures were
diluted to an OD600 of 0.4, which would be diluted to 0.2 following the addition of the
antibiotic. Dilutions of meropenem were made using LB broth to give final concentrations.
50µl of bacteria culture was added to the appropriate wells of a sterile, 96 well, flat bottom
microtitre plate, followed by 50µl of the appropriate meropenem dilution. Media controls
were then added to the plate for each meropenem concentration, consisting of 50µl of
each meropenem dilution plus 50µl of LB broth. The OD600 of each well was taken using
a FLUOstar Omega plate reader every 30 minutes for 24 hours. Between OD readings
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